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Ketamine has been used over the last 10-12 years as a surprisingly effective therapy for 
treatment resistant depression. This has led to the establishment of specialised 
ketamine treatment clinics in the United Kingdom and United States. However, 
treatment at these clinics is expensive and there is a concern that people suffering with 
depression will self-medicate with “street” ketamine and run the risk of using too high 
and too frequent doses. This might lead to detrimental changes in psychological 
wellbeing, brain functional activity, metabolism and brain structure; as has been 
observed in recreational ketamine users. 
There is a lack of evidence regarding the long-term effects and safety profile of ketamine 
exposure, and moreover the psychological and neurological changes observed in 
recreational ketamine users are likely confounded by additional psychotropic drug use. 
To investigate the long-term effects of ketamine, with and without these confounds, I 
conducted structural magnetic resonance imaging in both recreational ketamine users 
and mice (that received repeated doses of ketamine). In humans, repeat ketamine 
exposure induced decreases in brain volume in the frontal cortex, striatum and 
cerebellum. In mice, repeat ketamine exposure induced an increase in volume in the 
frontal cortex, which was associated with an increase in the amount of neurofilament 
and synaptophysin within the prefrontal cortex. I observed further decreases and 
increases in volume within the parietal, temporal and occipital cortices, striatum and 
cerebellum. Diffusion tensor imaging in mice revealed alterations in brain structure in 
the neuropil and corpus callosum, which partially replicates previously published 
changes observed in human ketamine users. These changes in the corpus callosum were 
associated with an increase in the amount of neurofilament and myelin basic protein. 
These data suggest remodelling of neural circuits under repeat ketamine exposure, the 
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1.1 What is ketamine? 
 
Ketamine is a drug, more specifically an N-methyl-D-aspartate (NMDA) receptor 
antagonist. It was originally developed as an anaesthetic in the 1960’s. In developed 
countries such as the United Kingdom it is mostly used in paediatric medicine and in 
veterinary medicine (Bokor and Anderson, 2014). The reason being that when it is used 
in adults it elicits psychotropic changes in thinking and behaviour. Such changes include 
altered thinking patterns, delusional thinking, altered sensory perception, memory 
deficits, hallucinations and disrupted sleep (Malhotra et al., 1996; Morgan, Mofeez, et 
al., 2004; Morgan, Riccelli, et al., 2004; Krystal et al., 2005; Morgan, Muetzelfeldt and 
Curran, 2010; Driesen et al., 2013; Morgan et al., 2014). However, ketamine continues 
to be used as an anaesthetic in situations and parts of the world where other 
anaesthetics are not available. The reason being that ketamine preserves breathing 
reflexes, normal blood pressure and cardiac function, unlike other anaesthetics which 
require additional supporting machinery to maintain these functions within the patient 
(Wolff and Winstock, 2006; Domino, 2010). 
As mentioned, ketamine can elicit psychotropic changes in adults. In a clinical setting 
this is undesirable and has limited the use of ketamine in the western world. However, 
the psychotropic effects of ketamine have led to its wide spread use as a recreational 
drug, used by people of all ages and demographics. Recreational ketamine use is 
particularly popular amongst people in their late teens and early twenties. This is true in 
the United Kingdom, United States of America, China and South East Asia (Global Drug 
Survey, 2011; Fang, Wang, Shi, Liu, & Lu, 2006; Joe-Laidler & Hunt, 2008; Leung et al., 
2008; Lua, Lin, Tseng, Hu, & Yeh, 2003) (Daly, 2016). Recreational ketamine use is also 
widespread throughout mainland Europe (Hatton, 2015; Daly, 2016; Codrea-Racio, 
2016; Malta, 2010; Labu 2017) (Reynaud-Maurupt et al., 2007; Papaseit et al., 2014; 
Anderson et al., 2017).  
The euphoric effects of ketamine, altered sensory perceptions, altered thought, abstract 
thinking and a feeling of freedom and floating are the reasons why people use ketamine 
recreationally. Furthermore, ketamine is relatively cheap; £20-£30 pounds per gram 
(Oliver, 2017), and is readily available which is probably why it is a popular drug, 
especially amongst younger adults looking to party for cheap. 
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Unfortunately, ketamine use can lead to both temporary and persistent sub-threshold 
psychotic symptoms like those experienced by psychotic and schizophrenic patients. 
These include, but are not limited to; difficulty concentrating, depressed mood, 
disrupted sleep, anxiety, suspiciousness, withdrawal from friends and family, delusions, 
hallucinations, disorganised speech and suicidal thoughts and actions. When these 
symptoms are present in a person but not together or at a great enough severity and/or 
frequency for a clinical diagnosis of a psychiatric illness then they are said to be at a sub-
threshold level (Krystal et al., 1994, 2005; Malhotra et al., 1996; Morgan, Mofeez, et al., 
2004; Morgan, Riccelli, et al., 2004; Pomarol-Clotet et al., 2006; Morgan, Muetzelfeldt 
and Curran, 2010; Driesen et al., 2013; Morgan et al., 2014). 
Alongside psychotropic changes repeat ketamine use has been reported to cause 
changes in brain structure, function and metabolism. These changes include a reduction 
in brain volume in the grey matter of the frontal cortex, altered white matter brain 
structure underlying the frontal cortex, disrupted neuronal activity in the hippocampus 
and altered brain metabolism in the thalamus (Liao et al., 2010, 2011; Edward Roberts 
et al., 2014; Morgan et al., 2014; Stone et al., 2014). 
It may seem surprising then that ketamine over the last 10-12 years has been used as an 
“off-label” therapy against treatment resistant depression (Zarate and Singh, 2006; 
DiazGranados et al., 2010; Lapidus et al., 2014). 
 
1.2 Ketamine as a therapy against treatment resistant depression 
 
Depression is a psychiatric disorder and there are many subtypes including but not 
limited to: 
• Major depression; this is the type of depression most people immediately think 
of when they hear the term depression. This type is characterised by low mood, 
loss of pleasure and/or interest in activities, feelings of guilt and/or 
worthlessness, lack of energy and feeling tired, disrupted and lack of sleep, 
agitation, lethargy and thoughts of suicide. 
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• Bipolar depression (AKA: manic depression); this is characterised by phases of 
high energy and elation, feelings of joy, excitement and happiness and phases of 
major depression. 
• Seasonal affective disorder; this is a form of major depression which typically 
occurs during winter and when there are low natural light levels. This form of 
major depression typically recedes in the spring and summer months. 
• Psychotic depression; people with this subtype of depression experience both 
major depression and psychotic symptoms.  
Depression is typically treated through cognitive behavioural therapy or anti-depressant 
medication or a combination of both (Mind, 2016; NHS, 2016). Types of anti-depressant 
medication include: 
• Selective serotonin reuptake inhibitors (SSRIs) 
• Serotonin and noradrenaline reuptake inhibitors (SNRIs) 
• Tricyclics and tricyclic-related drugs 
• Monoamine oxidase inhibitors (MAOIs) 
Tricyclic antidepressants and MAOIs were developed in the 1950s. Tricyclics work by 
blocking the reuptake of biogenic amines (dopamine, noradrenaline and adrenaline) and 
serotonin from the synaptic cleft / extracellular space, whereas MAOIs act by blocking 
the breakdown of noradrenaline and serotonin by the enzyme monoamine oxidase 
(Feighner, 1999; Artigas, Nutt and Shelton, 2002; Taylor et al., 2005). The effectiveness 
of these drugs in treating depression led to the monoamine hypothesis of depression 
(Delgado, 2000; Hirschfeld, 2000). In a nutshell this hypothesis states that depression 
arises due to a deficiency in noradrenergic and / or serotonergic signalling within the 
brain. In turn this led to the development of more specific drugs which target the 
noradrenergic and serotonergic neurotransmitter systems. In the 1980s SSRIs were 
developed. SSRIs function by blocking the reuptake of serotonin from the synaptic 
cleft/extracellular space (Feighner, 1999; Artigas, Nutt and Shelton, 2002). SNRIs were 
then developed in the 1990s. SNRIs act similarly to SSRIs but also block the reuptake of 
noradrenaline (Lambert and Bourin, 2002). 
Although tricyclics, MAOIs, SSRIs and SNRIs are effective in alleviating the symptoms of 
depression in a lot of people, they take 3-4 weeks to work and have limited efficiency in 
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others.  Furthermore, 10-30% of people with major and bipolar depression are resistant 
to these types of drugs (Zarate and Singh, 2006; Al-Harbi, 2012; McIntyre et al., 2014; 
Ionescu, Rosenbaum and Alpert, 2015; Singh et al., 2017b). 
However, quite surprisingly, over the last 10-12 years ketamine has become a successful 
alternative to conventional antidepressant medication and has been shown to be 
effective in relieving depressive symptoms in patients who were previously resistant to 
pharmacological interventions. A single intravenous infusion of 0.5mg/kg of ketamine 
has been shown to have rapid, strong symptom relief in as little as 2 hours with effects 
lasting up to 1-2 weeks (Zarate and Singh, 2006; Coyle and Laws, 2015; Kirby, 2015; Kraus 
et al., 2017; Singh et al., 2017b). Furthermore, these effects have been shown to occur 
in at least 70% of treatment resistant patients, of which roughly 1/3 achieved symptom 
remission within 24 hours (Murrough et al., 2013; Serafini et al., 2014; Han et al., 2016). 
The rapid and strong symptom relief incudes decreased depression ratings, elevated 
mood and a reduction in suicidal thoughts (Price et al., 2014; Feifel, 2016; Vande Voort 
et al., 2016). 
 
1.3 Proposed mechanism of action of ketamine’s antidepressant affect 
 
The primary mechanism of action of ketamine’s antidepressant effect is thought to 
involve the restoration of synaptic connectivity and glutamatergic signalling (which is 
thought to be disrupted in depression) (Abdallah et al., 2014). Within depression, and 
particularly within the prefrontal cortex, synaptic connectivity is significantly reduced. 
This is expressed as a reduction in glutamate neurotransmission due to decreased 
excitatory amino acid transporter (EAAT) levels, reduced BDNF expression and release, 
and reduced mTORC1 signalling resulting in a decrease in post-synaptic AMPA receptors. 
Upon treatment with ketamine, rapid restoration of prefrontal synaptic connectivity is 
believed to result within the prefrontal cortex of the depressed brain. This is thought to 
occur as follows: Ketamine preferentially inhibits NMDA receptors on inhibitory 
GABAergic interneurons, this causes a widespread prefrontal glutamate surge which 
activates post-synaptic AMPA receptors.  Combined with ketamine’s blockade of extra 
synaptic NMDA receptors on post-synaptic neurons, BDNF release in the post-synaptic 
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neuron is increased and activates mTORC1 signalling. The increase in mTORC1 signalling 
in turn increases post-synaptic protein synthesis and AMPA cycling. This results in the 
restoration of AMPA receptors to the post-synaptic membrane and the restoration of 
glutamatergic neurotransmission to normal levels.  
For a detailed discussion of the proposed mechanisms of action of ketamine in 
depression please see the following reviews; (Duman et al., 2012; Abdallah et al., 2014; 
Abdallah, Averill and Krystal, 2015). 
 
1.4 Ketamine treatment clinics and concerns moving forward 
 
The effectiveness of ketamine in helping to alleviate symptoms in treatment-resistant 
depression has led to the establishment of specialised ketamine treatment clinics in 
both the United Kingdom (UK) and United States of America (USA). These clinics offer 
ketamine infusions to patients with depression. These infusions are administered by 
medical professionals following a psychiatric assessment of the patient and a review of 
their medical history, as well as a clinical diagnosis for depression (Oxford Health, 2017; 
Portland Ketamine Clinic, n.d.; Ketamine Health Centres, n.d.; NY Ketamine Infusions 
LLC, 2018; Ketamine Wellness Centres, 2018). Examples of such clinics include: 
• Oxford Health NHS Foundation Trust (UK) 
• Portland Ketamine Clinic (USA) 
• Ketamine Health Centres Florida and Arizona (USA) 
• NY Ketamine Infusions (USA) 
• Ketamine Wellness Centres (USA) 
Ketamine infusions provided by such clinics have had widespread success and have been 
publicised widely in the media: 
• “Ketamine can have a “truly remarkable” effect on people with depression”. 
Independent Newspaper Online (Forster, 2017). 
• “Ketamine helps patients with severe depression 'when nothing else works', 
doctors say”. Independent Newspaper Online (Forster, 2017). 
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• “In the past 20 years, I’ve not seen anything like this……. Studies have shown that 
60% to 70% of people with treatment-resistant depression respond to ketamine”. 
Time Magazine Online (Oaklander, 2017) 
• “Ketamine could help thousands with severe depression, doctors say”. The 
Guardian Online (Marsh, 2017) 
• “Ketamine depression treatment should be rolled out” (BBC News, 2017). 
However, this service comes at a price. As the ketamine treatments are given “off-label” 
(prescribed for a condition other than that for which the drug has been officially 
approved) they are not provided free of charge by the National Health Service (NHS) in 
the UK (Oxford Health, 2017), nor are they covered by medical insurance companies in 
the USA (Ketamine Advocacy Network, 2015; Ketamine Wellness Centres, 2018). It costs 
roughly £200 per ketamine infusion in the UK; following an initial £150 consultancy fee 
for a clinical psychiatric assessment (Oxford Health, 2017). Whereas in the USA, 
ketamine infusions cost between $400-$800 depending on the clinic (Portland Ketamine 
Clinic, n.d.; Ketamine Health Centres, n.d.; NY Ketamine Infusions LLC, 2018; Ketamine 
Advocacy Network, 2015; Ketamine Wellness Centres, 2018). 
With an initial proposed treatment regime of 6 infusions over 2-3 weeks this type of 
therapy can get expensive quickly; costing over £1,200 in the UK and $2400-$4800 in 
the USA (NY Ketamine Infusions LLC, 2018; Portland Ketamine Clinic, n.d.; Ketamine 
Health Centres, n.d.). There is also no guarantee that 6 infusions are enough to keep 
symptoms of depression at bay and follow up booster infusions are recommended every 
3-5 weeks (Oxford Health, 2017; Portland Ketamine Clinic, n.d.). 
It is my opinion that such high costs for specialised treatment may lead patients to seek 
cheaper and more readily available alternatives, such as “street” ketamine. At £20-£30 
per gram “street” ketamine is a far cheaper alternative compared to infusions at a clinic. 
Furthermore, “street” ketamine is readily available from your local drug dealer and this 
form of ketamine powder is arguably easier to obtain off the street than ketamine 
infusions are following appointments for psychiatric assessment, clinical diagnosis and 




An obvious concern for public health in my opinion is that if patients with depression 
choose to self-medicate with “street” ketamine they run the risk of misusing the drug; 
taking too high a dose too frequently and potentially becoming addicted to the 
psychotropic effects of the drug (Zhu et al., 2016; Sanacora et al., 2017; Wilkinson et al., 
2017; Canuso et al., 2018). Indeed, an example of this can be seen in the literature: a 
case study of a man prescribed intranasal ketamine to treat his depression found that 
he was overusing. The man was prescribed 70-150mg every 4 hours as needed but self-
reported taking higher doses up to 12 times a day. The man reported doing this as 
ketamine was the only drug that had ever helped with his depression (Schak et al., 2016). 
Furthermore, there is a paucity of studies and/or clinical trials which have investigated 
the long term effects and/or safety profile of ketamine treatment for depression 
(Melvyn W. Zhang, Harris and Ho, 2016; Zhu et al., 2016; Singh et al., 2017b). This is an 
issue which has recently been reviewed in depth by Short et al (2017). In their paper 
Short and colleagues analysed 60 clinical trial studies, including 899 study participants, 
for their assessment of the safety profile and side effects of ketamine infusions for 
treatment resistant depression. The authors highlight the following: 
• 55 (of 60) studies reported on the short-term immediate side effects of ketamine 
following infusion but fail to follow this up at later time points. The main side 
effects reported include headaches, dizziness, dissociation, increased blood 
pressure, blurred vision, nausea, drowsiness, anxiety elevated heart rate and 
difficulty concentrating (Short et al., 2017). These side effects also desist shortly 
after the infusion. 
• Only 12 (of 60) studies reported on the long-term side effects but reporting was 
ad-hoc and there was no enough data to conclude on the risks of cognitive 
impairment, drug dependency and systemic damage (e.g. urinary tract damage 
/ structural, functional and metabolic brain alterations). Furthermore, no long-
term psychotropic side effects were reported on (Short et al., 2017). 
Short et al (2017) conclude that more investigations into the long-term effects of 
ketamine infusions are required to confidently state whether this drug should be 
continued as a treatment for depression. This is a conclusion shared by many in the field 




As well as a need to better understand the long-term effects of ketamine at clinical 
doses, I would argue that we also need to better understand the effects of ketamine at 
doses evident of misuse / overuse. The reason being that, as previously mentioned, 
people may choose to self-medicate with “street” ketamine as a cheaper and more 
easily attainable substitute to ketamine infusions offered by specialist clinics. Of interest 
to me is understanding the potential impact of repeat ketamine use (at higher than 
clinical doses, >0.05mg/kg) on brain structure, function and metabolism. 
In the next section I will provide an overview of the current literature on how repeat 
ketamine use effects brain structure, function and metabolism in humans. 
 
1.5 Structural, functional and metabolic effects of ketamine on the brain 
 
Attempts to understand the structural, functional and metabolic effects of ketamine 
on the brain have been performed using structural magnetic resonance imaging 
(sMRI), functional magnetic resonance imaging (fMRI) and proton magnetic resonance 
spectroscopy (1H-MRS). 
 
a) Functional brain alterations under ketamine 
 
fMRI is a technique used to study the brain's intrinsic functional organization, i.e. how 
the brain works (Fornito, Zalesky, & Breakspear, 2015). Studies of resting state 
functional brain activity in the absence of any specific task (rs-fMRI) have shown changes 
in activity within the prefrontal cortex following a single (acute) infusion of ketamine in 
healthy individuals (Honey et al., 2004, 2008; Deakin et al., 2008; De Simoni et al., 2013; 
Doyle et al., 2013a; Driesen, McCarthy and Bhagwagar, 2013). Such changes in acute 
studies have also been shown to correlate with psychotic symptoms and cognitive 
deficits often seen in schizophrenic patients (Deakin et al., 2008; N. Driesen, McCarthy, 
& Bhagwagar, 2013; G. D. Honey et al., 2008; R. a E. Honey et al., 2004). Furthermore, 
these changes have been shown to correlate with psychotic symptoms (at a sub-
threshold level for clinical diagnosis) and cognitive deficits in  healthy volunteers and 
patients with schizophrenia   (Lahti, Holcomb, et al., 1995; Lahti, Koffel, et al., 1995; Lahti 
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et al., 1999, 2001). Another fMRI study by Stone and colleagues (2015) found that 
increased paracentral lobule activity, in healthy participants given a single ketamine 
infusion, correlated with self-reported perceptual distortions and delusions of thought. 
Whilst the effects of single ketamine infusions on brain function have been studied in 
detail (Morgan and Curran, 2006; Bokor and Anderson, 2014; Sassano-Higgins et al., 
2016; Short et al., 2018), in contrast, the effects of repeat (chronic) ketamine use on 
brain function remain mostly unexplored in humans. However, it is plausible to 
hypothesise that repeat ketamine use may continue to alter functional activity in a given 
brain region leading to prolonged psychotropic side effects.  
One report from a Chinese cohort provides preliminary evidence for the effects of 
repeat ketamine use on functional activity: Liao and colleagues (2012) examined 
functional connectivity in ketamine-dependent individuals (n=41) compared to age-
matched healthy controls (n=44). They found that functional connectivity was decreased 
in the right anterior cingulate cortex of ketamine users but increased in the left 
precentral gyrus. Increased connectivity in the left precentral gyrus also correlated 
negatively with both estimated lifetime ketamine consumption and indices of ketamine 
craving. This suggests a potential relationship between left precentral gyrus function 
and ketamine addiction (Liao et al., 2012). 
The localisation of functional changes in the anterior cingulate cortex (ACC) resonates 
with previous rs-fMRI studies in users of other psychotropic drugs such as opioids, 
nicotine and alcohol, but the direction of change is opposite in ketamine users, who 
show a decrease, rather than increase as reported for these other drugs (Ma, Tai and 
Leung, 2012). This is potentially important, in light of meta-analytical evidence 
suggesting the presence of decreased functional connectivity in the ACC in both 
individuals at ultra-high risk for psychosis and in the first episode of psychosis (Fusar-
Poli et al., 2012; Cooper et al., 2014). Speculatively, ketamine may therefore lead to 
brain dysfunction that closely recapitulates psychotic disorders when used repeatedly 
(Liao et al., 2012). Moreover, the ACC represents part of a brain network involving the 
frontal cortex that is critical for emotional aspects of behaviour, decision-making, 
response selection, and general cognition (Allman et al., 2001; Kennerley et al., 2006; 
Walton et al., 2007; Kennerley and Wallis, 2009; Shackman et al., 2011). Decreases in 
ACC functional activity may therefore be consistent with the negative impact of 
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ketamine on cognition and executive function (Moghaddam et al., 1997; Liao et al., 
2011). 
More recently, a second study by Morgan and colleagues examined repeat ketamine use 
and the impairment of spatial memory processing (Morgan et al., 2014). By comparing 
frequent ketamine users (n=11) to poly-drug control subjects (users of multiple other 
psychotropic drugs, n=15) in a virtual reality task of spatial memory they found ketamine 
users to have spatial memory deficits. fMRI data collected during the task revealed that 
spatial memory deficits in ketamine users were associated with decreased activation 
(i.e. less neural activity) in the right hippocampus and left parahippocampal gyrus during 
a navigation task. The authors also found a similar association in decreased activity in 
the left caudate nucleus during updating of spatial memory. Clinical observations further 
found that frequent ketamine users exhibited schizotypal symptoms (symptoms like 
those present in schizophrenia) and dissociation, which were correlated to lower levels 
of hippocampal activation.  
Taken together the above two repeat ketamine studies provide evidence to suggest that 
repeat ketamine use causes alterations in neural network activity and brain activation, 
particularly in the frontal lobe and in the medial temporal lobe. The location of 
functional alterations in the frontal cortex of repeat ketamine users appear to partially 
overlap with those seen in healthy individuals given a single ketamine infusion. It is 
tempting then to speculate that acute neural plasticity changes induced by ketamine 
manifest into enduring disruptions in functional brain activity upon repeated usage. In 
turn, these changes may relate to impaired cognition and schizophrenia-like symptoms 
in repeat users. 
 
b) Metabolic brain alterations under ketamine 
 
Alongside fMRI, proton magnetic resonance spectroscopy (1H-MRS) has been used to 
examine the neurochemical changes which arise through ketamine use. 1H-MRS is a non-
invasive technique used to examine the neurochemistry of the living brain. Altered 
neurochemistry of the brain can indirectly indicate altered structure and function (Gujar 
et al., 2005) 
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Three reports describe glutamate metabolite estimation with 1H-MRS following single 
ketamine administration in humans. One reported increased anterior cingulate 
glutamine (Rowland et al., 2005), one reported increased anterior cingulate glutamate 
(Stone et al., 2012), and one reported no change in anterior cingulate glutamate + 
glutamine levels (Taylor et al., 2012). None of these studies reported any change in N-
acetyl-aspartate (NAA), a commonly used marker of neural activity and/or integrity, 
following acute ketamine treatment. 
Until recently, there were no 1H-MRS studies in repeat ketamine users. However, Stone 
and colleagues (2014) recently reported 1H-MRS data from ketamine users (n=15) as 
compared to poly-drug controls (n=13). The ketamine users, although not well matched 
for amphetamine use, displayed significantly greater severity of sub-threshold psychotic 
symptoms, assessed using the Comprehensive Assessment of At-Risk Mental State 
(CAARMS) (Yung et al., 2005. Ketamine users had significantly lower levels of thalamic 
NAA (scaled to creatine), but there were no significant group-level differences in either 
NAA, glutamate or glutamine (all scaled to creatine) in either the medial temporal lobe 
or anterior cingulate cortex (Stone et al., 2014). Anterior cingulate glutamate levels were 
positively correlated to the severity of abnormal perceptions measured using CAARMS, 
although this did not survive correction for multiple comparisons (Stone et al., 2014).  
These data are broadly in line with 1H-MRS findings in patients with schizophrenia. 
Recent meta-analyses suggest schizophrenia is associated with both psychotic state and 
age-dependent decreases in NAA (Brugger et al., 2011), and glutamate (Marsman et al., 
2013). Specifically, reductions in NAA have been reported in the thalamus of individuals 
at high clinical or genetic risk of psychosis, leading to more widespread reductions in 
patients with chronic schizophrenia, including the frontal cortex (Steen, Hamer and 
Lieberman, 2005; Brugger et al., 2011). Reports of changes in glutamate are more 
variable, but there is evidence to support age-related decreases in the frontal cortex, 
that may be more pronounced in chronic schizophrenia patients. In contrast, 1H-MRS 
studies in individuals at high clinical or genetic risk for schizophrenia, or patients in their 
first episode of psychosis have suggested higher levels of glutamate, particularly in the 
medial prefrontal cortex (Bartha et al., 1997; Théberge et al., 2004; Stone et al., 2009; 
Marsman et al., 2013); although some studies found no difference (Wood et al., 2007; 
Yoo et al., 2009). 
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How these neurochemical data relate to the effects of ketamine remains unclear, but it 
is interesting to note that 1H-MRS studies have generally reported decreases in either 
NAA or glutamate in those individuals dependent on alcohol (Jagannathan, Desai and 
Raghunathan, 1996; Parks et al., 2002), opiates (Haselhorst et al., 2002; Yücel et al., 
2007) and methamphetamine (Ernst et al., 2000; Biswal et al., 2010; Howells et al., 
2014). 
 
c) Structural brain alterations under ketamine 
 
Like functional and metabolic changes described in fMRI and 1H-MRS studies, little is 
known about any structural changes to the brain which might arise through repeat 
ketamine use. To my knowledge only four such studies exist in the literature: 
In the same Chinese cohort in whom the fMRI analyses were conducted, Liao and 
colleagues (2011) reported voxel-based morphometry (VBM) (John Ashburner and 
Friston, 2000; Giuliani et al., 2005) analysis of the brain of ketamine-dependent users 
(n=41) versus age-matched healthy controls (n=44). VBM is a method for analysing 
differences in brain volume between two distinct groups, as measured using MRI (John 
Ashburner and Friston, 2000). As with the fMRI dataset, subjects were excluded if they 
met criteria for dependence on other substances, but not nicotine dependence (Liao et 
al., 2011). Subjects were required to abstain from ketamine for at least 48 hours and 
nicotine for at least 12 hours before scanning and from other psychoactive substances 
for at least 2 weeks. Ketamine-dependent subjects displayed significant (p<0.05 Family 
Wise Error rate corrected) clusters (minimum voxel size = 100) of reduced grey matter 
volume in the left superior frontal cortex and right middle frontal cortex, as compared 
to controls. These apparent reductions in grey matter volume in both frontal cortex 
regions were negatively correlated with the duration of ketamine use, and the reduction 
in left superior frontal gyrus volume was negatively correlated with estimated total 
lifetime ketamine consumption (Liao et al., 2011). These structural changes appear to 
be consistent, at least in the direction of change, with observations reported from 
studies of brain morphometry in heroin and cocaine dependent-users (Lim et al., 2008; 
Liu et al., 2009), but strikingly, also in those with nicotine (Li et al., 2015) and/or alcohol 
dependence (Grodin et al., 2013). Notably, ketamine-dependent users were significantly 
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impaired in tests of executive function, but no explicit correlations were made between 
these data and the results of the VBM analysis (Liao et al., 2011). Nevertheless, these 
data suggest that the functional abnormalities that occur in the frontal cortex of repeat 
ketamine users are accompanied by structural alterations, which may be related to 
cognitive impairments in these individuals. 
In a second, independent Chinese cohort of ketamine addicts (n=21) compared to a very 
small number of healthy controls (n=3), Wang and colleagues (2013) reported on           
signs of cortical atrophy and hyperintense lesions in numerous brain regions, including 
the cortex, superficial white matter, striatum and brainstem (Wang et al., 2013). The 
density and size of these lesions increased in proportion to the amount of (self-reported) 
ketamine consumption and duration of ketamine use, although no statistical 
correlations were performed and the assessment of lesions was entirely qualitative 
(Wang et al., 2013). 
In addition to the Wang et al (2013) study, white matter changes in repeat ketamine 
users have been observed in diffusion tensor imaging (DTI) studies.  
DTI is a non-invasive MRI technique used to quantify structural changes in white (and 
grey) matter structure. This is based on changes to water diffusion in neural tissue (Le 
Bihan et al., 2001). DTI is based on the assumption that water molecules preferentially 
diffuse along axonal fibre bundles as opposed to across them (i.e. the path of least 
residence) (Mori and Zhang, 2006; Walhovd, Johansen-Berg and Karadottir, 2014). The 
diffusion of tissue water in a given neural tissue voxel is comprised primarily of axial 
diffusion (AD), which runs parallel to the axonal fibres. Secondary and tertiary diffusion 
run orthogonally to axonal fibres and are averaged together to calculate radial diffusivity 
(RD). These diffusivity measurements (axial diffusivity and radial diffusivity) can be 
combined and averaged to give a value of mean diffusivity (MD) or fractional anisotropy 
(FA). Values of FA range from 0 (isotropic); water molecules have the same likelihood to 
diffuse in all directions, to 1 (anisotropic); water molecules tend to diffuse in a single 
direction. 
In MRI voxels of the brain containing densely myelinated axon fibres, such as the corpus 
callosum and anterior commissure FA values are very close to 1 and axial diffusivity is 
high, suggesting that water preferentially diffuses along these fibres as opposed to 
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across the fibres. It is thought that disruption to myelination or damage to axons will 
allow water molecules to move freely in more directions (closer to anisotropic diffusion), 
resulting in lower axial diffusion and decreased FA (Concha, 2014). There is also some 
evidence to suggest that radial diffusivity may be related to the degree of myelination, 
whereas axial diffusivity may be more closely related to the level of axonal density (Song 
et al., 2003, 2005). Therefore, by examining radial and axial components separately, this 
may provide more detailed information about the structural basis for any differences 
observed. 
In repeat ketamine users white matter structural alterations have been observed by Liao 
and colleagues (2010), this is in the same cohort of repeat ketamine users (n=41) from 
which fMRI and VBM abnormalities were previously reported (Liao et al., 2011, 2012). 
In the DTI study, voxel-wise analysis of the white matter revealed bilateral reductions in 
FA in the frontal and left temporoparietal cortices, as compared to control subjects, 
suggesting altered brain structure in these regions (Liao et al., 2010). Furthermore, 
frontal cortex white matter FA values were negatively correlated with the severity of 
ketamine use (measured by estimated total ketamine consumption). However, there 
were no significant correlations between FA values and the age of onset of ketamine 
use, perhaps suggesting that the white matter changes reflect cumulative use (Liao et 
al., 2010). 
 As with the fMRI and VBM findings, these white matter alterations following repeat 
ketamine use parallel similar observations in other forms of repeat drug use (Goldstein 
and Volkow, 2002): Bilateral frontal cortex white matter FA alterations have been 
reported in alcoholics (Pfefferbaum et al., 2009) as well as amphetamine (Thompson, 
2004), methamphetamine (Alicata et al., 2009), cannabis (Arnone et al., 2008), heroin 
(Liu et al., 2008) and nicotine dependent individuals (Wang et al., 2009). These white 
matter changes overlap remarkably with reports of white matter changes in the frontal 
lobe of individuals at high-risk of psychosis and who subsequently transitioned to 
psychosis (Muñoz Maniega et al., 2008; Bloemen et al., 2010), in first episode psychosis 
patients prior to antipsychotic medication (Cheung et al., 2008; Reis Marques et al., 
2014) and in chronic patients receiving antipsychotic medication (Pomarol-Clotet et al., 
2010). However, there were no significant correlations between lower FA values and 
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ketamine-associated symptoms (hallucinations, dissociation, sleep disturbances or 
schizophrenia-like symptoms) in the repeat ketamine users (Liao et al., 2010). 
Therefore, whilst these findings suggest that ketamine use is clearly associated with 
alterations in white matter structure, they do not support a relationship with psychotic 
or schizophrenia-like symptoms.  
A second DTI study by Roberts and colleagues (2014) compared repeat ketamine users 
(n=16) and poly-drug controls (n=16). They found significant clusters of altered white 
matter structure (reduced axial diffusivity) in the frontal, parietal and somatosensory 
cortices. No differences in radial diffusivity were reported and the decreases in axial 
diffusivity were not significantly correlated to any measure of ketamine use or 
consumption (Edward Roberts et al., 2014). However, there was a significant positive 
correlation between dissociative symptoms in ketamine users and caudate–prefrontal 
cortex connectivity in the right hemisphere. These data partially concur with the findings 
of Liao and colleagues (2010) and show that the white matter underlying the frontal 




1.6 Limitations of human neuroimaging studies in repeat ketamine users 
 
Taken together, although the number of studies is sparse, the results of fMRI, sMRI and 
1H-MRS studies converge to suggest that repeat ketamine use leads to distinct 
alterations in brain structure and function. Specifically in the frontal lobe, repeat 
ketamine use leads to perturbations in brain function (Liao et al., 2012) which are 
accompanied by decreases in grey matter volume (Liao et al., 2011; Wang et al., 2013) 
and alterations in white matter structure (Liao et al., 2010; Edward Roberts et al., 2014). 
However, one should perhaps be cautious in making too many conclusions since there 
have been very few neuroimaging studies of repeat ketamine users; three of which 
come from one cohort (Liao et al., 2010, 2011, 2012). As such, they all suffer from several 
limitations.  
Ketamine users, across the available studies tend to take a variety of other psychotropic 
drugs. In the studies of Liao and colleagues (Liao et al., 2010, 2011, 2012) ketamine-
dependent individuals were not compared to poly-drug user controls, moreover, 
nicotine-dependent subjects were not excluded and there were differences in the levels 
of education between the ketamine users and the controls. The study by Wang and 
colleagues (2013) did not robustly control for these variables and had a very small 
control group for comparison (n=3). Subsequent studies have improved on this design 
by comparing ketamine users to poly-drug user controls, which are well matched for 
levels of education (Edward Roberts et al., 2014; Morgan et al., 2014; Stone et al., 2014). 
However, it is extremely difficult to find individuals that have exclusively used more 
ketamine, as compared to other drugs. For example, in the sample analysed using 1H-
MRS by Stone and colleagues (2014), ketamine users were not well matched for 
amphetamine use. This difficulty in finding suitable subjects is reflected in the smaller 
sample sizes reported in these studies, which may potentially reduce statistical power 
to detect subtle effects.  
Importantly, as discussed earlier, many of the other drugs used by ketamine users have 
been shown to impact on brain structure and function in similar ways to ketamine. 
Furthermore, drugs such as nicotine and alcohol have been shown to impact on the 
effects that other drugs have on the brain. For example, a recent study of cannabis users 
provides clear evidence that when cannabis users are compared to controls, there is a 
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distinct influence of co-morbid alcohol use on the directionality and effect size of the 
structural MRI results (Weiland et al., 2015). In addition, across the available repeat 
ketamine studies there is considerable variance in the frequency of use and the amount 
of ketamine consumed. Whilst some studies find evidence for correlations between 
brain structural and functional alterations and lifetime ketamine consumption (Liao et 
al., 2010, 2011, 2012), others do not (Edward Roberts et al., 2014; James M Stone et al., 
2014). Lastly, these studies cannot definitively rule out that the neuroimaging 
abnormalities observed in ketamine users do not represent pre-existing differences 
related to genetic or other environmental factors, as has recently been suggested for 
cannabis use (French et al., 2015; Pagliaccio et al., 2015). Together, these caveats render 
it extremely difficult to precisely infer the effects of ketamine alone in these individuals.  
One potential approach to address these limitations is to apply the same neuroimaging 
methods to rodents, where the timing, dose and duration of ketamine administration, 
as well as the background genetics and housing environment may be strictly controlled. 
This translational approach has several advantages (Finlay, Duty and Vernon, 2014). 
First, the effects of ketamine may be precisely modelled and studied using comparable 
methods in the absence of additional variables that are associated with human studies 
(e.g. other drug use). Second and perhaps more importantly, because rodent models 
permit invasive post-mortem investigations at the cellular and molecular level, the 
biological correlates of MRI signals altered by ketamine exposure may be investigated 
to reveal the underlying mechanisms. The power of this approach is exemplified by 
studies linking the effects of antipsychotic drugs on brain imaging to neuropathological 
changes at the cellular level, as well as the effects of therapeutic interventions in disease 




1.7 Alterations in neuronal structure and function following repeat ketamine 
exposure in rodents 
 
The idea to examine the pathophysiology of repeat ketamine exposure in rodent models 
is not a new one and there already exists a wealth of literature upon this topic. However, 
there are two important limitations which apply to these data. First, very few studies 
have employed a translational approach to link neuroimaging signals to 
neuropathological changes, although there are notable exceptions (Kim et al., 2012; 
Schobel, Chaudhury and Khan, 2013). Second, the majority of rodent studies on 
ketamine, including those using MRI, have focussed principally on neuronal elements at 
the expense of other central nervous system (CNS) components, including astrocytes, 
oligodendrocytes, myelin, microglia and the vasculature, all of which may contribute to 
MRI-detectable alterations in either brain structure or function (Zatorre, Fields and 
Johansen-Berg, 2012; Finlay, Duty and Vernon, 2014). Nevertheless, these pre-existing 
studies have revealed important observations that are worth brief discussion. 
A consistent finding from rodent studies following both single and repeat ketamine 
administration is a marked reduction in parvalbumin (a calcium binding protein) 
expression within γ-aminobutyric acid (GABA) interneurons of the prefrontal cortex and 
hippocampus (Keilhoff et al., 2004; Behrens et al., 2007; Zhang, Behrens and Lisman, 
2008; Kittelberger et al., 2012; Schobel, Chaudhury and Khan, 2013). Moreover, 
ketamine acting as an NMDA receptor antagonist, has been shown to preferentially 
inhibit parvalbumin positive interneurons in the prefrontal cortex (Quirk et al., 2009) as 
well as reduce GAD67 levels (an isoform of glutamic acid decarboxylase, the rate limiting 
enzyme in GABA synthesis) within these cells. Unsurprisingly, these structural 
alterations to GABAergic interneurons are accompanied by parallel functional changes 
in hippocampal and cortical networks, probed using electroencephalography (EEG) and 
other electrophysiological methods (Zhang, Behrens and Lisman, 2008; Featherstone et 
al., 2012, 2014; Kittelberger et al., 2012; Hinman et al., 2013). An example of this is 
decreased theta power in the hippocampus, which coincides with impairments in 
episodic memory encoding (Hinman et al., 2013) and behavioural extinction learning 




In addition to EEG and electrophysiological changes in the hippocampus, Schobel et al 
(2013) utilised fMRI to show that repeat intermittent ketamine administration in mice 
leads to increased functional activity in the hippocampus. In this study these fMRI 
changes predated atrophy of the hippocampus, as seen by sMRI and were brought about 
by ketamine induced increases in extracellular glutamate (Schobel, Chaudhury and 
Khan, 2013). Schobel et al (2013) also measured functional activity and atrophy of the 
hippocampus in a longitudinal study of individuals at high risk for psychosis; some of 
whom subsequently transitioned to psychosis during the follow up phase of the study. 
Interestingly, those individuals who went on to develop psychosis presented with the 
highest hippocampal activation. Again, these functional changes predated structural 
changes in hippocampal atrophy, as seen by structural MRI. It would appear then that 
structural and functional alterations, brought about by repeat ketamine administration 
in mice, may model some of the changes which occur in human subjects who go on to 
develop psychosis and suggest glutamate as a pathological driver of psychosis.  
As discussed in preceding sections, 1H-MRS studies in patients in their first episode of 
psychosis have also suggested higher levels of glutamate in the medial prefrontal cortex 
(Bartha et al., 1997; Théberge et al., 2004; Tibbo et al., 2004; Stone et al., 2009; 
Marsman et al., 2013). Single ketamine infusions in healthy volunteers have shown 
increases in glutamate and glutamine levels in the prefrontal cortex (Rowland et al., 
2005; Stone et al., 2012), although no studies have reported similar findings in human 
repeat ketamine users. There is evidence, however, for increased glutamate levels in the 
prefrontal cortex of rats (Kim et al., 2011a). In the study by Kim et al (2011), in-vivo 1H-
MRS and ex-vivo 1H high-resolution magic angle spinning (HR-MAS) spectroscopy were 
used to assess glutamate levels in the medial prefrontal cortex of rats repeatedly 
administered ketamine. Both 1H-MRS and HR-MAS spectroscopy demonstrated an 
increase in glutamate levels in the prefrontal cortex of ketamine administered rats. 
Furthermore, ex-vivo high resolution mass spectroscopy revealed a decrease in the ratio 
of glutamate: glutamine, which may suggest altered glutamate-glutamine cycling 
between neurons and astrocytes (Kim et al., 2011a), something which has not been 
pursued further. 
Taken together then, the functional changes in the brain that occur under repeat 
ketamine administration, appear to be initiated by local increases in extracellular 
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glutamate levels which may stem from changes to GABAergic interneurons and a 
suppressed inhibitory neurotransmitter system. Indeed, evidence from acute ketamine 
studies demonstrates that reductions in parvalbumin and GAD67 expression, in the 
prefrontal cortex and hippocampus, are related to reductions in miniature post-synaptic 
current (mIPSC) amplitude and frequency in layer 5 projection neurons, as well as 
increased extracellular glutamate levels (Zhang, Behrens and Lisman, 2008; Wang et al., 
2014). Furthermore, these changes reflect a model of glutamate disinhibition brought 
about by dysfunctional GABAergic interneurons. This model suggests that the 
preferential inhibition of GABAergic interneurons in the cortex and hippocampus leads 
to disinhibition of glutamatergic projection neurons and subsequently impaired 
regulation of the activity of these projection neurons (Anticevic et al., 2013; Frohlich and 
Van Horn, 2014; Heckers and Konradi, 2014). 
Whilst these are important findings, there remains a relative paucity of published data 
on cellular changes that may occur to glial cells and/or myelin because of repeat 
ketamine administration. This is somewhat surprising given the significantly higher 
proportions of glia to neurons in the CNS and the critical role these cells play in plasticity, 
regulating neural transmission and monitoring the neuropil (Eroglu and Barres, 2010; 
Eyo and Dailey, 2013; Pajevic, Basser and Fields, 2014; Wang and Young, 2014; Chung, 
Allen and Eroglu, 2015; Gundersen, Storm-Mathisen and Bergersen, 2015; Khakh and 
Sofroniew, 2015; Wu et al., 2015). Moreover, this represents a significant gap in our 
knowledge of the cellular effects of ketamine that contribute to alterations in brain 
structure and function following repeat use. In the following sections I shall discuss the 
importance of glia and myelin in the CNS and speculate on how they may be impacted 





1.8 The importance of myelin and oligodendrocyte integrity 
 
Myelin is a membranous sheath consisting of various lipids and proteins (Schmitt, 
Cantuti Castelvetri and Simons, 2014), which wraps around axons in a spiral-like fashion, 
and alongside oligodendrocytes, fibrous astrocytes and microglia, forms the white 
matter. Axons are myelinated by several oligodendrocytes which each myelinate a small 
stretch of the axon. Each myelinated portion of the axon is known as an internode and 
the gap between myelinated regions a node of Ranvier.  Not all neurons in the brain 
have myelinated axons, for example only 28% of axons in the mouse corpus callosum 
are myelinated (Sturrock) compared to 98.8% in the optic nerve (Honjin, Sakato and 
Yamashita, 1977). Similarly, the degree of myelination along axons differs between 
neurons in a particular region (Tomassy et al., 2014). The dense lipid nature of myelin 
causes it to act as a barrier against the diffusion of ions, which may only diffuse across 
the axonal membrane at nodes of Ranvier. This means that during action potential (AP) 
propagation along the axon, ions carry the AP further down the axon before diffusing 
across the membrane. This phenomenon is known as saltatory conduction and 
facilitates rapid, energy efficient, conduction along the axon (Harris and Attwell, 2012).  
Myelination, the elaboration of myelin surrounding neuronal axons, is essential for 
normal brain function. The development of the myelin sheath enables rapid 
synchronized communication between the neural systems responsible for higher order 
cognitive functioning. The importance of this is highlighted in thalamocortical neurons, 
which relay sensory signals from the thalamus to different cortical areas. Different 
cortical areas are different distances away from the thalamus, thus signals arising from 
thalamocortical neurons tend to travel over different distances on their way to the 
cortex. As these signals enter the cortex, they tend to travel similar distances to their 
target. However, signals arriving in different cortical areas do so within a narrow time 
window of each other, roughly 2ms. This is possibly due to greater myelination of axons 
in the thalamus and in white matter tracts leading to cortex than within the cortex itself. 
Such regional myelination facilitates rapid conduction of action potentials along longer 
axons, which travel greater distances to their cortical terminus. This selective 
myelination of longer axons allows for synchronous information processing across the 
thalamocortical network (Salami et al., 2003). 
38 
 
Any disruption to myelin integrity would therefore be predicted to radically alter the 
synchronicity of neural networks. This prediction is confirmed by the findings of Kim et 
al (Kim, Renden and von Gersdorff, 2013) at the calyx of held synapse, in the ascending 
auditory pathway. Here the exact timing of incoming signals is crucial for computing 
sound source localisation. In a genetically altered rat model that lacks compacted 
myelin, there are inconsistencies in the reliability of action potentials arriving at the 
synapse at specific times. Thus, disruption to myelination would lead to alterations in 
signalling within neural networks. A similar example can be seen in the olivary nuclei (of 
the medulla) and Purkinje cells (of the cerebellum). In these pathways synchronous 
activity is important for coordinating the timing of voluntary movement. Lang and 
Rosenbluth (2003) found that disrupted myelination in this neural network decreased 
the conduction velocity of signals from the olivary nuclei and led to desynchronous 
activity across the network (Lang and Rosenbluth, 2003). Hence, correct myelination is 
important for the synchronous activity of neurons within neural networks (Vicente et 
al., 2008; Pajevic, Basser and Fields, 2014). 
Damage to white matter and myelin integrity and subsequent disruptions to neural 
network activity is highly likely then to have adverse functional consequences on 
behaviour. Indeed, impaired white matter and myelin integrity has shown to be present 
in schizophrenia, bipolar depression, major depression and neurodegenerative 
disorders such as multiple sclerosis and Alzheimer disease (Fields, 2008; Nave, 2010; Yu 
et al., 2012; Mighdoll et al., 2014). More specifically, DTI studies in both schizophrenic 
and psychosis patients have shown that decreased FA values and increased diffusivity 
within white matter tracts of the frontal and parietal lobes are correlated with psychosis 
(Garver, Holcomb and Christensen, 2008) and negative symptom severity (Peters et al., 
2013). Furthermore, reduced FA values in psychotic patients not only correlate with the 
severity of negative symptoms, but also with a decrease in plasma levels of 
polyunsaturated fatty acids (Peters et al., 2013). As polyunsaturated fatty acids are 
necessary for myelin formation this would suggest a correlation between myelin 
impairment and negative symptom severity. Furthermore, reductions in FA values 
across the brain have been linked to cognitive impairments in traumatic brain injury, 
multiple sclerosis, ischemia and stroke (Kraus et al., 2007; Sigal et al., 2012; Sierra, 2014). 
Alongside neuroimaging data, myelin and oligodendrocyte deficits have been reported 
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from post-mortem brain samples from schizophrenia and depressed patients (Hof et al., 
2003; Uranova et al., 2004; Byne et al., 2006; Regenold et al., 2007; Parlapani et al., 
2009; Takahashi et al., 2011). Similarly, altered myelin and oligodendrocyte integrity has 
been linked to impairments in spatial working memory, recognition, social interaction 
and anxiety in rodents (Makinodan et al., 2009, 2012; Tanaka et al., 2009; Xu et al., 2009; 
Liu et al., 2012; Blasi et al., 2014). Clearly then, correct myelination is vital for functional 
brain activity and alterations to myelin structure can lead to cognitive and/or emotional 
changes. 
As discussed in previous sections, repeat ketamine use has been shown to alter white 
matter structure in the frontal lobe (Liao et al., 2010; Edward Roberts et al., 2014). One 
might speculate then, that this is the result of altered myelin structure and this 
alteration might contribute to cognitive and behavioural changes. However, altered 
myelin structure is just one of many possible cellular correlates of changing values in DTI 
parameters such as FA and AD. Other potential cellular correlates include changes in 
axonal size, density, and membrane structure; lipid, protein, and macromolecule 
content; and water compartmentalization or a combination of these events (Deoni et 
al., 2008; Almeida and Lyons, 2017; Stolp et al., 2018). Consequently, in the absence of 
post-mortem findings, the observed DTI signal changes in repeat ketamine users are 
ambiguous, hindering meaningful inferences between imaging findings, cellular 
correlates and changes to cognition and behaviour. 
To the best of my knowledge, there are no published animal studies which have 
investigated specifically the effects of ketamine administration on oligodendrocytes and 
myelin. There are, however, five studies which have investigated the effects of repeat 
administration of more potent NMDA receptor antagonists on oligodendrocytes and 
myelin, which provide useful generalisations. Two of these studies investigated the 
neurodevelopmental effects of early phencyclidine (PCP) administration on white 
matter integrity (Lindahl et al., 2008; R. Zhang et al., 2012). Whereas the other three 
studies investigated the effect of chronic dizocilpine (MK-801) administration on white 




PCP and MK-801, like ketamine, are NMDA-receptor antagonists which act in the same 
manner to antagonize these receptors (Morris, Cochran and Pratt, 2005; Lim, Taylor and 
Malone, 2012; Blot, Bai and Otani, 2013; Steeds, Carhart-Harris and Stone, 2014). All 
three antagonists bind within the ion channel pore of the NMDA receptor and ultimately 
prevent the flow of ions across the receptor (Foster and Fagg, 1987). MK-801 has greater 
affinity for the NMDA receptor than PCP, which in turn is more potent than ketamine 
(Daniell, 1990). 
The first PCP study conducted by Lindahl et al (2008) investigated the effects of daily 
intraperitoneal (IP) administration of 10mg/kg PCP in pregnant rats, starting from 
conception to embryonic day 20, relative to measurements in control mice whose 
mothers received daily injections of saline during pregnancy. Using a combination of 
western blotting and thresholding analysis of immunostained tissue sections, the 
authors found a reduction in NG2 positive oligodendrocyte precursor cells (OPCs) at 
post-natal day 2 (P2). At later stages; P16, P22 and P60, CNPase expression was also 
reduced. At all these stages the expression of myelin basic protein (MBP) was also 
reduced. As both markers of OPCs (NG2) and mature myelinating oligodendrocytes were 
reduced, but CNPase expression was increased, these results would suggest that 
exposure to PCP during embryonic development may delay oligodendrocyte maturation 
and subsequently lead to reduced levels of myelination at a given postnatal stage.  
A second neonatal PCP study by Zhang et al (2012), also found reductions in the level of 
MBP as confirmed by western blot analysis and optical density measurements of MBP-
stained tissue sections. These reductions were seen at P16, P22 and P32 in rats exposed 
to daily injections of PCP (10mg/kg; i.p.) during P2 to P14. Again, such results would 
suggest that early exposure to PCP leads to a maturational delay in oligodendrocyte 
development and myelination. The findings from these two studies are broadly 
consistent with the DTI findings from chronic ketamine users reported by Roberts et al 
(2014) and Liao et al (2010); in that administration of a non-competitive NMDA receptor 
leads to frontal white matter alteration. 
In a study by Wu and colleagues (2016), MK-801 (0.2mg/kg) was systemically 
administered to adult mice for 14 consecutive days. Using DTI the authors found a 
significant impairments in the white matter of the corpus callosum (Wu et al., 2016). 
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In an earlier study, Xiu et al (2014) administered MK-801 (1mg/kg) systemically to adult 
mice for 14 consecutive days and observed a reduction in the volume of the total white 
matter across the entire cerebrum, as measured by post-mortem stereology. Focussing 
on the corpus callosum, a significant decrease in white matter volume, MBP and CNPase 
expression and disrupted myelin architecture were all reported in these MK-801 treated 
mice. In a follow up study Xiu et al (2015) found that the myelinated fibres of the corpus 
callosum, of mice treated with MK-801, were impaired with splitting lamellae of myelin 
sheaths and segmental demyelination. Furthermore, the total length of the myelinated 
fibres in the corpus callosum significantly decreased when compared to those of the 
mice treated with saline (Xiu et al., 2015). 
Given that NMDA receptor antagonism induces changes in both myelination and 
expression of various cell markers across the oligodendrocyte lineage it is feasible to 
hypothesize that similar cellular changes may occur under repeat ketamine 
administration. If so, understanding such cellular changes will allow better 
interpretation of white matter perturbations seen in repeat ketamine users (Liao et al., 
2010; Edward Roberts et al., 2014). In this context, pre-clinical studies directly linking 
neuroimaging findings to post-mortem histology have great potential. 
 
1.9 Ketamine induced excitotoxicity and potential myelin damage? 
 
If repeat ketamine administration does induce similar cellular changes in the white 
matter, as have been seen for PCP and MK-801, then the next logical question is what 
might be the mechanism responsible for such changes and how are myelination and/or 
oligodendrocyte lineage cells affected by ketamine. One potential mechanism might be 
glutamate excitotoxicity. 
Like most cells containing surface NMDA receptors, oligodendrocytes and their 
progenitors are susceptible to excitotoxic damage (Matute, 2006). In vitro work has 
shown that excitotoxic levels of kainite, α-amino-3-hydroxy-5-methyl-4-
isoxazolepropionic acid (AMPA) and glutamate cause reductions in the number of 
mature oligodendrocytes (Mcdonald, Althomsons and Hyrc, 1998; McDonald, Levine 
and Qu, 1998). Glutamatergic excitotoxicity in the optic nerve can trigger the 
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degradation of oligodendrocyte myelinating processes (Káradóttir et al., 2005). 
Furthermore, glutamatergic excitotoxicity has been shown to cause the loss of myelin at 
paranodes, the initial region of myelination next to the node. This results in an increase 
in nodal length and exposes repolarizing kv1.2 channels to the neuropil. Together these 
changes contribute to a ‘leakier’ membrane along axons resulting in an action potential 
of lower amplitude and faster refractory period (Fu et al., 2009). Taken together, it is 
clear how this pathological cascade, driven by excess glutamate would lead to myelin 
damage, impaired neuronal synchrony within networks and aberrant behaviour. 
In support of a role for glutamate in NMDA antagonist mediated demyelination, 
ketamine administration is known to lead to an increase in prefrontal cortex glutamate 
levels in both humans (Stone, Dietrich and Edden, 2012; Wang et al., 2014) and rodents 
(Kim et al., 2011b; Wang et al., 2014). It is therefore conceivable that glutamate spill 
over may occur at synapses (Danbolt, 2001). Excess glutamate may then bind to NMDA 
receptors expressed on oligodendrocytes and cause excitotoxic damage. Over time and 
with repeat ketamine use, this may lead to oligodendrocyte cell death and damage to 
myelin. Such changes in turn may alter neural network activity and subsequently lead to 
deficits in cognition and/or to the emergence of psychosis, delusions and memory 
impairments as seen in repeat ketamine users. 
Evidence of possible NMDA receptor antagonist induced excitotoxicity can be seen in 
the study of Olney et al (1989). In this study the authors tested a variety of NMDA 
receptor antagonists (including MK-801, PCP and ketamine) for signs of neuronal 
pathology upon repeat administration. The authors found that a dose of 40mg/kg of 
ketamine induced vacuole formation in cortical projection neurons resident in layers III 
and IV of the cingulate cortex of Sprague Dawley rats (indicative of pathology). However, 
such indicators of pathology were not present with lower doses of ketamine (5mg/kg, 





1.10 Ketamine-induced disruption of astrocytes function and disrupted neural 
network activity 
 
Astrocytes, which exist in both the grey and white matter of the brain, regulate neuronal 
network activity through neurotransmitter uptake, metabolism and volume 
transmission (McKenna, 2007; Albrecht et al., 2010; Domingues, Taylor and Fern, 2010; 
Pascual et al., 2012). Yet surprisingly I could only find one study which examined the role 
of astrocyte pathophysiology following repeat exposure to ketamine. In this study, 
Featherstone et al (2012), administered daily injections of 20mg/kg ketamine to mice 
for 14 days. Six months later, the authors found a persistent alteration in hippocampal 
theta activity which correlated with an increase in the number of glial-fibrillary acidic 
protein (GFAP) positive astrocytes in this area as well as a 50% decrease in the number 
of excitatory amino acid transporter 2 (EAAT2) positive cells. EAAT2 is predominately 
found in astrocytes throughout the brain, where it is responsible for 95% of glutamate 
uptake from the synapse (Danbolt, 2001; Huang and Bergles, 2004; Zhou and Danbolt, 
2013, 2014). Given the fact that there is no extracellular degradation of glutamate in the 
brain (Danbolt, 2001; Zhou and Danbolt, 2014), I think that it is feasible to suggest that 
a reduction in EAAT2 expression in mice, given repeat ketamine, may contribute to 
increased extracellular glutamate levels in the hippocampus. This in turn would likely 
contribute to altered neural network oscillations and subsequent cognitive deficits in 
this brain region. Furthermore, as mentioned earlier, repeat ketamine administration 
also increases the level of extracellular glutamate in the prefrontal cortex (Zhang, 
Behrens and Lisman, 2008; Wang et al., 2014). Hence, a similar scenario may occur in 
the prefrontal cortex; whereby astrocyte EAAT2 expression is decreased and glutamate 
uptake is impaired leading to increased extracellular glutamate and disrupted neural 
network oscillations that lead to cognitive deficits.  
Regarding  astrocyte modulation of neurotransmitter levels, it has recently been shown 
that astrocytes may modulate hippocampal tonic inhibition by releasing GABA via 
reverse transport (Héja et al., 2009, 2012): Under enhanced network activity glutamate 
uptake by astrocytes appears to be coupled to the reversal of GABA transporters (GAT) 
-2/3, which in turn leads to GABA release through GAT and increased tonic inhibition. 
Moreover, recent findings from the Alzheimer disease field have shown that reactive 
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GFAP positive astrocytes may respond to hyperactivity within a neuronal network by up-
regulating the synthesis and release of GABA (Jo et al., 2014; Wu et al., 2014). This 
increased release of GABA from astrocytes further exacerbated excitatory versus 
inhibitory imbalances present in the hippocampus, which in turn was associated with 
cognitive memory impairments. Alongside GABA release, astrocytes may also release 
glutamate which can aid synchronize neural activity in the hippocampus (Angulo et al., 
2004; Fellin et al., 2004; Volterra and Meldolesi, 2005). 
GABAergic disinhibition and excitatory versus inhibitory activity imbalances exist in 
rodent models of repeat ketamine administration. Hence, astroglia neurotransmission 
and its effects on neural network oscillations may be another line of enquiry worth 
investigating to further understand the cellular effects of repeat ketamine 
administration on the brain. 
In summary, due to the key role astrocytes play in the control of extracellular 
neurotransmitter levels, via reuptake and release, and in turn the regulation of neural 
network oscillations, it is important to investigate these cell types more systematically 
in models of repeat ketamine administration to understand better what is driving 




As far as I am aware only one paper, so far, has looked at microglia in a repeat model of 
ketamine administration (Hou et al., 2013). In this model mice were administered 
100mg/kg of ketamine once daily for seven days and the microglia population in the 
prefrontal cortex was investigated histologically. Here the authors found no change in 
the number of Iba-1 positive microglia in the prefrontal cortex. However, the authors 
did not use a stringent unbiased stereological method to investigate differences in 
microglia number (Cotel et al., 2015). Furthermore, they did not differentiate between 
resting and activated microglia, which serve different functions in the brain (Benarroch, 
2013). Iba-1 is a good histological marker for identifying microglia; however, Iba-1 
antibodies will bind to and illuminate both resting and active microglia (Laskaris et al., 
2015). If the researchers did not differentiate between these subtypes of microglia by 
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morphology and counted all the Iba-1 positive microglia they may have missed subtle 
changes in the ratio of resting: activated microglia. Such a scenario is evident in a PCP 
study conducted by Zhu et al (2014). In this study mice were administered 20mg/kg of 
PCP once daily for 14 days and changes to the number of microglia investigated in both 
the hippocampus and prefrontal cortex (Zhu et al., 2014). The authors found no 
difference in the number of microglia in either the hippocampus or prefrontal cortex by 
stereological assessment (optical fractionator) of Iba-1 positive cells. However, they did 
find a significant increase in the number of CD11b positive reactive microglia in the 
prefrontal cortex. Hence, by investigating subtypes of microglia the authors were able 
to find a distinction between PCP treated mice and controls. Closer inspection of cellular 
sub-populations may therefore reveal important cellular changes in a disease model 
which otherwise may be accidently overlooked. Since ketamine is a derivative of PCP 
and acts in a similar manner to block the NMDA receptors (Morris, Cochran and Pratt, 
2005; Blot, Bai and Otani, 2013; Steeds, Carhart-Harris and Stone, 2014), closer 
inspection of microglial sub-populations under repeat ketamine administration may also 
reveal changes in the ratio of resting: activated microglia. 
 
1.12 Potential relevance to the neurobiology of schizophrenia 
 
As described in the preceding sections, ketamine users can experience schizophrenia-
like symptoms (Krystal et al., 1994; Morgan, Mofeez, et al., 2004; Muetzelfeldt et al., 
2008). Furthermore, ketamine may worsen symptoms in schizophrenic patients (Lahti, 
Holcomb, et al., 1995; Lahti, Koffel, et al., 1995; Lahti et al., 2001) and such findings 
suggest that repeat ketamine users and schizophrenics may share underlying 
neurological changes which give rise to their symptoms. Indeed, as we have described, 
ketamine users and schizophrenic patients show similar structural, functional and 
biochemical changes  in the brain(Steen, Hamer and Lieberman, 2005; Muñoz Maniega 
et al., 2008; Pomarol-Clotet et al., 2010; Brugger et al., 2011; Liao et al., 2011, 2012; 
Fusar-Poli et al., 2012; Marsman et al., 2013; Cooper et al., 2014; Stone et al., 2014; Reis 
Marques et al., 2014). 
46 
 
On a cellular level, similar pathological changes have been reported in both rodent 
models of repeat ketamine use and post-mortem brain tissue from schizophrenic 
patients. Most notably, parvalbumin expression is reduced in the prefrontal cortex and 
hippocampus of both rodent models and schizophrenia patients (Beasley and Reynolds, 
1997; Bitanihirwe et al., 2009; Lewis et al., 2012; Glausier, Fish and Lewis, 2014; 
Enwright et al., 2016). These findings and those which show that ketamine may induce 
schizophrenia-like symptoms have helped contribute to the NMDA receptor hypothesis 
in schizophrenia (Stone, Morrison and Pilowsky, 2007; Howes, McCutcheon and Stone, 
2015). This hypothesis suggests that the preferential inhibition of NMDA receptors on 
GABAergic interneurons in the cortex and hippocampus leads to disinhibition of 
glutamatergic projection neurons, and subsequently to impaired regulation of the 
activity of these projection neurons. This in turn is thought to cause desynchronous 
neural network activity which may give rise to altered cognition and psychopathology 
(Gonzalez-Burgos and Lewis, 2012; Anticevic et al., 2013; Frohlich and Van Horn, 2014; 
Heckers and Konradi, 2014).  
However as discussed, neural networks in the brain do not only consist of neurons but 
also astrocytes, oligodendrocytes, myelin and microglia. Furthermore, if any of these 
constituents (or different multiple combinations of these cell types) are disrupted or 
damaged then neuronal integrity and/or functional activity may become compromised. 
If this occurs, then desynchronous neural network activity usually results and cognitive 
abilities deteriorate. 
The current literature suggests that alterations to myelin, oligodendrocytes, astrocytes 
and microglia may contribute to altered brain activity in schizophrenia and to the 
subsequent development of symptoms of the disorder. As covering the schizophrenia 
literature in detail is beyond the scope of this introduction, I will only highlight a few 
changes here. Furthermore, several in-depth reviews on glia and myelin in schizophrenia 
can be found in the literature (Davis et al., 2003; Segal et al., 2007; Schnieder and Dwork, 
2011; Takahashi et al., 2011; Xia et al., 2014; Laskaris et al., 2015; Müller et al., 2015). 
Reductions in gene expression in several oligodendrocyte and myelin-related genes 
have been found in the prefrontal cortex and hippocampus of schizophrenia patients. 
Genetic association studies also link oligodendrocyte and myelin-related genes to the 
aetiology of schizophrenia. Furthermore, analyses of post-mortem brain tissue from 
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schizophrenic patients have revealed changes in oligodendrocyte cell density in the 
prefrontal cortex as well as altered myelin architecture. Similarly, genetic association 
studies have found links between astrocyte-related genes (e.g. EAAT2 (Spangaro et al., 
2012; Mariachiara and Bramanti, 2014)) and the aetiology of schizophrenia. Altered 
astrocyte gene expression (e.g. increased GFAP, decreased EAAT2) has also been shown 
to change in the prefrontal cortex and hippocampus of schizophrenia patients. 
Moreover, increases in the number of reactive microglia have been found in the 
prefrontal cortex of schizophrenia patients which correlate with increased expression of 
pro-inflammatory cytokines, such as IL-6 (Potvin et al., 2008; Beumer et al., 2012; Pedrini 
et al., 2012; Song et al., 2013), found in the blood. It would appear then that some of 
the glial changes seen in schizophrenia patients, such as decreased EAAT2 expression in 
the hippocampus and increased IL-6 concentrations in the blood plasma, mimic similar 
changes seen in repeat ketamine users (Fan et al., 2015) and rodent models (Behrens, 
Ali and Dugan, 2008; Featherstone et al., 2012). 
There is a concern here then that if people suffering from depression choose to self-
medicate with ketamine, they may unwillingly cause further psychopathological, 
structural and functional changes to the brain reflective of changes seen in 
schizophrenia. 
 
1.13 Limitations of rodent studies 
 
Despite the clear potential for rodent models to provide informative data linking 
neuroimaging signals to their cellular correlates in the context of drug use and 
psychiatric disorders, it is important to acknowledge that this approach is not without 
limitations. 
An obvious limitation, yet worth stating, is that the rodent brain is far simpler than the 
human brain, particularly when it comes to cortical anatomy. Another major issue in any 
rodent study of human drug use is modelling the dosage and timing of drug 
administration, in a way that most accurately reflects the quantity and pattern of use 
seen in humans. This is perhaps best exemplified by rodent studies on the effects of 3,4-
methylenedioxymethamphetamine (MDMA) (Green et al., 2012). Drug dosages taken 
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by humans may only be approximated for rodents. Ketamine users, for example take (on 
average) between 0.125g - 3g of ketamine per day/night (Wang et al., 2013; Edward 
Roberts et al., 2014). An 70kg person taking 1g of ketamine would equate to a dose of 
14.3mg/kg and this is sufficient to induce pathological changes in the brain (Wang et al., 
2013). In rodents, similar doses of (16mg/kg – 30mg/kg) also induce noticeable 
pathological changes (Sun et al., 2011; Featherstone et al., 2012; Schobel, Chaudhury 
and Khan, 2013)(Robert E Featherstone et al., 2012; Schobel et al., 2013; Sun et al., 
2011). Hence, although an approximation, studies using doses of ketamine within this 
range may be considered to have some relevance to doses ketamine users are exposed 
to. 
In parallel to dosage issues, the route of drug administration in humans and rodents is 
different. The most common way in which people take ketamine is to inhale it as a 
powder (De Luca et al., 2012), whereas the most common way to administer ketamine 
to rodents is via systemic intraperitoneal (IP) injection (Keilhoff et al., 2004; Zhang, 
Behrens and Lisman, 2008; Kittelberger et al., 2012; Featherstone et al., 2014). These 
routes of administration will clearly lead to different pharmacokinetic profiles of drug 
absorption thus altering how quickly and how much of a drug reaches its target receptor 
in the brain and how quickly it is metabolized and cleared from the system. Nasal 
absorption of ketamine in humans allows for direct entry of the drug into the CNS and 
delays first-pass metabolism in the liver. To date however, no studies have examined 
the effect of intranasal ketamine in rodents. A further, more important and often 
underappreciated difference between rodents and humans is that the former 
metabolize drugs faster and thus the half-life of drugs is often considerably shorter in 
rodents (Lin and Lu, 1997; Reagan-Shaw, Nihal and Ahmad, 2008; D. Zhang et al., 2012). 
Furthermore, differing proportions of active metabolites may induce different side-
effects in humans and rodents, as is seen in the case of MDMA metabolism (Green et 
al., 2012).  
Accepting these limitations, one may suggest that the most robust and translational 
approach is in fact to combine results from parallel human and animal imaging studies 
to formulate conclusions on the effects of certain drugs on changes to the structure and 
function of the brain, as exemplified in the work of Schobel and colleagues (2013). 
Human studies can inform us of the changes which occur in the brains of drug users. 
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Comparison of these data to animal studies, provided that due care is given to dose, 
timing and route of drug administration has the potential to provide important 
information as to what changes in the human users may be specific to ketamine. 
Moreover, they offer tractable means to map the cellular mechanisms, which underlie 




MRI data from repeat ketamine users compared to poly-drug controls is limited to very 
few studies, but these provide important insights into the neural correlates of ketamine 
misuse. These studies highlight structural changes in white matter, bilateral decreases 
in frontal lobe grey matter volume and biochemical changes in the thalamus and frontal 
cortex in ketamine users. Current human neuroimaging methods, however, lack enough 
resolution to reveal the biological mechanism driving these morphological changes at 
the cellular level. 
Furthermore, human imaging studies are subject to several confounding influences 
which may affect interpretation of the data. Whilst there is considerable literature from 
rodent models of repeat ketamine treatment; documenting detailed post-mortem 
cellular and molecular measurements, these studies have focused principally on 
neuronal changes. Only a few studies (Kim et al., 2012; Schobel, Chaudhury and Khan, 
2013) have combined these assessments with translational small animal MRI methods. 
There remains a clear gap in our understanding of the impact of ketamine on both 
myelination and glial cells, and how this contributes to altered brain structure and 
activity and ultimately disordered behaviour in terms of cognitive impairments and sub-

















Chapter 2 Grey matter volume reductions in 






As discussed in chapter 1 (general introduction); over the last 10-12 years ketamine has 
been used as an “off-label” therapy for treating patients who are resistant to 
conventional anti-depressant medication (AKA: treatment-resistant depression) and has 
been proven highly effective (Zarate and Singh, 2006; DiazGranados et al., 2010; Lapidus 
et al., 2014). However, this type of therapy is not a “one-off” treatment, rather patients 
may require several ketamine infusions to keep their depressed symptoms at bay 
(Diamond et al, 2014; NY Ketamine Infusions LLC, 2018; Portland Ketamine Clinic, n.d.; 
Ketamine Health Centres, n.d.). 
As repeat ketamine use, particularly when taken at recreational doses (higher than 
clinical doses) has been shown to cause psychotropic effects, functional, metabolic and 
structural changes in the brain, there remains a question as to how safe repeat use of 
ketamine is as a therapy (Feifel, 2016; Melvyn W Zhang, Harris and Ho, 2016; Short et 
al., 2017; Singh et al., 2017b). This concern is reinforced by the potential that patients 
will opt to self-medicate with “street” ketamine as a cheaper and more readily available 
substitute to ketamine infusions at a specialised clinic. If people choose to self-medicate 
then there is a risk that they will use higher doses more frequently than would be 
prescribed through a clinic, which could have long-term psychiatric and neurological 
consequences. 
As such, it is important to understand what changes may occur in the brain under repeat 
ketamine use at higher than clinical doses and what the potential changes in brain 
structure may be. 
In the literature, recreational repeat ketamine use has been shown to cause reductions 
in brain volume in the frontal cortex, as seen by MRI (Liao et al., 2011; Wang et al., 2013). 
However, so far only two studies have published such results. To ascertain whether 
these results are true of repeat ketamine use in general, and not just to a small number 
of people, independent studies are needed to replicate these results. Therefore, in this 
chapter I present my analysis on the effects of repeat ketamine use, on brain structure, 








1. Repeat ketamine users will present with significant reductions in brain volume 
in the frontal cortex, striatum, brainstem and cerebellum as seen in previous 
studies (Liao et al., 2011; Wang et al., 2013) 
2. Reductions in brain volume in ketamine users will correlate with greater 
amounts of ketamine taken and / or more frequent ketamine use and / or a 
longer history of ketamine use 
3. Ketamine users will score worse on tests of psychological wellbeing as seen in 
previously published studies (Liao et al., 2011; Edward Roberts et al., 2014; 





1. To investigate the effects of repeat ketamine, use on brain structure between 
human ketamine users and poly-drug-user controls, by analysing MRI volumetric 
differences across the whole brain. To compare my results to those seen in 
previously published independent studies and see whether previous findings 
have been replicated 
2. To assess whether there is any correlation between either; the amount of 
ketamine taken, the frequency of ketamine consumption or the years of 
ketamine use with any changes in brain volume 
3. To assess whether there are differences in measures of psychological wellbeing 
between ketamine users and controls 
4. To assess whether there is any correlation between the amount of ketamine 
taken, the frequency of ketamine consumption or the years of ketamine use with 




2.3  Materials and methods 
 
a) Participants 
Recruitment of participants was performed by Professor Celia Morgan, University 
College London. 
48 participants were recruited for this study using a database of existing drug users at 
the clinical psychopharmacology unit, University College London (UCL), and via word of 
mouth. After giving informed consent, all participants were required to provide a self-
report of their drug use history. Participants were also required to have no history of 
head injury, to be right handed and fluent in English. 
Participants were grouped into two groups; ketamine users (participants that use 
ketamine at least three times per week) and poly-drug controls (participants with no 
history of regular ketamine use). I then matched groups for age, sex and education level. 
6 participants were excluded that did not match these demographics. A further 6 
participants were excluded as reliable MR images could not be obtained.  This left 36 
participants (17 ketamine users and 19 controls) from whom structural MR images were 
processed for analysis. 
The study was approved by both the Imperial College Research Ethics Committee and 
the UCL Graduate School ethics committee. All participants were paid for their 
participation and travel. 
 
b) Assessment of psychological wellbeing 
All assessments of psychological wellbeing were performed by Fiona Pepper, King’s 
College London.  
Psychotic symptoms were assessed using the Comprehensive Assessment of At-Risk 
Mental State (CAARMS) abnormalities of thought content (bizarre + non-bizarre), 
abnormalities of perceptions and abnormalities of speech production subscales (Alison 
R Yung et al., 2005). These subscales form part of a structured questionnaire used by 
psychiatrists to assess whether a person meets the threshold for a clinical diagnosis of a 
psychotic disorder. The threshold for a diagnosis is as follows: 
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• A severity score of 6 on the disorders of thought content severity subscale, 5 or 
6 on the perceptual abnormalities subscale and/or 6 on the disorganized speech 
subscale. 
• A frequency scale score of 4 or more on the disorders of thought content, 
perceptual abnormalities and /or disorganized speech subscales 
• Psychotic symptoms present for longer than 1 week 
The psychiatrist asks the participant questions and records their answers using a sliding 
scale. Psychotic symptoms are those symptoms experienced in episodes of psychosis 
and include but are not limited to; difficulty concentrating, depressed mood, disrupted 
sleep, anxiety, suspiciousness, withdrawal from family and friends, delusions, 
hallucinations, disorganised speech and suicidal thoughts or actions. 
The Schizotypal Personality Questionnaire (SPQ) (Raine, 1991) was used to assess 
schizotypal symptoms using  DSM-III-R criteria for schizotypal personality disorder, 
found in the third edition of the diagnostic and statistical manual for mental disorder 
(DSM). It is a 74-item questionnaire were each item is scored with a 1 or 0 depending on 
whether the participant answered yes or no, the higher the cumulative score for the 
participant the greater the schizotypal personality. Schizotypal symptoms include; 
strange thinking/behaviour, unusual beliefs, social discomfort, lack of emotion or 
inappropriate emotional responses, social anxiety and paranoia. 
 
c) MRI acquisition 
Acquisition of participant MR images was performed by Dr Emer Hughes, Imperial 
College London. 
All participants underwent MR imaging on a Philips 3 Tesla Intera magnetic resonance 
scanner (Medical Systems, Best, The Netherlands), software release 2.1.3, equipped 
with a sensitivity encoding (SENSE) head volume coil located at the Robert Steiner 
Magnetic Imaging Center at The Hammersmith Hospital (London, UK). An initial localizer 
scan was performed followed by acquisition of a whole-brain T1-weighted 3-
dimensional magnetisation prepared rapid gradient echo (3D-MPRAGE) image 
(repetition time (TR)= 9.6ms, echo time (TE)= 4.5 ms, flip angle 8°, slice thickness=1.2 




Figure 1. A representative T1-Weighted 3D-MPRAGE MR image from one of the study 
participants. A) Axial view. B) Sagital view. C) Coronal view. 
 
d) Freesurfer MRI processing and analysis 
Processing and analysis of MR images was then done using both a Region of Interest 
(ROI) based approach and a complimentary whole-brain voxel-wise approach. 
An ROI based method of cortical reconstruction and volumetric segmentation was 
performed with the Freesurfer image analysis suite, which is documented and freely 
available for download online (http://surfer.nmr.mgh.harvard.edu/). The technical 
details of these procedures are described in many prior publications (Dale and Sereno, 
1993; Dale, Fischl and Sereno, 1999; Fischl and Dale, 2000; Fischl, Liu and Dale, 2001; 
Fischl et al., 2002, no date; Ségonne et al., 2004; Fischl, Salat, et al., 2004; Fischl, van der 
Kouwe, et al., 2004; Han et al., 2006; Jovicich et al., 2006). 
This processing includes motion correction and averaging of T1-weighted images to 
remove acquisition artefacts (Reuter, Rosas and Fischl, 2010), removal of non-brain 
tissue using a hybrid watershed/surface deformation procedure (Ségonne et al., 2004). 
This is followed by automated Talairach transformation to align each MR image to a 
reference image before segmenting the subcortical white matter and deep grey matter 
volumetric structures into regions of interest (Fischl et al., 2002; Fischl, Salat, et al., 
2004; Desikan et al., 2006). Intensity normalization was then performed to improve the 
signal-noise ratio (Sled, Zijdenbos and Evans, 1998), followed by delineation  of the 
cortical grey matter/white matter boundary and  grey matter/cerebrospinal fluid border 
(Dale and Sereno, 1993; Fischl, Sereno and Dale, 1999; Fischl and Dale, 2000; Fischl, Liu 
and Dale, 2001; Segonne, Pacheco and Fischl, 2007). The cerebral cortex was then 
automatically split into regions of interest and cortical grey matter volume, cortical 
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thickness, cortical surface area, subcortical white matter volume and deep grey matter 
volume ROI measurements calculated (Fischl, van der Kouwe, et al., 2004; Desikan et al., 
2006). 
Multivariate general linear model (GLM) statistics were performed using IBM SPSS 
statistics 22 to determine group-level differences in individual cortical ROI volumes, 
thickness and surface area, as well as cortical volume (as a whole), subcortical grey and 
white matter volume. Total intracranial volume (TIV) was used as a covariate in 
statistical modelling of volume differences: there is natural biological variance in brain 
size across individuals, this means that for participants in each group whole brain volume 
will differ, as will the volume of each brain ROI. For example, participants with a larger 
brain are likely to also have a larger hippocampus and/or cortex. This difference is 
controlled by covarying for TIV in the GLM. Thus, variance in brain size can be excluded 
as a factor when interpreting any difference in brain ROI volume between groups.  
Mathworks MATLAB R2014a was used for false discovery rate (FDR) correction (q=0.05) 
of multiple comparisons (Genovese, Lazar and Nichols, 2002; Glickman, Rao and Schultz, 
2014). 
 
e) CAT12 and SPM12 MRI processing and analysis 
A whole-brain, voxel-wise tensor-based morphometry (TBM) analysis was implemented 
using the Computational Anatomy Toolbox (CAT12) plugin for Statistical Parametric 
Mapping (SPM12) software, to compliment and extend the ROI analysis. This software 
is documented and freely available for download online (http://www.neuro.uni-
jena.de/cat). The technical details of this methodology are described in prior 
publications (J Ashburner and Friston, 2000; Good et al., 2001; Tohka, Zijdenbos and 
Evans, 2004; Ashburner and Friston, 2005; Ashburner, 2007; Manjón et al., 2010; Gaser 
and Dahnke, 2012; Malone et al., 2015). 
T1-weighted MR images were transformed (moved), using an affine registration, to 
ensure all images were approximately aligned within the same stereotaxic space. A non-
linear transformation was then performed to register (move, stretch and adjust) the 
images to the Montreal Neurological Institute (MNI) 152 standard brain template. 
Logarithmic Jacobian (logJ) determinants were calculated from the inverse warp fields 
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in standard space. logJ determinants in this case are files which store information as to 
how each 3D voxel within an MR image has been distorted (moved, stretched and 
adjusted) to fit the MNI 152 brain template. Group-level comparisons of the logJ 
determinants reveal any volume differences between groups in specific voxels within 
the MR image. The logJ determinants were smoothed, with a 12mm full-width-at-half-
maximal isotropic Gaussian kernel, to improve the signal-noise ratio before analysis. 
Multivariate GLM statistics were performed on logJ determinant images, with TIV as a 
covariate, to determine voxel-wise group-level differences in volume. FDR correction 
(q<0.05) was applied to correct for multiple comparisons. 
 
f) Correlations 
Partial correlations were performed in IBM SPSS statistics 22 to investigate potential 
correlations between: 
1. The amount of ketamine taken, the frequency of ketamine consumption or the 
years of ketamine use with the volume of the accumbens, caudate, cerebral 
cortex and cerebellar cortex, within ketamine users only. These partial 








Table 1. Partial correlations between measures of ketamine use and ROI brain volume 
 
 
2. The amount of ketamine taken, the frequency of ketamine consumption or the 
years of ketamine use with scores of psychological wellbeing, within ketamine 
users only. These partial correlations included additional covariables outlined in 
table 2. 
Table 2. Partial correlations between measures of ketamine use and psychological wellbeing  
 
 
3. The volume of the accumbens, caudate, cerebral cortex and cerebellar cortex 






Ketamine - amount used (g per session) Total intracranial volume (TIV)
Ketamine - frequency of use ( days per month) Alcohol - amount used (units per session)
Ketamine - years of use Alcohol frequency of use (days per month)
Accumbens volume Alcoho - years of use
Cerebral cortex volume Cannabis - years of use
Cerebellar cortex volume Ecstasy - years os use
Cocaine - years of use
Amphetamine - amount used (g per session)
Amphetamine - frequency of use (days per month)
Amphetamine - years of use
Heroin - amount used (g per session)
Heroin - frequency of use (days per month)
Heroin - years of use
Variables Co-varables
Ketamine - amount used (g per session) Alcohol - amount used (units per session)
Ketamine - frequency of use ( days per month) Alcohol frequency of use (days per month)
Ketamine - years of use Alcoho - years of use
CAARMS severity - abnormalities of thought content Cannabis - years of use
CAARMS severity - perceptual abnormalities Ecstasy - years os use
CAARMS frequency - abnormalities of thought content Cocaine - years of use
CAARMS frequency - perceptual abnormalities Amphetamine - amount used (g per session)
CAARMS frequency - abnormalities of speech production Amphetamine - frequency of use (days per month)
SPQ - total score Amphetamine - years of use
SPQ - cognitive and perceptual Heroin - amount used (g per session)
SPQ - disorganisation Heroin - frequency of use (days per month)
Heroin - years of use
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Table 3. Partial correlations between ROI brain volume and scores of psychological wellbeing 
 
 
2.4 Results and discussion 
 
a) Participant demographics and drug use 
 
Amongst the 17 ketamine users the average amount of (self-reported) ketamine use per 
session was 4g. The average number of (self-reported) days per month ketamine was 
used was 17 days. Because participants were recruited by word of mouth and from a 
database of known drug users, I compared the use of other drugs, other than ketamine, 
between the two groups. I found that the number of alcohol users, nicotine users (i.e. 
cigarette smokers) and cannabis users were statistically well matched between groups 
(Table 4).  
 
Variables Co-variables
Accumbens volume Total intracranial volume (TIV)
Cerebral cortex volume
Cerebellar cortex volume
CAARMS severity - abnormalities of thought content
CAARMS severity - perceptual abnormalities
CAARMS frequency - abnormalities of thought content
CAARMS frequency - perceptual abnormalities
CAARMS frequency - abnormalities of speech production
SPQ - total score




 Table 4. Participant demographics and measures of drug use 
 
 
However, the number of ecstasy, cocaine and amphetamine users was not statistically 
well matched (ecstasy; x2=12.4, p<0.001. cocaine; x2=12.9, p<0.001. amphetamine; 
x2=20.7, p<0.001) and there were more ecstasy, cocaine and amphetamine users in the 
ketamine user group (ecstasy n=17, cocaine n=16, amphetamine n=16) than in the 
control group (ecstasy n=9, cocaine n=9, amphetamine n=5). In addition, 6 ketamine 
users also reported using heroin whereas none of the controls did (Table 4). 
In addition to reporting what drugs they used, some participants also gave details as to 
the quantity of each drug used, the frequency of drug use and the number of years they 
had been taking the drug (Table 5). It is important to note here that not all participants 
gave these details for each drug used. However, analysing the data which was provided 
I discovered the following: 
Alcohol 
• Ketamine users drank more alcohol per session than controls (ketamine; 12 
units, controls; 5 units, t=2.47, p=0.03). 
• Ketamine users drank alcohol more frequently than controls (ketamine; 15 days 
per month, controls; 7 days per month, t=2.42, p=0.03) 
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• Ketamine users started drinking at an earlier age, as they had used alcohol for a 
greater number of years than controls (ketamine; 16 years, controls; 10 years, 
t=2.70, p=0.01) 
Cannabis 
• Ketamine users started using cannabis at an earlier age as they reported having 
used cannabis for a greater number of years than controls (ketamine; 14 years, 
controls; 8 years, t=3.35, p<0.001) 
Ecstasy 
• Ketamine users started using ecstasy at an earlier age as they reported having 
used ecstasy for a greater number of years than controls (ketamine; 10 years, 
controls; 5 years, t=3.17, p<0.001) 
Cocaine 
• Ketamine users started using cocaine at an earlier age as they reported having 
used cocaine for a greater number of years than controls (ketamine; 9 years, 
controls; 4 years, t=3.07, p=0.01) 
For further details please see table 5. 
It is important to note here that the participant data on the amount, frequency and 
duration of drug use is all self-report data, which is subject to estimates and errors in 
memory recall and therefore may not be entirely accurate. Unfortunately, this is an 
inherent problem with this type of data (Schacter, Guerin and St Jacques, 2011; 
Althubaiti, 2016). 
However, if we accept that the self-report data was accurate then the two groups were 
not well matched for other drug use. This is unfortunately a limitation of this type of 
study and one which occurs frequently in the literature (Liao et al., 2010, 2011, 2012; 






Table 5. Details of other drug use amongst participants who responded to further questions on 
the amount, frequency and length of use. 
 
 
b) Grey matter volume reductions in ketamine users observed using Freesurfer ROI 
analysis 
 
To investigate whether there were any group-level differences in brain structure I used 
the Freesurfer analysis suite to analyse brain volumes in distinct regions of interest (ROI). 
I first analysed 12 gross cortical grey matter, subcortical grey matter and subcortical 
white matter regions. I found that ketamine users had a significantly smaller cerebral 
cortex (ketamine; 540.95cm3, controls; 572.91cm3, F=7.14, p=0.01), smaller cerebellar 
cortex (ketamine; 121.95cm3, controls; 131.01 cm3, F=7.52, p=0.01), smaller nucleus 
accumbens (ketamine; 1.14 cm3,controls; 1.24 cm3, F= 10.47, p<0.001) and smaller 
caudate nucleus (ketamine; 7.34 cm3, controls; 8.07 cm3, F=7.31, p=0.01). For further 
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details see Table 6 and Figure 2 for an illustration of where these differences occur in 
the brain. 










Figure 2. Transparent brain displaying significant gross volume differences between ketamine 
users and poly-drug controls. ROIs are shaded in the following colours: Cerebral cortices in blue, 
cerebellar cortices in green, caudate nuclei in white and nuclei accumbens in red. 
 
Similar to published findings (Liao et al., 2011; Wang et al., 2013), my results show 
reductions in brain volume in the cerebral cortex and cerebellar cortex. In addition to 
what has been published previously, I also report reductions in brain volume in the 
nucleus accumbens and caudate nucleus of repeat ketamine users (Table 6). 
The reduced cortical grey matter volumes present in ketamine users reported in the Liao 
et al (2011) study are specific to the superior frontal cortex and middle frontal cortex. In 
my study, to specifically locate in which region of the cortex volume reductions are 
situated, I used Freesurfer to sub-divide the cerebral cortex into its 34 constituent ROIs.  
I then analysed for group-level differences in volume measurements across all 34 ROIs. 
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After FDR multiple comparison correction (q≤0.05) I found significantly smaller volumes 
in ketamine users in 10 of 34 cortical ROIs (see table 7 for details): 
• Inferior parietal cortex (ketamine; 26.67cm3, controls; 31.73 cm3, F=15.32, 
p<0.001) 
• Temporal pole (ketamine; 4.55cm3, controls; 5.08cm3, F=11.52, p<0.001) 
• Caudal middle frontal gyrus (ketamine; 13.78cm3, controls; 16.19cm3, F=9.06, 
p<0.001) 
• Supramarginal gyrus (ketamine; 23.21cm3, controls; 25.43cm3, F=7.68, p=0.01) 
• Paracentral gyrus (ketamine; 7.38cm3, controls; 8.02cm3, F=7.11, p=0.01) 
• Middle temporal gyrus (ketamine; 24.06cm3, controls; 26.02cm3, F=5.81, p=0.02) 
• Superior frontal gyrus (ketamine; 48.34cm3, controls; 52.08cm3, F=5.80, p=0.02) 
• Isthmus of the cingulate cortex (ketamine; 4.84cm3, controls; 5.31cm3, F=5.34, 
p=0.03) 
• Superior temporal gyrus (ketamine; 25.03cm3, controls; 27.02cm3, F=4.89, 
p=0.03) 
• Banks of the superior temporal sulcus (ketamine; 5.51cm3, controls 6.18cm3, 
F=4.46, p=0.04) 
 
Consistent with the study by Liao et al (2011) I found volume reductions in ketamine 
users in the superior frontal cortex and middle frontal cortex. Hence, I have reproduced 
similar findings to those in the literature in an independent cohort of ketamine users. 
This provides further evidence to support the hypothesis that repeat ketamine use alters 
brain structure in the frontal lobe. Furthermore, I have added new information to the 
field by showing that ketamine users also present with smaller volumes in regions of the 
parietal and temporal cortices (table 7). In summary, repeat ketamine use appears to 








Table 7. Volume measurements for cortical ROIs from ketamine users and controls 
 
 
Cortical volume in Freesurfer is a combined measure of cortical thickness and cortical 
surface area. I was interested to see whether the cortical volume differences observed 
were due to changes in cortical thickness, surface area or a combination of the two. I 
found no significant differences in cortical thickness between the two groups across any 
of the 34 cortical ROIs (Table 8). However, I did find significant reductions in cortical 
surface area in ketamine users in 2 of 34 cortical ROIs (Table 9); in the temporal pole 
(ketamine; 7.22cm2, controls; 8.22cm2, F=13.22, p<0.001) and inferior parietal cortex 
(ketamine; 103.22cm2, controls; 114.13cm2, F=10.31, p<0.001). It would appear then 
that the smaller volumes found in the temporal pole and inferior parietal cortex of 
ketamine users are driven predominately by reductions in cortical surface area. 
Whereas, the smaller volumes in the caudal middle frontal gyrus, supramarginal gyrus, 
paracentral gyrus, middle temporal gyrus, superior frontal gyrus, isthmus of the 
cingulate cortex, superior temporal gyrus and banks of the superior temporal sulcus are 
likely due to a combination of reduced cortical thickness and smaller surface areas. 
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Table 9. Cortical surface area measurements from ketamine users and controls 
 
 
Although I have been able to localise the reductions in cortical brain volume to specific 
cortical regions, such as the superior frontal cortex and middle frontal cortex, these 
regions are still relatively large; on the order of thousands of MRI voxels per region. It 
could be that within a given cortical ROI the volume difference observed only occurs in 
a subset of these thousands of voxels. Furthermore, although Freeurfer facilitates the 
subdivision of the cerebral cortex it does not do so for other gross brain regions, such as 
the cerebellar cortex.  
To qualitatively assess in which voxels reductions in brain volume are, in ketamine users, 




c) Brain volume differences in repeat ketamine users and poly-drug controls; 
observed using voxel-wise TBM analysis 
 
Whole brain voxel-wise TBM analysis of volume between ketamine users and controls 
did not reveal any significant differences after false discovery rate (FDR) correction for 
multiple statistical comparisons (q≤0.05). However, without FDR correction there were 
observable differences between groups (p≤0.05). The location of these (uncorrected) 
differences are summarised in table 10 and can be seen in Figure 3. 
 
Table 10. Comparison of Freesurfer gross ROI volume differences and TBM (uncorrected) 











However, as these results do not survive multiple comparison correction it is important 
not to overinterpret them, as there is a strong probability that these data may be false 
positives. The likely reasons for the results not surviving multiple comparison correction 
may be that the effect sizes are not large enough to survive FDR correction across 
hundreds of thousands of individual statistical tests (1 test per MRI voxel across > 
500,000 voxels in an MR image of the human brain). This may be because the volumetric 
differences in each voxel were not large enough and/or the n number for each group 
was too small. On the contrary, the reason why positive results were seen in the 
Regions were significant (p<0.05) volume changes reside are highlighted in green. Regions 
were no significant changes reside are highlighted in red. Please note ROI results are FDR 




Freesurfer analysis is that significantly fewer individual statistical tests had to be 
corrected for multiple comparisons (Freesurfer; ≤ 34 individual tests, TBM; > 500,000 
individual tests), which increases the likelihood that volume differences with smaller 
effect sizes (Cohens D ≈ 0.7 – 1.3) survive. 
Unless otherwise stated, when I subsequently refer to volume differences between 




Figure 3. Axial brain slices displaying TBM analysis of volumetric differences between ketamine 
users and poly-drug controls. Smaller volumes in ketamine users are displayed in red. Numbers 
in the bottom left corner of each image indicate MNI z-coordinates. Data shown are thresholded 
at p<0.05 (uncorrected).  
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d) Increased sub-threshold psychotic symptoms and schizotypal personality in 
ketamine users 
 
In addition to structural alterations and as was discussed in chapter 1 the literature 
shows that repeat ketamine users also present with disruptions in psychological 
wellbeing, compared to controls. Such differences include the presence of schizotypal 
symptoms, impaired executive function and dissociation (Liao et al., 2011; Edward 
Roberts et al., 2014; Morgan et al., 2014). 
In this study I analysed whether there were any differences in measures of psychological 
wellbeing between ketamine users and controls. Amongst data collected by 
collaborators were scores of psychiatric symptoms assessed using the comprehensive 
assessment of at-risk mental state (CAARMS) questionnaire (A.R. Yung et al., 2005), as 
well as a score of schizotypal symptoms assessed using the schizotypal personality 
questionnaire (SPQ) (Raine, 1991). 
In my analysis of CAARMS scores between groups I found that ketamine users scored 
significantly higher than controls in terms of the severity of abnormalities of thought 
content (ketamine; 2.5, controls; 0.4, t=4.2, p<0.001) and severity of perceptual 
abnormalities (ketamine; 3, controls; 1.6, t=2.4, p=0.02). Ketamine users also scored 
significantly higher than controls in terms of the frequency of abnormalities of thought 
content (ketamine; 3.4, controls; 0.25, t= 4.8, p<0.001), frequency of perceptual 
abnormalities (ketamine; 3.1, controls; 0.9, t=3.9, p<0.001) and frequency of 
abnormalities of speech production (ketamine; 2.6, controls; 0.7, t=2.8, p<0.001) 
In summary, ketamine users scored significantly higher than controls on the CAARMS 
questionnaire. However, on average these scores were not great enough to reach the 
threshold for clinical diagnosis of psychosis. In other words, ketamine users have 




Table 11. Measures of psychological wellbeing in ketamine users and controls 
 
Ketamine users also scored higher on the SPQ compared to controls. The SPQ is a 
questionnaire designed to assess the extent of schizotypal symptoms. It is a 74 item 
questionnaire were each item is scored as a 1 or 0 depending on whether the participant 
answered yes or no, the higher the cumulative score the greater the schizotypal 
personality (Raine, 1991). 
In my analysis of SPQ scores, ketamine users scored higher than controls on the SPQ 
cognitive and perceptual subscale (ketamine; 9.4, controls; 2.6, t=2.8, p=0.01), 
disorganized speech subscale (ketamine; 8.7, controls; 4, t=2.6, p=0.01) and total SPQ 
score (ketamine; 27.5, controls; 11, t=2.9, p= 0.01) (Table 11). 
Hence, ketamine users have a stronger schizotypal personality than controls. Taken 
together with higher sub-threshold psychotic symptoms, ketamine users have a reduced 
level of psychological wellbeing compared to poly-drug controls. 
As ketamine users, in this study, presented with reductions in brain volume and 
reductions in psychological wellbeing I decided to investigate whether there was any 
correlation between the two. I also decided to investigate whether there was any 
correlation between the amount, frequency and/or duration of ketamine use with either 




e) Correlations between reduced brain volumes, psychological wellbeing and 
ketamine use metrics in ketamine users 
 
To assess whether there was any correlation between smaller brain volumes and 
increased scores of psychological wellbeing I performed partial correlations in SPSS, for 
ketamine users only. I did so whilst covarying for TIV to control for variance in whole 
brain volume across individuals. I found no significant difference in any of the following: 
 
 
It would appear then that there is no relationship between reduced brain volumes and 
decreased psychological wellbeing in ketamine users. This could be because volume 
reductions and decreased psychological wellbeing, arising through repeat ketamine use, 
are both by-products of functional changes. Indeed, functional changes have been 
shown to correlate with altered psychological wellbeing in both single and repeat 
ketamine exposure (Honey et al., 2004, 2008; Deakin et al., 2008; De Simoni et al., 2013; 
Doyle et al., 2013b; Driesen et al., 2013; Morgan et al., 2014; Stone et al., 2015). Or, it 
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could be that due to a low number of participants (ketamine users, n= 17), this study 
lacks the statistical power to detect any correlation. Conversely, in the study by Liao et 
al (2011) there were 44 ketamine users participating in the study and significant negative 
correlations were observed between the duration of ketamine use and decreased grey 
matter volumes. 
Another explanation, however, is that the other drugs used by ketamine users are the 
main drivers / sole drivers of altered psychological wellbeing in ketamine users. To test 
this, I investigated whether metrics of ketamine use correlated with scores of 




Thus, there appears to be no relationship between either the frequency of ketamine 
use, or in the amount of ketamine use with the level of psychological wellbeing. As 
previously stated, the ketamine users in this study reported an average use of 4 ± 3.4g 
of ketamine per session. It might well be that if a certain threshold of ketamine use is 
met (e.g. 0.6g three times per week) psychological wellbeing will deteriorate, however, 
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this will then not worsen with greater quantities or more frequent use of ketamine (in a 
type of ceiling effect where a maximum perturbation is reached). Or again, it could be 
that due to a low number of participants (ketamine users, n= 17), this study lacks the 
statistical power to detect any correlation. 
It might well be that pre-existing genetic and/or environmental factors are partly 
responsible for the difference in psychological wellbeing observed between ketamine 
users and controls. However, when I analysed self-report data regarding the number of 
participants who reported personal mental health problems, a family history of mental 
health problems, family history of alcoholism and/or a family history of drug abuse, I 
found no significant difference between groups: 
• Personal mental health problems (ketamine users; 4, controls; 3, x2= 0.34, p= 
0.56) 
• Family history of mental health problems (ketamine users; 5, controls; 5, x2= 
0.04, p= 0.84) 
• Family history of alcoholism (ketamine users; 3, controls; 2, x2= 0.38, p= 0.54) 
• Family history of drug abuse (ketamine users; 7, controls; 3, x2= 2.88, p= 0.09) 
 
I think that it is more plausible that the other drugs used by ketamine users are partly, 
if not wholly, responsible for their reduced psychological wellbeing. Ketamine users in 
this study, compared to controls, had been users of alcohol, cannabis, ecstasy and 
cocaine for a greater number of years (Table 5). Ketamine users also reported drinking 
more alcohol, more frequently. This is an issue as evidence from the literature shows 
that the consumption of other drugs, such as alcohol, cannabis, ecstasy and cocaine can 
increase schizotypal personality, as measured by the SPQ (Van Dam, Earleywine and 
DiGiacomo, 2008a; Compton, Chien and Bollini, 2009; Fridberg et al., 2011; Baskak et 
al., 2012). 
To determine whether other drug use was partly or wholly responsible for reduced 
psychological wellbeing I would have liked to correlate the frequency and amount of 
ketamine use (separately) with CAARMS scores and SPQ scores, whilst controlling for 
the frequency, amount and length (years of use) of other drug use. Unfortunately, 
however I lacked enough statistical power to do so. This was due to a small n number 
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(n=4). The reason for a small n number was that only ketamine users were tested (n=17). 
However, not all ketamine users were users of all other drugs. For example, only 6 users 
reported using heroin and only 4 of those gave further details as to the amount, 
frequency and length of heroin use. Therefore, I unfortunately cannot state whether 
other drug use is related to reduced psychological wellbeing in ketamine users, in this 
study. 
My initial analysis showing a lack of a correlation between ketamine use and reduced 
psychological wellbeing raises doubts as to whether ketamine use correlates with 
structural changes observed. It is plausible that other drug use also influences the 
structural differences observed between ketamine users and controls. 
As seen already, I cannot adequately control for other drug use metrics due to a low n 
number and lack of statistical power. Thus, I was unable to investigate any correlation 
between ketamine use and structural changes whilst controlling for other drug use. I 
was, however, able to correlate ketamine use with reductions in brain volume whilst 
only controlling for TIV. I found the following significant correlations: 
• Negative correlation between the frequency of ketamine use and the volume of 
the cerebellar cortex (r=-0.816, p<0.001). i.e. the greater the frequency of 
ketamine use the smaller the volume of the cerebellum 
• Negative correlation between the amount of ketamine use and the volume of 
the caudate nucleus (r=-0.512, p=0.05). i.e. the greater the amount of ketamine 
used the smaller the volume of the caudate nucleus. 
The following correlations were not significant 
• Frequency of ketamine use and volume of the nucleus accumbens (r=0.39, 
p=0.15), caudate nucleus (r=0.19, p=0.50) or cerebral cortex (r=0.032, p= 0.91 
• Amount of ketamine use and volume of the nucleus accumbens (r=0.45, p=0.10), 
cerebral cortex (r=0.33, p=0.24) or cerebellar cortex (r=-0.258, p=0.35). 
Although, I found two significant correlations between ketamine use and brain volume 
I cannot confidently state that the relationship is correct as it may be influenced using 
other drugs, which I was unable to control for. This is a concern reinforced by evidence 
in the literature linking other drug use to structural alterations in brain regions like those 
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assessed here. Examples include; frontal grey matter atrophy in alcoholism, frontal 
cortex volume and surface area reductions in poly-drug users (users of alcohol, cannabis, 
cocaine and amphetamine), cortical thinning in the frontal cortex, left middle temporal 
gyrus and right inferior parietal lobule in young adult cigarette smokers and smaller grey 
matter volume in the right prefrontal cortex and bilateral cingulate cortices in heroin 
users (Liu et al., 2009; Kumra et al., 2012; Grodin, Lin, C. a. Durkee, et al., 2013; Li et al., 
2015; Pennington et al., 2015). 
Thus, although I have shown that there are reductions in volume in several brain regions, 
in ketamine users, I cannot confidently state that the results seen are due to repeat 
ketamine use alone. It could be that other drug use is contributing to the volume 
differences observed. This conclusion is not restricted to this study but can be extended 
to studies in the literature, the study by Liao et al (2011) on reduced prefrontal cortex 
grey matter in ketamine users being an example. In this study ketamine users were 
compared to healthy controls. Although subjects in both groups reported alcohol use 
only ketamine users reported using other drugs, including; ecstasy, marijuana, cocaine, 
amphetamines and heroin (Liao et al., 2011). None of these drugs were controlled for in 
analysing structural differences between groups and therefore care should be taken 
when interpreting whether ketamine alone is responsible for the differences observed. 
This caution should also be extended to the DTI study and fMRI study by Liao et al (2010) 
and Liao et al (2012) which used the same cohort of study participants. 
The difficulty in matching other drug use between ketamine users and control groups is 
one accepted in the literature and is common to research on recreational drug use 
(Morgan et al., 2014). In future studies, a potential way around the issue of other drug 
use is to conduct studies with a larger number of participants, as well as obtaining details 
of the amounts, frequency and length of use of all other drugs used from all participants. 
This would allow for better matching of ketamine users to poly-drug controls and would 
facilitate the exclusion of participants who were outliers or did not match well for certain 
drug use. For example, if there were a greater number of participants within my study 
then I might be able to exclude ketamine users who also use heroin so that I get a better 
match between groups. Better matching of groups for other drug use would allow for 
more confident interpretations of structural differences observed. Furthermore, this 
would enable one to perform correlations between measures of ketamine use and 
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measures of volume change and scores of psychological wellbeing whilst controlling for 
other drug metrics. In turn, one could determine the extent to which other drug use was 
impacting on structural differences observed. In addition, with larger n numbers you 
would expect to see larger effect sizes (due to a smaller standard deviation from the 
mean). This would be useful for TBM analysis as changes with larger effect sizes are 
more likely to survive multiple comparison correction. 
Having said all this, an alternative to increasing the number of study participants would 
be to study the effects of repeat ketamine administration in an environment free from 
other drug use. Hypothetically this would involve studying ketamine users who only 
used the drug ketamine (and no other drugs) and comparing them to healthy controls 
(who did not use any drugs). However, practically this scenario is not realistic as no group 
of people exist who only use ketamine, without using another drug. This does not mean 
however that we cannot study repeat ketamine administration in an environment free 
from other drug use and this is where studies in animal models, such as mice, can be 
used to study this. 
By using mice to study the effects of repeat ketamine administration, on brain structure, 
one eradicates the problem of other drug use by simply administering only ketamine 
and no other drug to the mice. Additionally, by using mice one can regulate the amount, 
frequency and duration of drug administration to investigate whether these factors 
modulate brain structural alterations under ketamine. Moreover, comparable MRI 
techniques that have been used to study ketamine in humans can be used to study 
changes in mice. The benefit of this is it enables the comparison of results in mice to 
those seen in humans. This is also made possible as the gross anatomy of the mouse 
brain is like that of humans. For example, both mice and humans have bilateral cerebral 
cortices connected by a band of white matter (known as the corpus callosum), albeit of 
different complexity. The cerebral cortex in both species can also be split on a functional 
and anatomical basis into the frontal, parietal, temporal and occipital cortices; which 
run in the same sequence from the rostral end of the brain to the caudal end (Price, D. 
et al, (2011). Building Brains. John Wiley & Sons Incorporated; Hendelman, W., (2005). 
Atlas of Functional Neuroanatomy. Second Edition. CRC Press; Paxinos, G, and Franklin, 
K.B.J., (2001). The mouse brain in stereotaxic coordinates: Second Edition. Academic 
Press, New York.). 
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This is an approach which has been used successfully in laboratories to study ketamine 
(in the context of understanding the cellular mechanism of psychosis), schizophrenia 
pathology, antipsychotic drugs and neurodegenerative disease models (Lerch, Carroll, 
Dorr, et al., 2008; Lerch, Carroll, Spring, et al., 2008; Carroll et al., 2011; Vernon et al., 
2012, 2014, 2011; Schobel, Chaudhury and Khan, 2013; Ellegood et al., 2014; Portmann 
et al., 2014; Harrison et al., 2015; Holmes et al., 2017; Lieberman et al., 2018). 
An additional benefit of using mice is that post-mortem investigations can be performed 





In this chapter I was able to show that structural MR differences exist in the brains of 
repeat ketamine users versus poly-drug controls. Ketamine users have smaller cerebral 
cortices, cerebellar cortices, nucleus accumbens and caudate nuclei. I was also able to 
demonstrate that ketamine users present with significantly worse scores of 
psychological wellbeing. However, I did not find any significant correlations between the 
level of psychological wellbeing and reduced brain volumes in ketamine users. 
Due to poor matching of other drug use between groups and thus poor statistical power, 
I was unable to correlate structural changes or scores of psychological wellbeing to the 
amount or frequency of ketamine use. Therefore, I am unable to confidently state that 
the group-level differences observed are due to ketamine alone. 
One way to test the effects of repeat ketamine exposure on the brain is to study repeat 
ketamine administration in mice where the dose and frequency of ketamine 
administration can be controlled, and no other drugs are present. In the next chapter, I 
will present my study on mice which looks at the effects of repeat ketamine 
administration on brain structure and compares the results to changes seen in human 













Chapter 3  The effects of repeat ketamine 






As discussed in Chapter 2, studies investigating the effects of chronic ketamine exposure 
on brain structure in human users suffer from potentially compromising factors 
including pre-existing genetic and environmental factors and the use of other 
psychotropic drugs. Such factors may influence the results seen regarding changes in 
brain structure and are extremely difficult to adequately control for. Furthermore, to my 
knowledge, there is no cohort of ketamine users with the same pre-existing genetic and 
environmental circumstances and who only take ketamine and no other recreational or 
psychotropic drug. This makes it very difficult to investigate the effects of repeat 
exposure to ketamine alone, in human users. 
In contrast, it is possible to study the effects of repeat ketamine exposure without other 
confounding influences, upon brain structure in mice, using structural MRI and/or 
histological methods. The advantage of using mice, with homogenous genetics, identical 
environmental housing and controlled drug administration to investigate the effects of 
repeat ketamine administration is that one can be certain that any structural alterations 
observed are due solely to the drug that has been administered. Furthermore, post-
mortem studies can be carried out on mice to assess the underlying cellular and 
molecular correlates of any observed MRI changes. 
An example of where this approach has been effective, in the context of ketamine 
specifically, is in a study by Schobel et al (2013). In this study Schobel and colleagues 
measured cerebral blood flow (a marker of functional brain activity) and hippocampal 
volume in both mice (administered repeat doses of ketamine) and humans at high risk 
of developing psychosis. The authors found, in both mice and humans, increased 
cerebral blood flow to the hippocampus which predated structural atrophy in that brain 
region, and which in humans predicted a transition to psychosis. Furthermore, the 
authors were able, in mice, to show that an increase in extracellular glutamate, and a 
reduction in the number of parvalbumin positive GABAergic interneurons, was 
responsible for the increased cerebral blood flow in the hippocampus and which led to 
its subsequent atrophy. This study nicely demonstrates the use of MRI techniques in 
mice to investigate the cellular correlates which may be responsible for similar MR 
changes observed in humans. This approach has also been successful in studies 
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investigating schizophrenia pathology, the effects of antipsychotic drugs on brain 
structure and structural alterations in the brain which arise in neurodegeneration (Lerch, 
Carroll, Dorr, et al., 2008; Lerch, Carroll, Spring, et al., 2008; Carroll et al., 2011; Vernon 
et al., 2011, 2012, 2014; Harrison et al., 2015; Holmes et al., 2017; Lieberman et al., 
2018). 
Taking inspiration from such studies, in this chapter I set out to investigate the effects 
of repeat ketamine administration on mouse brain volume, using structural MRI (sMRI). 
My aim was also to compare my findings to the differences previously reported in 
human repeat ketamine users, to understand better the potential influence of other 
drug use in results observed in human users; both in my study and in the literature.  
As explained in chapter 1, another MRI technique for studying alterations in brain 
structure is diffusion tensor imaging (DTI). Although there was no DTI data to analyse 
from the ketamine users / poly-drug controls in chapter 2, there are two published DTI 
studies that report altered white matter structure in repeat ketamine users (Liao et al., 
2010; Edward Roberts et al., 2014). In the first of these studies Liao et al (2010) found 
that ketamine users present with reduced fractional anisotropy (FA) values (i.e. altered 
brain structure) in the white matter underlying the frontal cortex and left tempero-
parietal cortex, compared to healthy controls. These reductions in FA within the frontal 
cortex were negatively correlated with the estimated total ketamine consumption; the 
more ketamine consumed the greater the decrease in FA. However, in this study as in 
the study by Liao et al (2011), on the same participants, other drug use was not 
controlled for and it could be that the group-level differences observed are not due 
wholly (if at all) to ketamine consumption. 
In a second study Roberts et al (2014) compared ketamine users to poly-drug controls 
and found reduced axial diffusivity (AD) (i.e. altered brain structure) in the white matter 
underlying the frontal, parietal and somatosensory cortices. However, in contrast to the 
Liao et al (2010) study, these changes could not be correlated to any ketamine use 
metrics.  
It is important to note that these changes in DTI metrics may result from either 
pathological change at the cellular level (e.g. demyelination, axonal loss, oedema, 
inflammation), or neural plasticity (e.g. dendritic arborisation, axonal growth) (Zatorre, 
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Fields and Johansen-Berg, 2012; Stolp et al., 2018). This is highlighted when considering 
changes in diffusion-based metrics such as fractional anisotropy, which may be the 
result of changes in myelin, membrane permeability, axonal number or size, or a 
combination of all of those factors (Zatorre, Fields and Johansen-Berg, 2012). To date, 
there are no published studies that report on the impact of repeat ketamine exposure 
on the mouse brain to complement the small body of human work in this area. Based 
on this, I decided to also use DTI to investigate the effects of repeat ketamine 
administration on mouse brain structure. 
The general aim of this chapter then was to confirm whether repeat ketamine exposure 
alone is the driver of structural changes observed in the previous chapter and in the 
studies by Liao et al (2010), Liao et al (2011) and Roberts et al (2014). To achieve this, I 
investigated differences in brain structure between mice repeatedly administered 
ketamine and mice repeatedly administered saline. 
I tested two different frequencies of ketamine administration: intermittent 
administration (mice received ketamine once every three days for thirty days) and daily 
administration (mice received ketamine once daily for fourteen consecutive days). The 
rationale for these dosing regimen was that in my study of human chronic ketamine 
users (Chapter 2) and in previously published studies (Liao et al., 2010, 2011; Wang et 
al., 2013; Edward Roberts et al., 2014) ketamine users differed in their frequency of drug 
intake. In my study, for example, ketamine users on average used the drug 17±11 days 
of the month (Chapter 2, table 4). Hence, there are some users who use the drug 
intermittently, and others which use the drug almost (if not) daily. Because my human 
study lacked the statistical power and control to determine whether frequency of drug 






3.2 Experimental aims and hypotheses 
 
a) Hypotheses 
1. There will be differences in brain structure in mice repeatedly administered 
ketamine versus mice repeatedly administered saline in 
a. region of interest volume measurements 
b. TBM volume measurements 
c. FA, MD, AD and RD 
 
b) Aims 
1. To determine if there are differences in brain structure between mice repeatedly 
administered ketamine and mice administered saline, as assessed using MRI 
a. Region of interest measurements of brain volume 
b. Tensor based morphometry (TBM) measurements of brain volume 
c. DTI measures of fractional anisotropy (FA), mean diffusivity (MD), axial 
diffusivity (AD) and radial diffusivity (RD) 
2. To determine whether the frequency of ketamine administration, in mice, 
modulates any structural differences observed 
3. To qualitatively compare differences in brain volume in mice, repeatedly 










Young adult (9-10-week-old) male, wild-type, C57BL/6J mice (Charles River, Harlow, UK) 
were housed in conventional metal top cages under a 12-hour light/dark cycle, 5 mice 
to a cage with free access to food and water. Young adult mice were chosen as this 
roughly matches the demographic of repeat ketamine users in human studies that have 
investigated the effects of ketamine on brain structure: 
• Liao et al (2010,2011,2012); mean age of ketamine users was 26.9 ± 4.87 years, 
33 of 41 participant were male 
• Roberts et al (2014); mean age of ketamine users was 27 ± 6.74 years and the 
mean age of first use was 19.9 ± 6.27 years, 93% of study participants were male 
• My study (chapter 2); mean age of ketamine users was 28.7 ± 5.11 years, 12 of 
17 participants were male. 
After a 10-day habituation period, mice were randomly assigned into ketamine and 
control treatment groups, and drug and vehicle injections began. All in-vivo 
experimental procedures were carried out in accordance with the Home Office Animal 
Scientific Procedures Act, United Kingdom, 1986. 
 
b) Ketamine Administration 
Human ketamine users differ in their frequency of drug use, for example, see Chapter 2 
and previously published (Liao et al., 2010, 2011; Wang et al., 2013; Edward Roberts et 
al., 2014). In my ketamine user dataset for example, the ketamine users were, on 
average, taking the drug 17 days a month. Hence, there are some individuals who use 
the drug intermittently and others that use the drug almost (if not) daily. Although my 
human study lacked the necessary statistical power to determine whether frequency of 
drug use had any impact on changes in brain structure, previous reports in the literature 
in larger samples suggest this is the case  (Liao et al., 2010). Taking these factors into 
account, I decided to test whether frequency of ketamine exposure had any impact on 
brain structure in my mouse experiments. I tested two different frequencies of ketamine 
administration; intermittent administration (mice received ketamine once every three 
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days for thirty days) and daily administration (mice received ketamine once daily for 
fourteen consecutive days). 
Mice (n=60) were put into one of these two separate experiments; daily administration 
(DAY) or intermittent administration (INT). Within these experiments mice were 
randomly assigned into one of two groups; ketamine (KET) or saline (SAL), resulting in 
the following comparative groups: KET-DAY (n= 15) v SAL-DAY (n=15) in the daily 
experiment and KET-INT (n=15) v SAL-INT (n=15) in the intermittent experiment. Mice 
were administered intraperitoneal injections (i.p.) of either ketamine hydrochloride 
(ketamine) (Bio-Techne, Abingdon, UK) at 20mg/kg or 0.9% saline, respectively. KET-INT 
mice were given a single injection of ketamine at 20mg/kg and SAL-INT mice a single 
injection of 0.9% saline once every three days for thirty days (Figure 4). KET-DAY mice 
were given a single injection of ketamine and SAL-DAY mice a single injection of saline 
for 14 recurrent days (Figure 5). 
 
 






Figure 5. Experimental design for daily ketamine administration 
 
My rationale for choosing a dose of 20mg/kg of ketamine was that a study assessing the 
effects of repeat ketamine administration in mice, similar to my intermittent 
experiment, found that a dose of 16-32mg/kg was both necessary and sufficient to 
induce pathological changes in brain structure, as seen by structural MR (Schobel, 
Chaudhury and Khan, 2013). These, changes mimicked those seen in a cohort of at-risk 
patients who transitioned to psychosis. As ketamine users present with sub-threshold 
levels of psychosis, I rationalised that doses of ketamine in mice, which lead to similar 
structural changes as seen in humans with psychosis, would be relevant. Furthermore, 
a study of repeat ketamine administration at 20mg/kg doses in mice aged 9-11 weeks, 
similar to my daily experiment, has shown long-lasting structural changes to the brain 
at the cellular level alongside prolonged changes in EEG (Featherstone et al., 2012). 
Thus, it was my rationale that a 20mg/kg dose would be both necessary and sufficient 






c) MRI preparation 
 
Brains were prepared for ex-vivo MR image acquisition as per the method documented 
in Wood et al (2016) and Richetto et al (2016). Ex-vivo imaging was preferred to in-vivo 
imaging in order to obtain multiple MR images of the highest resolution possible (Lerch 
et al., 2012). Moreover, my image acquisition lasted 12.5 hours and in-vivo imaging of 
mice for that length of time was not feasible as it would not have been ethical, healthy 
for the mice nor practical to keep mice under anaesthetic and in an MRI scanner for that 
length of time. 
After the last injection and a subsequent two-day drug wash out period, mice were 
sacrificed via an overdose injection of sodium pentobarbital (13mg/10g bodyweight). 
Mice were then gravity perfused with phosphate buffered saline (PBS) (Sigma-Aldrich, 
UK), followed by perfusion with 4% paraformaldehyde (PFA) (Sigma-Aldrich, UK). The 
head was then removed, and skin and excess connective tissue removed, and the skull 
placed in 4% PFA for overnight fixation. The head was then stripped of the lower jaw 
and muscle tissue surrounding the skull before being transferred to PBS for 12-15 days, 
prior to ex-vivo MRI acquisition. 
 
d) Ex-vivo MRI Acquisition, Processing and Analysis 
 
A 7 Tesla horizontal small-bore magnet (Agilent Technologies Inc. Santa Clara, USA) and 
a quadrature volume radiofrequency coil (39 mm internal diameter, Rapid Biomedical 
GmbH) were used for all MRI acquisitions. Fixed brain samples were placed securely up 
to three at a time in an MR-compatible holder and immersed in proton-free 
susceptibility matching fluid (FluorinertTM FC-70; Sigma-Aldrich, UK) before image 
acquisition. The following were then acquired: 
• T2-weighted 3D Fast Spin-Echo structural images of each mouse brain (matrix 
size= 256 x 256 x 256 with isotropic 112.5 µm voxels, TR= 3000 ms, TE= 40ms) 
(Figure 6) 
• Diffusion tensor images from each mouse brain using a four shot Echo Planar 
Imaging (EPI) sequence (matrix size= 192 x 128 (40 slices), 150 x 225 x 500 µm 
89 
 
voxels, TR= 4000 ms, TE= 43ms), consisting of 30 diffusion directions with b= 




Figure 6. A representative T2-weighted MR image of a mouse brain taken from my study. 
 
e) MRI processing of T2 structural images for volume analysis 
 
MR images were then processed using a combination of FSL (Jenkinson et al., 2012), 
ANTs (Avants et al., 2011) and in-house C++ software utilizing the ITK library, available 
from https://github.com/spinicist/QUIT (Richetto et al., 2016; Wood et al., 2016). Multi-
head scans were bias-field corrected (Tustison et al., 2010) before being split into 
individual sample images and skull stripped. 
A simple rigid registration was then performed between each subject image and the 
Dorr Atlas image (Dorr et al., 2008) to ensure all subject images were approximately 
aligned with one another within the same 3D space. The Dorr atlas image is an average 
3D image of 40 adult C57BL/6J mice (Dorr et al., 2008). 
An average study template image was then constructed using MR images from all the 
study animals (Avants et al., 2010). One template was created from all intermittent 
treated mice and another was created from all daily treated mice, to analyse data in 
these separate experiments. These templates were then non-linearly registered 
(moved, stretched and adjusted) to the atlas image. All subject images from each 
respective experiment (daily or intermittent administration) were non-linearly 
registered to their respective study template. Logarithmic Jacobian (logJ) determinants 
were calculated from the inverse warp fields in standard space. logJ determinants in this 
case are files which store information as to how each 3D voxel in an MR image has been 
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distorted (moved, stretched ad adjusted) to fit the study template. The inverse 
transforms from the atlas to the study template and from the study template to each 
subject were applied to calculate the total brain volume and individual brain ROI 
volumes of each subject. ROIs match those found in the Dorr MR mouse brain atlas and 
encompass the entire mouse brain (Dorr et al., 2008). 
Or in more layman terms: What the above mouse MR pipeline does is take each T2 
structural mouse brain image and split it into 62 ROIs; which incorporate the entire 
mouse brain. It then registers (moves/ rotates/ stretches and adjusts) each ROI, from 
individual mouse brain images, to the corresponding ROI from the study template (an 
average of all individual mouse brain images from each experiment). The way in which 
each ROI is registered is recorded in a file known as an inverse transform, from this file 
a measure of volume can be extracted for that specific ROI. Average volume 
measurements for each ROI from ketamine mice can then be compared to average 
volume measurements from saline mice. This comparison was performed for both my 
intermittent and daily experiments. Similarly, the logJ determinant file from each mouse 
was used to compare how each voxel, in each mouse brain, was distorted to match the 
study template. Comparing how each specific voxel in the mouse brain was distorted in 
each mouse gives an indirect measure of volume changes. In this way volume 
differences can be compared between ketamine treated mice and saline treated mice, 
at each voxel in the brain.  
Multivariate GLM statistics were performed using IBM SPSS statistics 22 to determine 
group-level differences in brain ROI volumes. Whole brain volume was used as a 
covariate and FDR correction (q=0.05) was applied, in Mathworks MATLAB R2014a, to 
correct for multiple comparisons. Voxel-wise group-level differences were determined 
using the Jacobian determinant images with permutation testing in FSL randomise, 
whole brain volume estimates were included as a covariate and multiple comparisons 
were FDR corrected (q=0.05). 
 
f) DTI Processing and Analysis 
 
DTI MR images were processed using a combination of FSL (Jenkinson et al., 2012), ANTs 
(Avants et al., 2011) and in-house C++ software utilizing the ITK library, available from 
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https://github.com/spinicist/QUIT (Richetto et al., 2016; Wood et al., 2016). FSL topup 
was used to remove distortion artefacts in the raw diffusion data (Andersson, Skare and 
Ashburner, 2003). DTI parameter maps for Mean Diffusivity (MD), Axial Diffusivity (AD), 
Radial Diffusivity (RD) and Fractional Anisotropy (FA) were calculated using FSL dtifit. 
The recorded rigid and non-linear registration transforms for aligning T2 structural scans 
were concatenated and applied to all DTI parameter maps to align them to the study 
template. All parameter maps were resampled to match the study template voxel size 
using a Gaussian interpolator (125µm full-width half-maximum). 
Values from each DTI parameter map were calculated for each ROI in the Dorr atlas (Dorr 
et al., 2008). Multivariate GLM statistics were then performed using IBM SPSS statistics 
22 to determine group-level differences in DTI parameter values for each ROI. Voxel-
wise group-level differences, in each DTI parameter, were also analysed using 
permutation testing in FSL randomise. In both ROI and voxel-wise analyses multiple 
comparisons were FDR corrected (q=0.05) in Mathworks MATLAB R2014a. 
 
3.4 Results and discussion 
 
a) Region of interest volume differences in mice repeatedly administered ketamine 
versus saline 
 
I used an atlas-based ROI method of analysis to determine group-level differences in 
regional brain volumes between mice repeatedly administered ketamine versus saline. 
To do so I used a combination of FSL, ANTs and in-house C++ software along with the 
Dorr atlas (Dorr et al., 2008). From here on in I will refer to this combination of tools as 
the Mouse MR pipeline. 
 
i) Intermittent experiment 
Within the intermittent experiment I found significant volume differences in 3 of 62 ROIs 
at p≤0.05 and FDR q≤0.05 (Table 12). Ketamine mice had a significantly larger frontal 
lobe and stria medullaris and a significantly smaller fornix, compared to control mice:  




• Stria medullaris: KET-INT; 0.98 ± 0.03 mm3, SAL-INT; 0.94 ± 0.04 mm3, F=9.68, 
p<0.001 
• Fornix: KET-INT; 0.86 ± 0.03 mm3, SAL-INT; 0.89 ± 0.03 mm3, F=9.68, p<0.001 
A greater volume of the cerebral cortex frontal lobe in KET-INT mice is a surprising initial 
finding as I expected to see a reduction in volume in this region, as analogously observed 
in human ketamine users (chapter 2)(Liao et al., 2011; Wang et al., 2013). 
 
i) Daily experiment 
Within the daily experiment I found no significant differences in volume between KET-
DAY and SAL-DAY mice in any of the 62 ROIs (Table 13); after correcting for multiple 
comparisons (FDR q≤0.05). This is also a surprising result as I hypothesised that any 
volume difference observed in the intermittent experiment would be exacerbated in the 
daily experiment. My rationale being that a greater frequency of ketamine 



























Table 13. Region of interest volume measurments between KET-DAY and SAL-DAY mice. 
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b) Volume differences between mice repeatedly administered ketamine versus 
saline, as seen by TBM analysis 
 
In chapter 2, I first analysed volume differences between ketamine users and controls 
using a region of interest approach. I then performed a complimentary TBM analysis to 
specifically locate where, in each region, volume changes were. I used a similar approach 
in this chapter when analysing my mouse MR data. From my ROI analysis of volume 
differences between KET-INT and SAL-INT mice I found KET-INT mice to have a 
significantly larger frontal lobe. To specifically locate in which voxels of the frontal lobe 
this difference was I performed a whole-brain voxel by voxel TBM analysis.  
 
i) Intermittent experiment 
Within the intermittent experiment I found significant qualitative, group-level volume 
differences in voxels spanning multiple brain regions (Figure 7). A summary of which 
regions contain voxels with a significant difference in volume can be found in Table 14. 
 
 
Figure 7. Coronal brain slices displaying TBM analysis of volumetric differences between KET-
INT and SAL-INT mice. Smaller volumes in KET-INT mice are displayed in blue. Larger volumes in 
KET-INT mice are displayed in red. Data shown are thresholded at p<0.05, FDR corrected at 
q=0.05. L = Left, R = Right. 
 
  
Of the 62 ROIs previously analysed 42 contain voxels that either show a larger volume 
(red blobs) or a smaller volume (blue blobs) in KET-INT mice. Some regions, such as the 
hippocampus, show both larger volumes in a cluster of voxels (left hippocampus) and 
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smaller volumes in another subset of voxels (right hippocampus) (panel 7, Figure 7). 
Unilateral differences in volume can also be seen in clusters of voxels in other brain 
regions. For example, within the parietal lobe (panel 4, Figure 7) a cluster of voxels in 
the lower cortical layers of the left cortex show smaller volumes in KET-INT mice, 
whereas in the upper layers of the left cortex there is a cluster of voxels depicting larger 
volumes. Furthermore, this pattern is reversed in the right hemisphere of the parietal 
cortex (panel 4, Figure 7); a cluster of voxels in the lower cortical layers depict larger 
volumes and a cluster of voxels in the upper layers depict smaller volumes. Such 
converse changes across the parietal lobe and hippocampus might explain why no 
overall difference in volume were seen at the ROI level; as the sum of voxels depicting 
smaller volumes cancels out the sum of voxels depicting larger volumes. 
Looking more closely at the frontal lobe we can see that a small cluster of voxels, 
depicting a larger volume in KET-INT mice, is responsible for an overall larger volume in 
KET-INT mice at the ROI level. 







Table 14. ROI analysis versus voxel-wise analysis for volumetric differences in the intermittent 
experiment. Regions where significant (p<0.05, FDR q<0.05) volume changes reside are 


























ii) Daily administration 
In contrast to the atlas-based analysis, voxel-wise TBM analysis revealed significant 
differences in volume between KET-DAY and SAL-DAY mice in multiple brain regions 
(Figure 8). A summary of which regions contain voxels with a significant difference in 
volume can be found in Table 15. 
 
 
Figure 8. Coronal brain slices displaying TBM analysis of volumetric differences between KET-
DAY and SAL-DAY mice. Smaller volumes in KET mice are displayed in blue. Larger volumes in 
KET mice are displayed in red. Data shown are thresholded at p<0.05, FDR corrected at q=0.05. 
L = Left, R = Right. 
 
 
Of the 62 ROIs previously analysed 45 contain voxels that show a significant difference 
in volume. There are some bilateral differences in volume between KET-DAY and SAL-
INT mice. For example, there is a bilateral decrease in volume in the corpus callosum 
(panels 2-4, Figure 8). There is also a bilateral increase in volume in voxels of the upper 
layers of the parietal cortex (panel 4, Figure 8). Overall, like the intermittent experiment, 




Table 15. ROI analysis versus voxel-wise analysis for volumetric differences in the daily 
experiment. Regions where significant (p<0.05, FDR q<0.05) volume changes reside are 






iii) Comparing results across daily and intermittent experiments 
In both the daily and intermittent experiments ketamine has altered brain volume across 
multiple voxels in multiple brain regions. Some regions contain similar clusters of voxels 
depicting the same direction of change in volume, for example: 
• Frontal cortex; in both experiments there are voxels within and next to the 
prefrontal cortex which depict an increase in volume in mice given ketamine. 
This cluster of voxels is larger in KET-INT mice and spans more of the prefrontal 
cortex and motor cortex (panel 1, Figure 7) than in KET-DAY mice (panel 1, Figure 
8) 
• Parietal cortex; in both experiments there are voxels within the upper layers of 
the parietal cortex (more so in the left hemisphere of the somatosensory areas) 
that depict larger volumes in both KET-INT mice (panels 4&5, Figure 7) and KET-
DAY mice (panels 4&5, Figure 8) 
• Cerebellar cortex; in both experiments there are voxels within the cerebellar 
cortex that show a smaller volume within mice given ketamine (panel 10 Figure 
7 and panel 10 Figure 8). The cluster size is roughly equal in both experiments. 
These data suggest that repeat ketamine exposure has common effects on brain 
structure regardless of the interval of repeat administration, which suggests that these 
changes may be driven by similar cellular and molecular mechanisms. However, there 
are also clusters of voxels in the same anatomical, location across both experiments, 
which show opposite changes in volume in mice given ketamine. For example, in the 
corpus callosum of KET-INT mice there is an increase in volume (panel 2, Figure 7), 
whereas in KET-DAY mice there is a decrease in volume (panel 2, Figure 8). This would 
suggest that the interval of repeat ketamine administration has different effects on brain 
structure which might arise through different cellular and molecular mechanisms. 
Moreover, there are also structural changes present in the intermittent experiment that 
are not present in the daily experiment and vice-versa. Examples include; 
• A large cluster of voxels in the left striatum of KET-INT mice that displays a 




• A large cluster of voxels in the right visual cortex of KET-DAY mice that displays a 
significant reduction in volume (panel 8, Figure 8), which is not present in KET-
INT mice. 
 
c) Comparing the effects on brain volume of repeat ketamine administration in 
mice to repeat ketamine use in humans 
 
Consistent with and extending the published findings of Liao et al (2011) and Wang et al 
(2013), the data presented in chapter 2 of this thesis provides evidence that repeat 
ketamine use in humans results in significant reductions in brain volume in the cerebral 
cortex, cerebellum and caudate/putamen (i.e. striatum). In the subsequent section, I 
compare these volume changes to those observed in mice exposed to both daily and 
intermittent ketamine administration. 
 
i) Cerebral cortex 
Data presented in chapter 2 of this thesis suggests that chronic ketamine users present 
with a smaller cerebral cortex, specifically in the frontal lobe; superior frontal cortex and 
middle frontal cortex, consistent with published data (Liao et al., 2011; Wang et al., 
2013). However, in contrast to these data, in my mouse ketamine experiments I did not 
find any general reduction in cortical volume. The atlas-based segmentation data 
suggested that mice exposed to ketamine intermittently (KET-INT), but not daily (KET-
DAY), have a significantly larger frontal lobe. The TBM analysis of structural MR images 
from both KET-INT and KET-DAY mice, which has increased sensitivity, extends this to 
reveal clusters of voxels with significantly increased volume in the prefrontal cortex 
(PFC; panel 1 Figure 7 and panel 1 Figure 8), supplementary motor area (panels 4-6 
Figure 7 and panels 4-6 Figure 8), anterior cingulate cortex (ACC; panel 3 Figure 7 and 
panel 3 Figure 8), visual cortex and auditory cortex (panels 6&7 Figure 7 and panels 6&7 
Figure 8). Thus, at the level of the frontal lobe, the impact of ketamine exposure in 
humans and mice appears to be completely opposite. It is important to note however, 
that the TBM analysis also reveals sparse, but statistically significant clusters of voxels in 
the somatosensory cortex, motor cortex, insular cortex, piriform cortex and visual cortex 
with reduced volume in both KET-INT and KET-DAY mice.  
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Overall then, with regards to the impact of repeat ketamine exposure, there are both 
similarities and differences across the two species. The mechanism by which these 
different changes arise is for the moment unclear and species-specific effects are 
possible and cannot be definitively excluded.  
It is conceivable, however, that these differences, particularly in the frontal lobe are the 
by-product of additional drug use in human ketamine users. I hypothesize that heavy 
and frequent use of multiple psychotropic drugs by ketamine users is having a 
detrimental effect on the frontal lobe leading to cerebral atrophy. Indeed, in the study 
by Liao (2011), the data were not controlled for smoking status and there is evidence to 
suggest that smoking directly impacts on brain volume (Li et al., 2015; Peng et al., 2018). 
 
ii) Cerebellum 
Data published by Wang et al (2013), report cerebellar atrophy in ketamine users 
compared to a small number of non-poly drug users as controls. Controlling (insofar as 
possible) for poly-drug use, my own data in chapter 2, confirms that ketamine users have 
a significantly reduced volume of the cerebellar cortex, as compared to poly-drug 
controls. Atlas based segmentation of the mouse ketamine data, did not find any 
significant differences in the total volume of the cerebellar cortex in either KET-INT or 
KET-DAY mice, compared to vehicle controls. In contrast, the more sensitive TBM 
analysis revealed that both KET-INT and KET-DAY mice have clusters of voxels with 
significantly reduced volume in cerebellar cortex lobules 4 and 5 (panel 10 Figure 7 and 
panel 10 Figure 8). Notably, this analysis also revealed clusters of voxels with significant 
volume increases in both KET-INT and KET-DAY mice in lobule 6 of the cerebellar cortex. 
These contradictory effects in the mouse TBM data therefore likely explain the lack of 
overall differences in total cerebellar cortex volume. These data also suggest that repeat 
ketamine exposure has both common and distinct effects on the volume of the 
cerebellum across species, as revealed by the greater sensitivity and higher resolution 
of the mouse data. 
 
iii) Striatum 
Like in the cerebellum, Wang et al (2013) reported evidence for atrophy of the striatum 
of ketamine users. My own data on ketamine users also provides evidence for decreased 
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volume of the nucleus accumbens and caudate nucleus (Chapter 2) as compared to poly-
drug controls. Atlas-based segmentation analysis revealed that neither the volumes of 
the striatum nor the nucleus accumbens were significantly different to vehicle controls 
in both KEY-INT and KET-DAY exposed mice. Again however, the more sensitive TBM 
analyses of these datasets revealed clusters of voxels with reduced volume in the left 
striatum of both KET-INT and KET-DAY mice, as compared to vehicle controls. These, at 
least qualitatively, appear to be largest in the KET-INT exposed mice. However, it is also 
worth noting that TBM analysis revealed small clusters of voxels with increased volume 
in the left nucleus accumbens of both KET-INT and KET-DAY mice as compared to vehicle 
controls.  
 
d) Region of interest analysis of DTI differences in mice repeatedly given ketamine 
or saline 
 
As discussed in chapter 1 and the introduction to this chapter, DTI is used to measure 
structural changes in the brain by measuring the diffusion of water through neural tissue 
(Le Bihan et al., 2001). MD is a measure of the mean rate of water diffusion in a given 
locus in all directions. AD is a measure of water diffusion parallel to the orientation of 
axons and white matter fibres. RD is a measure of the diffusion of water orthogonal to 
the orientation of axons and white matter fibres. FA is a measure of the preferential 
diffusion of water molecules in each direction. Values of FA range from 0 (isotropic 
diffusion) to 1 (anisotropic diffusion). Differences in any of these parameters between 
ketamine and saline mice would suggest a difference in the cellular composition of 
neural tissue in that given region of the brain.  
Using the mouse MR pipeline, I split each of the DTI scans into the following DTI 
parameter maps; FA, MD, RD and AD. Differences in any of these parameters between 
ketamine and saline mice would be predicted to suggest a difference in the cellular 
composition of neural tissue in that given position within the brain, which may be more 
sensitive than volumetric changes alone.   
I first used the MR pipeline to extract values of FA, MD, AD and RD for each of the 62 
ROIs comprising the Dorr atlas (Dorr et al., 2008), from parameter maps from every 
mouse in my daily and intermittent experiments. I then compared average values for 
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each DTI parameter between KET-INT and SAL-INT mice and between KET-DAY and SAL-
DAY mice. 
 
i) Mean diffusivity (MD) 
I first compared average values of MD in KET-INT mice versus SAL-INT mice. I found no 
significant differences in any of the 62 ROIs (Figure 9 and Table 16). 
 
 
Figure 9. Coronal sections of group mean MD images from KET-INT and SAL-INT mice. L= left, R= 
Right. 
  
Next, I compared average MD values between KET-DAY and SAL-DAY mice. I found 
significant reductions, at p≤0.05 and FDR q≤0.05, in MD in 24 of 62 ROIs (Figure 10 and 
Table 17). Of these 10 were grey matter ROIs; entorhinal cortex, parieto-temporal lobe, 
frontal lobe, inferior olivary complex, superior olivary complex, interpeduncular nucleus, 
pontine nucleus, superior colliculus, midbrain and amygdala. A further 13 were white 
matter ROIs; arbor vita of the cerebellum, inferior cerebellar peduncle, corpus callosum, 
fimbria, fornix, optic tract, mammillothalamic tract, stria medullaris, fasciculus 
retroflexus, cerebral peduncle, medial lemniscus, facial nerve and lateral septum. The 




Of the 13 white matter ROIs which displayed a significant decrease in MD, 2 were in the 
cerebellum; arbor vita of the cerebellum and the inferior cerebellar peduncle. These two 
changes resulted in an overall decrease in MD in the cerebellum (KET-DAY; 3.18 ± 0.24 






















Figure 10. Coronal sections of group mean MD images from KET-DAY and SAL-DAY mice. L= left, 
R= Right. 
 
ii) Axial diffusivity (AD) 
Next, I compared average AD values between KET-INT and SAL-INT mice. I found no 
significant difference in AD in any of the 62 ROIs (Figure 11 and Table 18). 
 
 








I then compared average AD values between KET-DAY and SAL-DAY mice. I found 
significant reductions in AD in 20 of 62 ROIs in KET-DAY mice (Figure 12, Table 19). Each 
of these 20 ROIs also displayed significant reductions in MD in KET-DAY mice. In total, 9 
of the 20 ROIs were in the grey matter; entorhial cortex, parieto-temporal lobe, frontal 
lobe, inferior olivary comples, superior olivary complex, interpendunclar necleus, 
pontine nucleus, midbrain and amygdala. Additionally, 10 of the regions were in the 
white matter; arbor vita of the cerebelum, inferior cerebellar peduncle, fimbria, fornix, 
mammilothalamic tract, stria medullaris, fasiculus retroflexus, cerebral peduncle, 
medial lemniscus and facial nerve. The last ROI displaying a significant reduction in AD 
in KET-DAY mice was the fourth ventricle. 
Again, there was a significant decrease in AD in 2 ROIs within the cerebellum; arbor vita 
of the cerebellum and inferior cerebellar peduncle, thus there was an overall decrease 
in AD within the cerebellum (KET-DAY; 4.04 ± 0.29 mm2s-1, SAL-DAY; 4.34 ± 0.21 mm2s-
1, t=2.91, p=0.01). 
 
 
















iii) Radial diffusivity 
As with measures of MD and AD, I found no significant differences in RD between KET-
INT and SAL-INT mice (Figure 13 and table 20). 
 
 
Figure 13.  Coronal sections of group mean MD images from KET-INT and SAL-INT mice. L= left, 
R= Right. 
 
However, I did find significant differences in RD in 24 of 62 ROIs when comparing KET-
DAY mice to SAL-DAY mice (Table 21 and Figure 14).Of these 24 regions, 21 also 
displayed a significant reduction in MD in KET-INT mice as follows; entorhinal cortex, 
parieto-temporal lobe, frontal lobe, inferior olivary complex, superior olivary complex, 
interpeduncular nucleus, pontine nucleus, superior colliculus, midbrain, amygdala, 
arbor vita of the cerebellum, inferior cerebellar peduncle, corpus callosum, fimbria, 
fornix, optic tract, mammillothalamic tract, stria medullaris, medial lemniscus, facial 
nerve and lateral septum. Additionally, the following regions displayed significant 
reductions in RD; inferior colliculus, stria terminalis and basal forebrain. 
Again, as with MD and AD results KET-DAY mice displayed significantly reduced RD in 



















Figure 14.  Coronal sections of group mean MD images from KET-DAY and SAL-DAY mice. L= left, 
R= Right. 
 
iv) Comparing reductions in MD, AD and RD in KET-DAY mice 
In the KET-DAY mice, of the 24 ROIs which showed significant reductions in MD, a total 
of 17 also presented with significant reductions in both AD and RD; entorhinal cortex, 
parieto-temporal lobe, frontal lobe, inferior olivary complex, superior olivary complex, 
interpeduncular nucleus, pontine nucleus, superior colliculus, midbrain, amygdala, 
arbor vita of the cerebellum, inferior cerebellar peduncle, fimbria, fornix, 
mammillothalamic tract, medial lemniscus, and facial nerve. 
These data (decreased MD, AD and RD) suggest that water diffusion is restricted in all 
directions in these brain regions following repeat daily ketamine exposure.  It may be 
hypothesised that these DTI changes could reflect alterations in common cellular 
compartments, although since both grey and white matter regions are present, this 
requires a detailed post-mortem investigation of both tissue types to confirm. Such a 
general reduction in water diffusion may suggest a physical block or barrier that hinders 
tissue water diffusion. This could reflect an increase in cell number, or an increase in the 
amount of sub-cellular structures in the neuropil, with many more cellular possibilities 
including dendritic branching, an increased number of glial ramifications, increased 
myelination, or a change in the amount and/or orientation of the cerebral vasculature 
(Alexander et al., 2007; Beaulieu, 2009; Zatorre, Fields and Johansen-Berg, 2012; Aung, 
Mar and Benzinger, 2013; Stolp et al., 2018).  
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Of the remaining 7 ROIs displaying a reduction in MD, 3 also displayed a reduction in AD; 
the cerebral peduncle, fasciculus retroflexus and fourth ventricle. Except for the fourth 
ventricle, these changes may be interpreted to suggest restricted water diffusion along 
axons or white matter tracts, possibly due to changes in either axonal or myelin 
thickness, and/or the density of myelin and axons, as well as a change in cell density, 
number and/or morphology (Alexander et al., 2007; Beaulieu, 2009; Zatorre, Fields and 
Johansen-Berg, 2012; Aung, Mar and Benzinger, 2013; Stolp et al., 2018). 
The remaining 4 regions displaying decreases in MD also displayed decreases in RD; 
namely the stria medullaris, corpus callosum, optic tract and lateral septum. These data 
suggest restricted water diffusion across axons and white matter in these regions 
possibly due to changes in myelin content and/or structural organisation (Alexander et 
al., 2007; Beaulieu, 2009; Aung, Mar and Benzinger, 2013). 
Importantly, each of these possible cellular correlates may not be mutually exclusive 
and may occur concurrently, thus detailed post-mortem studies are required to 
establish which of these cellular processes is driving the effects of ketamine. 
 
v) Fractional anisotropy (FA). 
Unlike for MD, AD and RD, I found significant differences in FA between KET-INT and 
SAL-INT mice in 17 ROIs (Figure 15 and Table 22). 10 of these ROIs displayed significant 
increases in FA, both in the grey matter; cuneate nucleus, mammillary bodies, inferior 
olivary complex, entorhinal cortex, and the white matter; fimbria, facial nerve, corpus 
callosum, cerebral peduncle and ventral tegmental decussation. 7 ROI displayed 
significant reductions in FA, again these were both in the grey matter; parieto-temporal 
lobe, frontal lobe, occipital lobe, midbrain, interpeduncular nucleus, dentate gyrus of 
















I next investigated whether there were any differences in FA between KET-DAY and SAL-
DAY mice. I found 6 regions displaying significant increases in FA (Figure 16 and Table 
23); dentate gyrus of the hippocampus, fimbria, stratum granulosum of the 
hippocampus, lateral septum, inferior colliculus and medial lemniscus. Of these 6 
regions, 3 also displayed significant reductions in MD in KET-DAY mice; fimbria, lateral 
septum and media lemniscus. Furthermore, the inferior colliculus also displayed a 
significant reduction in RD in KET-DAY mice. 
 
 
Figure 16. Coronal sections of group mean FA images from KET-DAY and SAL-DAY mice. L= left, 
R= Right. 
 
Comparing differences between daily and intermittent administration of ketamine 
revealed a common reduction in FA in the fimbria of mice exposed to either intermittent 
or daily ketamine. In contrast, whilst there were significant increases in FA in the dentate 
gyrus of KET-DAY mice, there was a significant decrease in FA in the same region in KET-












e) Voxel-based analysis of DTI parameter maps; MD, AD, RD and FA 
 
To complement and extend the atlas based analysis, I next analysed the DTI parameter 
maps on a voxel by voxel basis. Like the TBM analysis in which I extracted volume 
measurements from each voxel in each mouse brain image, using the MR mouse 
pipeline I was also able to extract measures of MD, AD, RD and FA from each voxel of 
my DTI parameter maps from all animals in my two experiments. I was then able to 
compare average vales between KET-INT and SAL-INT mice and between KET-DAY and 
SAL-DAY mice. 
 
i) Daily ketamine administration (MD, AD and RD) 
As I found significant decreases in MA, AD and RD in multiple brain regions in KET-DAY 
mice I decided to first analyse these parameter maps in a voxel by voxel manner. This 
analysis revealed several voxel clusters with significant (p≤0.05 and FDR q≤0.05) 
decreases in MD, AD and RD, spanning multiple brain regions which map onto those 
identified by the atlas-based analysis (Figures 17-19 respectively).  
 
Figure 17. Coronal brain slices displaying mean diffusivity (MD) differences between KET-DAY 
and SAL-DAY mice. Smaller MD in KET-DAY mice are displayed in blue. Larger MD in KET-DAY 




Figure 18. Coronal brain slices displaying axial diffusivity (AD) differences between KET-DAY and 
SAL-DAY mice. Smaller AD in KET-DAY mice are displayed in blue. Larger AD in KET-DAY mice are 
displayed in red. Data shown are thresholded at p<0.05, FDR corrected at q=0.05. 
 
 
Figure 19. Coronal brain slices displaying radial diffusivity (RD) differences between KET-DAY and 
SAL-DAY mice. Smaller RD in KET-DAY mice are displayed in blue. Larger RD in KET-DAY mice are 
displayed in red. Data shown are thresholded at p<0.05, FDR corrected at q=0.05. 
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59 of 62 previously assessed brain regions displayed voxel clusters with significant 
decreases in MD (table 24), 60 of 62 previously analysed ROIs displayed voxel clusters 
with significant decreases in AD (Table 25) and 59 of 62 brain regions displayed voxel 
clusters with significant decreases in RD (Table 26).  
In general, the differences in MD, AD and RD between KET-DAY and SAL-DAY mice are 
very extensive, particularly within the frontal cortex, basal ganglia, hippocampus, 
thalamus, ventral midbrain and most major white matter tracts. Thus, daily repeat 
ketamine administration clearly has a profound effect on mouse brain microstructure.  
  
ii) Interittent ketamine administration (MD, AD and RD) 
 
Although I did not find any significant differences in MD, AD and RD in my ROI analysis 
of KET-INT mice, I analysed this dataset for voxel-level differences in these parameters, 
based on the increased sensitivity of this method, including the ability to reveal whether 
there may be both increases and decreases in these parameters within a given ROI. This 
is important, since the atlas ROI are large and interpolate the signal to an average across 
all voxels contained in the ROI. Hence, if there are differential effects within a given ROI, 
these will not be seen and will likely average out to no net change. Furthermore, since 
the analysis is conducted on a per voxel basis, rather than a global average of the ROI, it 
is inherently more sensitive to detect subtle perturbations of brain structure.  
It is not surprising therefore that a voxel-wise analysis of the DTI data revealed 
significant (p≤0.05 and FDR q≤0.05) differences in MD, AD and RD in clusters of voxels 





Figure 20. Coronal brain slices displaying mean diffusivity (MD) differences between KET-INT 
and SAL-INT mice. Smaller MD in KET-INT mice are displayed in blue. Larger MD in KET-INT mice 
are displayed in red. Data shown are thresholded at p<0.05, FDR corrected at q=0.05. 
 
 
Figure 21. Coronal brain slices displaying axial diffusivity (AD) differences between KET-INT and 
SAL-INT mice. Smaller AD in KET-INT mice are displayed in blue. Larger AD in KET-INT mice are 





Figure 22. Coronal brain slices displaying radial diffusivity (RD) differences between KET-INT and 
SAL-INT mice. Smaller RD in KET-INT mice are displayed in blue. Larger AD in KET-INT mice are 
displayed in red. Data shown are thresholded at p<0.05, FDR corrected at q=0.05. 
 
45 of 62 previously assessed brain regions displayed voxel clusters with significant 
differences in MD (Table 27), 40 of 62 previously analysed ROIs displayed voxel clusters 
with significant decreases in AD (Table 28) and 47 of 62 brain regions displayed voxel 
clusters with significant decreases in RD (Table 29). 
Unlike in KET-DAY mice, decreases in MD, AD and RD in KET-INT mice are clearly much 
more restricted and the size of the voxel clusters is noticeably smaller. Furthermore, 
unlike in KET-DAY mice, where the effects on, MD, AD and RD reflect a rather common, 
almost global decrease, the KET-INT mice appears to show a balance between both 
increases and decreases in MD, AD and RD in KET-INT mice, which often overlap within 
a specified ROI and may be lateralised, rather than bilateral. These factors likely combine 
to explain the overall lack of significance in the atlas data for the KET-INT dataset, and 
highlight the power of voxel-wise analysis to complement and extend the atlas-based 
analysis. 
For example, regions displaying clusters of voxels with bilateral decreases in  MD, AD 
and RD in KET-INT mice included the cerebral cortex (frontal, parietal, temporal and 
occipital lobes) where decreases were more widespread in the left hemisphere of each 
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region, the  corpus callosum, where decreases were more pronounced in the right 
hemisphere and the amygdala, where decreases were more pronounced in the right 
hemisphere (panel 6 in Figures 20-22). 
Similarly, there are examples of regions displaying clusters of voxels with unilateral 
decreases in MD, AD and RD in KET-INT mice including the left striatum (panel 4 in 
Figures 20-22), right hippocampus (panel 7 in Figures 20-22) and left lobule of the 
cerebellar cortex (panels 11&12 in Figures 20-22). Examples of regions displaying 
clusters of voxels with unilateral increases in MD, AD and RD in KET-INT mice include the 
left piriform cortex (panels 5&6 in Figures 20-22), right thalamus (panel 6 in Figures 20-
22), left amygdala (panel 7 in Figures 20-22) and right lobule of the cerebellar cortex 
(panels 10&11 in Figures 20-22). 
Despite these differences, it is notable that several brain regions in both KET-DAY and 
KET-INT mice show similar directional changes in MD, AD and RD, albeit of lower 
magnitude in the KET-INT mice. Examples include significant decreases in MD, AD and 
RD within the cerebral cortex (particularly in the upper layers of the left hemisphere) 
and in the corpus callosum. As mentioned above, the clusters of voxels displaying these 
decreases do however appear smaller and less widespread in KET-INT mice compared 





Table 24. Region of interest analysis versus voxel-wise analysis for mean diffusivity (MD) 
differences in the daily experiment. Regions where significant (p<0.05, FDR q< 0.05) changes 





Table 25. Region of interest analysis versus voxel-wise analysis for axial diffusivity (AD) 
differences in the daily experiment. Regions where significant (p<0.05, FDR q< 0.05) changes 





Table 26. Region of interest analysis versus voxel-wise analysis for radial diffusivity (RD) 
differences in the daily experiment. Regions where significant (p<0.05, FDR q< 0.05) changes 





Table 27. Region of interest analysis versus voxel-wise analysis for mean diffusivity (MD) 
differences in the intermittent experiment. Regions where significant (p<0.05, FDR q< 0.05) 
changes reside are highlighted in green. Regions where no significant changes reside are 




Table 28. Region of interest analysis versus voxel-wise analysis for axial diffusivity (AD) 
differences in the intermittent experiment. Regions where significant (p<0.05, FDR q< 0.05) 
changes reside are highlighted in green. Regions where no significant changes reside are 





Table 29. Region of interest analysis versus voxel-wise analysis for radial diffusivity (RD) 
differences in the intermittent experiment. Regions where significant (p<0.05, FDR q< 0.05) 
changes reside are highlighted in green. Regions where no significant changes reside are 





iii) FA differences in both daily and intermittent experiments 
In KET-INT mice I found widespread significant differences in FA, compared to controls 
(Figure 23). For example, there were significant bilateral decreases in FA in clusters of 
voxels in the cerebral cortex; frontal, parietal, temporal and occipital lobes. There were 
significant bilateral increases in FA in the corpus callosum (panels 3-7, Figure 23), lower 
cortical layers of the frontal lobe (panel 2, Figure 23) and hippocampus (panel 8, Figure 
23). There were also unilateral decreases in FA in voxel clusters of the right insular cortex 
(panel 3, Figure 23), left thalamus (panel 6, Figure 23), right internal capsule (panel 6, 
Figure 23) and right medial cerebellar nucleus (panel 11, Figure 23). Furthermore, there 




Figure 23. Coronal brain slices displaying fractional anisotropy (FA) differences between KET-
INT and SAL-INT mice. Smaller FA in KET-INT mice are displayed in blue. Larger FA in KET-INT 
mice are displayed in red. Data shown are thresholded at p<0.05, FDR corrected at q=0.05. 
 
For a comparison between where significant differences in FA are located, in KET-INT 




Table 30. Region of interest analysis versus voxel-wise analysis for fractional anisotropy (FA) 
differences in the intermittent experiment. Regions where significant (p<0.05, FDR q< 0.05) 
changes reside are highlighted in green. Regions where no significant changes reside are 




In KET-DAY mice I found significant differences in FA in 58 of 62 previously analysed ROIs 
(Figure 24 and Table 31).  
 
Figure 24. Coronal brain slices displaying fractional anisotropy (FA) differences between KET-
DAY and SAL-DAY mice. Smaller FA in KET-DAY mice are displayed in blue. Larger FA in KET-DAY 
mice are displayed in red. Data shown are thresholded at p<0.05, FDR corrected at q=0.05. 
 
Compared to differences observed in KET-INT mice, differences in FA in KET-DAY mice 
are restricted to smaller clusters of voxels. In KET-DAY mice there are significant bilateral 
decreases in FA in clusters of voxels in the corpus callosum and fornix. Further significant 
decreases in FA in clusters of voxels, in KET-DAY mice, can be seen in the cerebral cortex, 
right thalamus, midbrain and cerebellar cortex. Whereas examples of clusters of voxels 
displaying significant increase in FA, in KET-DAY mice, can be seen in the corpus 
callosum, fornix, left thalamus, right occipital cortex and right medial cerebellar nucleus. 
Further comparing results found in KET-INT mice to those found in KET-DAY mice; similar 
increases in FA can be seen in the corpus callosum (panel 4 in Figures 23&24), fornix 
(panel 5 in Figures 23&24), left thalamus (panel 6 in Figures 23&24), right occipital lobe 
(panel 9 in Figures 23&24) and right medial cerebellar nucleus (panel 11 in Figures 
23&24). Moreover, similar decreases in FA can be seen in the upper layers of the left 
cerebral cortex of the frontal lobe (panels 2-4 in Figures 23&24), deeper layers of the 
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right parietal lobe; somatosensory cortex (panel 7 in Figures 23&24) and in lobule 6 of 
the cerebellar cortex (panel 11 in Figures 23&24). 
These data suggest that repeat ketamine exposure in mice affects the structure of a 
common series (or network) of brain regions, irrespective of the frequency of 
administration (daily vs. intermittent). However, the magnitude of these changes does 
appear to be dependent on the frequency of drug exposure. Specifically, at least for MD, 
RD and AD, effects of greater magnitude are observed following daily administration, as 
opposed to intermittent administration. Regarding FA, the larger magnitude changes are 
found following intermittent, as compared to daily ketamine administration. The reason 
for these apparent differences, depending on which DTI metric is considered is 
intriguing, but currently lacks a mechanistic explanation. Nonetheless, this highlights the 
power of pre-clinical studies where MRI changes can then be explored post-mortem at 
the cellular level. Indeed, in the context of ketamine effects on brain structure, a testable 
hypothesis given the data, is whether similar cellular mechanisms may be driving the 






Table 31. Region of interest analysis versus voxel-wise analysis for fractional anisotropy (FA) 
differences in the daily experiment. Regions where significant (p<0.05, FDR q< 0.05) changes 






iv) Comparing the effects of repeat ketamine exposure in mice with repeat ketamine 
use in humans on changes in brain structure, as seen by DTI 
 
Human studies of the impact of ketamine on brain microstructure as revealed by DTI are 
very sparse in the literature. To date, only the studies of Liao et al (2010) and Roberts et 
al (2014), have examined differences in DTI metrics between human repeat ketamine 
users, with each study focussing only on white matter and no data available on grey 
matter. These studies do however; find evidence for significant structural alterations in 
the white matter of the frontal and tempero-parietal lobe. More specifically, Liao and 
colleagues found decreased FA in white matter tracts of the frontal lobe and 
temporoparietal lobe (Liao et al., 2010). In contrast, Roberts and colleagues (2014) 
found reductions in AD in the white matter bundles innervating the grey matter of the 
cerebral cortex; anterior corona radiata, forceps major, anterior forceps minor, superior 
longitudinal fasciculus, inferior longitudinal fasciculus, posterior thalamic radiation, and 
fronto-occipital fasciculus.Although mice and humans have similar gross brain 
anatomies (e.g. they both have a cerebral cortex and corpus callosum), detailed 
anatomy differs in complexity by several orders of magnitude between the two species. 
For example, the human cerebral cortex is highly folded and contains multiple gyri and 
sulci, the gyri being innervated by white matter fibre bundles. This cerebral architecture 
is not present in mice and nor are the fibre tracts listed above as displaying significant 
reductions in AD in the study of Roberts et al (2014). Taken together, this makes any 
comparison of DTI changes seen in white matter bundles in the brain of human ketamine 
users to those seen in mice difficult.  
Nevertheless, rough comparisons can be made particularly for major white matter tracts 
or grey matter lobes that are broadly speaking, present in both species. For example, I 
found clusters of voxels displaying decreased FA in both KET-INT and KET-DAY mice in 
the grey matter of the frontal lobe and parieto-temporal lobe, both of which are 
innervated by myelinated fibres arising from the corpus callosum and external capsule. 
Furthermore, in KET-DAY mice, I found significant decreases in AD in the following 
cerebral white matter bundles; corpus callosum, cerebral peduncle, fasciculus 
retroflexus, fimbria, fornix, mammillothalamic tract and stria medullaris. Hence, as the 
direction of change in FA and AD is the same in the frontal lobe, parieto-temporal lobe 
and white matter bundles of both mice (given repeat ketamine) and human ketamine 
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users then there is likely to be a common cellular/molecular mechanism responsible for 
these changes. 
This conclusion is further re-enforced by the rather interesting animal study involving 
non-human primates; the cynomolgus monkey, in which ketamine induced decreases in 
FA, similar to those seen in humans, have been reproduced (Li et al., 2017). In this study 
ten male adolescent cynomolgus monkeys were divided into two groups and given 
either 1mg/kg of ketamine or saline daily, via intravenous injection for 3 months. The 
monkeys then underwent DTI scanning and images were compared between the two 
groups. Like the findings from humans in Liao et al (2010), monkeys given ketamine 
presented with reduced FA in the left middle temporal gyrus and left frontal gyrus.  
The cynomolgus monkey is evolutionarily closer to humans and the monkey brain is 
more like that of the human brain, in comparison to how similar the mouse brain is to 
the human brain. The results from Li et al (2017) then support the conclusions drawn in 
Liao et al (2010); that repeat ketamine administration is responsible for the decrease in 
FA in white matter bundles of the frontal lobe and temporoparietal lobe. Moreover, 
these results support a common mechanism, for ketamine-induced decreases in FA, 
across all three species. 
f) Summary 
 
In this chapter I have demonstrated that both daily and intermittent ketamine 
administration results in significant structural and microstructural re-arrangement of 
the mouse brain as compared to those mice exposed to vehicle-control. Whilst ketamine 
exposure affects similar series or networks of brain regions, there are differences in the 
magnitude of the effect, which appear to be dependent on the frequency of drug 
administration. For example, with respect to volume change, ketamine appears to have 
a greater effect when given intermittently and KET-INT mice present with a greater 
number of large cluster changes in volume, throughout the brain. In contrast, in terms 
of structure as indexed by DTI, ketamine appears to have a greater effect when given 
daily on MD, RD and AD, but not FA, the latter being more strongly affected in the KET-
INT mice.  
Overall, my data suggest that whilst there is some degree of convergent overlap in the 
directionality of volume changes following repeat ketamine exposure across species, 
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particularly in the striatum, there is also clearly divergence, particularly regarding the 
effects of ketamine on the volume of the frontal lobe and nucleus accumbens between 
mice and humans. Of course, species-specific differences in the response to ketamine 
cannot be definitively excluded. Nonetheless, it is equally plausible that these 
differences arise as a function of exposure to additional drugs in the human users. For 
example a reduction in cerebral volume as has been seen to occur in independent 
studies for the following drugs, nicotine, alcohol, cocaine and heroin (Lim et al., 2008; 
Liu et al., 2009; Grodin, Lin, C. A. Durkee, et al., 2013; Li et al., 2015).  
The mechanisms driving the observed effects of ketamine at the cellular level are also 
unclear, but the mouse model offers the opportunity to probe this, guided by the MRI 
findings, as presented in Chapter 4 of this thesis and discussed in the preceding sections. 
It should be noted, however, that all animal studies modelling clinical and/or human 
conditions need to make approximate choices and thus several limitations and caveats 
apply. This should be kept in mind when considering the highly contextual nature of MRI 
data (see Chapter 1). Specifically, it is conceivable that the dose and duration of the 
ketamine exposure in the mouse model employed in this study is not enough to 
recapitulate the spectrum of changes in brain volume observed in the human users. 
Since I did not have access to specific data on these parameters, this is an obvious 
limitation. Nonetheless, I did find some common effects of ketamine on brain volume 
across species, supporting my choices about the dose and frequency of ketamine 
injection. These were based on careful consideration of the available literature and 
reflect a pragmatic and rational start-point for future studies to address the impact of 
additional ketamine doses and / or longer duration of exposure on mouse brain 
structure. These studies should also be extended to include an assessment of the impact 
of early exposure to ketamine during vulnerable periods of brain development such as 
adolescence. Indeed, the demographic data on the ketamine users (Chapter 2) strongly 
suggests that these individuals may have begun using drugs (including alcohol and 
tobacco) much earlier than the poly-drug controls, as evidenced by the longer duration 
of exposure, despite matching for age. Animal studies also clearly point to long-term 
detrimental effects of adolescent ketamine exposure on adult brain function and 
cognitive behaviour, using a similar dose range to that used in the current study 
(Featherstone et al., 2012). However, MRI data for these models is currently lacking and 
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represents an important gap in our knowledge, as does any evidence for sex-specific 
effects. 
A further point to consider in the interpretation of these data is that the effects observed 
in human ketamine users on brain volume may also very likely reflect complex 
interactions between drug use and pre-existing genetic variation between individuals, 
as well as the possibility of additional environmental hits in terms of socio-economic 
status and so on. Support for this possibility is provided by studies of the effects of 
cannabis exposure on cortical thickness, which is clearly moderated by individuals 
genetic pre-disposition, as indexed by the polygenic risk score, indicative of “loading” 
for a greater or lesser number of single nucleotide polymorphisms in schizophrenia 
susceptibility genes (French et al., 2015). There is also considerable comorbidity 
between schizophrenia and substance use disorder, which is partially attributable to 
shared polygenic liability (Hartz et al., 2017). Notably then, many of the ketamine users 
in the human data set report at least one family member with a history of mental health 
problems (see Chapter 2). Since these disorders are highly heritable such gene x 
environment interactions driving the MRI data are likely, which would not be 
recapitulated in my mouse model.  Future studies are therefore required to explore any 
potential genetic risk factor x ketamine interactions. 
On the other hand, both human ketamine users and mice treated with repeat doses of 
ketamine present with decreases in FA in the frontal lobe and parieto-temporal lobe, as 
well as with decreases in AD in cerebral white matter tracts. Hence, it is likely that a 
common cellular/molecular mechanism is responsible for these changes and this is 

















Chapter 4 Cellular correlates of neuroimaging 
changes seen in two mouse models of 






As discussed elsewhere in this thesis, both human ketamine users (chapter 2) and mice 
exposed to repeat doses of ketamine (chapter 3) present with decreases in FA in the 
frontal and parieto-temporal lobe grey matter, accompanied by decreases in AD in 
cerebral white matter tracts (Liao et al., 2010, 2011; Wang et al., 2013; Edward Roberts 
et al., 2014). It is therefore plausible that a common cellular mechanism may be 
responsible for these changes, which requires the cellular correlates of these MR 
changes be investigated further.  
Furthermore, mice repeatedly exposed to ketamine (chapter 3) display changes in the 
volume of the cerebral cortex, dependent on the frequency of ketamine administration. 
Specifically, mice exposed to intermittent injections of ketamine (once every 3 days for 
30 days) were found to have a significantly larger frontal lobe, as compared to saline 
controls. A similar effect was present in mice exposed to daily injections of ketamine, be 
it to a much lesser extent. These data are the exact opposite  of what has been previously 
reported in human ketamine users, which describe a decrease in frontal lobe grey 
matter volume (Liao et al., 2011; Wang et al., 2013). Whilst the cellular nature of the 
grey matter loss in humans is unknown, the fact that the opposite occurs in mice, 
particularly following intermittent drug exposure, is intriguing and requires further 
investigation. 
Acute injections of ketamine induce elevations in glutamate release in the both the 
mouse and human frontal cortex (Kim et al., 2011a; Stone, Dietrich and Edden, 2012). 
Similarly, acute ketamine exposure is associated with elevated 2-deoxyglucose (2-DG) 
uptake, indicative of increased neural activity and functional connectivity between the 
frontal cortex and several other brain regions, including the thalamus and hippocampus 
(Dawson et al., 2014). Acute exposure to ketamine also results in elevated cerebral 
protein synthesis (Autry et al., 2011) and increases in both plasticity (e.g. ARC) and 
synaptic (e.g. PSD-95) proteins, as well as increased density of dendritic spines (Li et al., 
2010).  It is therefore plausible that intermittent, but not daily ketamine administration 
induces a recurrent cerebral plasticity, resulting in a structural adaptation to ketamine 
exposure, in this case, increased volume in the mouse frontal cortex. Support for this 
hypothesis also comes from MRI studies on learning in mice, in which morphological 
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changes detected by MRI associated with learning a behavioural task (e.g. Morris water 
maze) have been seen to increase synthesis of proteins associated with synaptic 
plasticity such as GAP-43, BDNF, synaptic and astrocyte proteins (Lerch et al., 2011; Sagi 
et al., 2012). 
Whilst these data offer several testable hypotheses about the effect of ketamine 
exposure on grey matter, with regards to what cellular changes may underlie ketamine-
driven changes in the DTI parameters; FA and AD is much less clear. Indeed, dissecting 
how changes in DTI metrics relate to specific structural alterations at the cellular level is 
fraught with difficulty and has multiple possible solutions that may not be mutually 
exclusive. For example, in the case of FA, a change in this metric may reflect changes in 
myelin, membrane permeability, axonal number or size, or a combination of all those 
factors (Jones, Knösche and Turner, 2013). Additional cellular changes may also occur, 
including, but not limited to; an increase in glial cell number, or an increase in the 
amount of sub-cellular structures in the neuropil characterised by increased dendritic 
branching or spine formation, increased glial ramification, or a change in the amount 
and/or orientation of the cerebral vasculature (Alexander et al., 2007; Beaulieu, 2009; 
Zatorre, Fields and Johansen-Berg, 2012; Aung, Mar and Benzinger, 2013; Stolp et al., 
2018). However, there is a paucity of information on what may underlie ketamine-
induced structural changes, detectable by MRI. Given the overlap between DTI findings 
in humans (Edward Roberts et al., 2014) and the mouse data in this thesis (Chapter 3) 
such data would be of great interest to the field. 
To address the issues, in this chapter, I have conducted an in-depth investigation of the 
putative cellular correlates underlying structural neuroimaging changes I observed in 
mice exposed to either daily or intermittent ketamine administration (chapter 3). Such 
post-mortem work is labour-intensive, and this requires clear a priori hypotheses about 
regions of interest (ROI) to focus on. I therefore reviewed the neuroimaging data from 
chapter 3 and chose to focus on two specific brain regions for these investigations, 
specifically, the mouse frontal cortex and corpus callosum. The rationale for these 
choices reflects the differences and similarities between the human and mouse MRI 
data. For example, a larger frontal lobe volume in the mouse, particularly after 
intermittent administration, compared to decreased volume in humans.  
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The choice of the corpus callosum, a major white matter tract in the mouse brain, is 
based on my findings that mice exposed to repeat daily doses of ketamine have smaller 
callosal volumes, in contrast to those mice given repeat intermittent ketamine, which 
have larger volumes (section 3.4.b). Furthermore, both daily and intermittent dosing of 
ketamine in mice resulted in reduced MD, AD and RD values in this region, along with 
increases in FA (section 3.4.e), consistent with published human data (Liao et al., 2010; 
Edward Roberts et al., 2014). 
 




1. There will be no significant group-level difference in the number of neurons in 
the frontal lobe. 
2. There will be a significant difference in the number of astrocytes and microglia 
in the frontal lobe and corpus callosum 
3. There will be no significant difference in the number of active astrocytes and 
active microglia in the prefrontal cortex of the frontal lobe and in the corpus 
callosum 
4. There will be a significant difference in the amount of myelin in the prefrontal 
cortex of the frontal lobe and in the corpus callosum 
5. There will be significantly fewer parvalbumin expressing interneurons in the 
prefrontal cortex of the frontal lobe, in mice repeatedly given ketamine 
6. There will be a significant increase in the amount of synaptophysin in the 
prefrontal cortex of the frontal lobe and in the corpus callosum, of ketamine 




1. To investigate whether there is a group-level difference in cell number in the 
frontal lobe and/or corpus callosum, between mice repeatedly administered 






2. To investigate whether there is a group-level difference in the number of 
activated astrocytes and/or microglia in the prefrontal cortex of the frontal lobe 
and/or corpus callosum, between mice repeatedly administered ketamine 
versus saline. 
3. To investigate whether there is a group-level difference in the number of axons 
and amount of myelin content in the prefrontal cortex of the frontal lobe and/or 
corpus callosum, between mice repeatedly administered ketamine versus saline. 
4. To investigate whether there is a group-level difference in the number of 
parvalbumin expressing interneurons in the prefrontal cortex of the frontal lobe, 
between mice repeatedly administered ketamine versus saline. 
5. To investigate whether there is a group-level difference in the amount of 
synaptophysin in the prefrontal cortex of the frontal lobe, between mice 




4.3 Materials and methods 
 
a) Tissue processing 
 
After completion of all MR imaging, fixed brains (n=10 per group; KET-INT, SAL-INT, KET-
DAY, SAL-DAY) were dissected from the skull, and incubated in 4% PFA / 0.01M PBS for 
24 hours, followed by cryoprotection in 30% buffered sucrose solution for 48 hours at 
+4°C. Brains were then mounted on the stage of a freezing microtome (Microm HM 430, 
Wallendorf, Germany), coated with Shandon M-1 embedding matrix (ThermoFisher 
Scientific, Waltham, MA, USA) and 40μm coronal sections were cut and stored 
sequentially in 96 well plates containing an anti-freeze cryoprotectant solution (TCS: 
25% glycerin [vol/vol] 30% ethylene glycol [vol/vol] in 0.2 mol/L phosphate buffer + 
0.05% sodium azide), stored at +4°C. 
 
b) Cresyl Fast Violet (Nissl) staining 
 
To visualize neuronal cytoarchitecture, and to facilitate stereological analyses, 40μm 
brain sections were mounted as a 1 in 6 series on to chrome-gelatin coated slides and 
left to air-dry overnight at room temperature. The slides were then incubated for 10 
minutes in 0.05% cresyl fast violet solution (VWR) with 0.05% acetic acid (VWR) at room 
temperature. Stained sections were then differentiated through a series of graded 
Industrial Methylated Spirit (IMS) solutions (70%, 80%, 90%, 95% and 2x100%) before 





Either a 1 in 6 (prefrontal cortex) or 1 in 12 (frontal lobe and corpus callosum) series of 
brain sections were immunostained free-floating for markers of astrocytes, microglia, 
myelin, axons, interneurons and pre-synaptic proteins (Table 32). Endogenous 
peroxidase activity was quenched with 1% H2O2 in PBS, washed and then blocked in 15% 
normal serum (Vector Laboratories, Peterborough, UK) diluted in PBS-T. The species of 
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normal serum was directed against the host species of the secondary antibody. After 
blocking, sections were incubated overnight at 4°C in primary antibody in 10% normal 
serum in PBS-T. Sections were then washed and incubated at room temperature in 
biotinylated secondary antibody at 1:1000 dilution for 2 hours (Table 32) followed by 
washing and incubation in Vectastain Elite ABC kit (1+1:1000, Vector Laboratories) for 2 
hours before visualization by incubation with a 3’3-diaminobenzidine (DAB) peroxidase 
(HRP) staining kit (Vector Laboratories, Peterborough, UK. Sections were then mounted 
on to chrome-gelatin coated slides, air-dried overnight, differentiated through a series 
of graded Industrial Methylated Spirit (IMS) solutions (70%, 80%, 90%, 95% and 
2x100%), cleared in xylene (VWR) and coverslipped in DPX (VWR).  
 
Table 32. Primary and secondary antibodies used for immunostaining 
 




1 in 20,000 Goat anti rabbit  
(Vector BA1000) 
1 in 1,000 
Rabbit anti-s100b 
(Abcam 41548) 
1 in 2,000 Goat anti rabbit  
(Vector BA1000) 
1 in 1,000 
Microglia 
Rabbit anti-Iba 1 
(Menapath MP-290-CR05) 
1 in 1,000 Goat anti rabbit  
(Vector BA1000) 
1 in 1,000 
Rat anti-mouse CD68 
(AbD Serotec, MCA 1957) 
1 in 1,000 Goat anti rat  
(Vector BA9400) 
1 in 1,000 
Myelin 
Rat anti myelin basic 
protein (Abcam 7349) 
1 in 1,000 Goat anti rat  
(Vector BA9400) 




1 in 500 Goat anti-chicken 
(Vector 9010) 
1 in 1,000 
Interneurons 
 Rabbit anti-parvalbumin 
(Swant PV25) 
1 in 5,000 Swine anti-rabbit 
(Dako E0353) 




(Upstate, ADI-VAM-SV011)  
1 in 100 Goat anti-mouse 
(Vector BA9200) 





Design-based stereology enables the accurate measurement of cell counts (Schmitz and 
Hof, 2005). Design-based stereology is done by first designing a random and systematic 
sampling scheme such that the objects measured are sampled independent of size, 
shape, spatial orientation and distribution (West, 2002). This is important, as the 
measurements of objects will therefore be unbiased to any differences in the 
149 
 
morphology and size of any brain regions being compared. Furthermore, this 
assumption of three-dimensional spatial independence allows for the reduction of 
systemic errors in counting, as compared to other counting methods (Gundersen and 
Jensen, 1987). 
To perform design-based stereological measurements, 40μm brain sections at 1 in 6 or 
1 in 12 intervals which contained the following regions of interest; Frontal lobe (6 
sections between Bregma +0.38mm and +2.8mm), prefrontal cortex (6 sections 
between Bregma +1.34mm and +2.54mm) and corpus callosum (5 sections between 
Bregma +1.7mm and +2.7mm) were collected. These sections were stained for specific 
markers of interest, such as cresyl fast violet for neurons or for markers for astrocytes 
and microglia. These sections were then compared to the Dorr MRI mouse brain atlas 
(Dorr et al., 2008) and to a stereological reference atlas of mouse brain anatomy 
(Paxinos, G. and Franklin, 2001) to accurately draw anatomical boundaries of the regions 
of interest (Figures 25-27). All stereological measures in this study were carried out using 
Stereoinvestigator software (Microbrightfield Inc.) connected to a Zeiss Axioskop 2 MOT 
(Zeiss) with an MBF bioscience camera DC1394 (IIDC). 
Cell counts were performed using an optical fractionator technique (West, 2002). This 
combines an optical dissector, which is a method used to count nuclei in a three 
dimensional context with a fractionator, which is a method for systematic and uniform 
sampling of a two-dimensional area (West, 2002).  The optical dissector includes the 
optical section planes by moving the focal plane along the z-axis and estimates cell 
numbers without any bias towards their size or shape. The fractionator (Gundersen & 
Jensen, 1987), applies systematic random sampling sites, thus reducing the total number 
of cells counted, as well as removing any sampling bias. 
To count cells using the optical fractionator, first, data regarding the thickness of the 
sections and periodicity was recorded. The region of interest was identified in each 
section and a contour is drawn around it at a low magnification. An appropriately sized 
grid is then superimposed onto the drawn contour to provide a succession of systematic 
random sampling sites. A counting frame was then defined at a high magnification such 
that there was a uniform distribution of counting frames for every sampling site defined 





Figure 25.Region of interest identification; corpus callosum. Mouse MR images (A1-5) and 
serological atlas images (B1-5) of the mouse brain were compared to identify the corpus 





Figure 26.Region of interest identification; frontal lobe. Mouse MR images (A1-6) and serological 
atlas images (B1-6) of the mouse brain were compared to identify the frontal lobe (shaded in 





Figure 27.Region of interest identification; prefrontal cortex. Mouse MR images (A1-6) and 
serological atlas images (B1-6) of the mouse brain were compared to identify the prefrontal 




Table 33. Grid sizes and counting frame sizes for stereological cell counting. 
 
 
Cells were then counted at each sampling site, to include those within the defined 
counting frame and those that lie in contact with the upper and right borders (coloured 
green) of the frame, while excluding those outside the counting frame or in contact with 
the left and lower borders of the counting frame (coloured red) (Figure 28).Counts 
obtained by the optical fractionator were within the limits of the Gundersen mean co-
efficient of error (COE) of 0.05-0.1. 
All cell counts were performed whilst blind to the experimental group the animal 
belonged to. 
 
Figure 28. Sample images demonstrating the counting of neurons (A), Iba-1 positive microglia 
(B) and S100b positive astrocytes (C) within the borders of the counting frame. Cells within the 
frame and in contact with the green borders were counted (represented by purple dots). 
 
e) Thresholding image analysis 
 
If a protein or marker is densely distributed in a region, the intensity of immunostaining 
can make it difficult to accurately discriminate individual cells. For example, GFAP 
staining for fibrous astrocytes within any given region. Therefore, attempts to quantify 
such staining using counting methods proves difficult. In such cases, semi-automated 
thresholding image analysis was employed to obtain a measure of the amount of 
staining per microscope field. 
Nissl positive neurons s100b positive atrocytes
Fronta lobe Frontal lobe Corpus callosum Frontal lobe
Counting Frame Width (X) (µm) 60 120 100 120
Counting Frame Height (Y) (µm) 60 120 100 120
Sampling Grid (X) (µm) 600 600 200 600




This technique was employed in the current study to quantify the level of glial activation; 
astrocytes (GFAP) and microglia (CD68), as well as the amount of myelin content (MBP), 
axon density (neurofilament), parvalbumin expressing interneurons and pre-synaptic 
protein (synaptophysin). To quantify immunoperoxidase staining for a given marker in 
each region; non-overlapping images were acquired over 3-6 consecutive sections per 
region (Table 34). Images were acquired using a Leica DRMB microscope (Leica 
Microscopy & GmBH, Wetzlar, Germany) with a Lumenera infinity 3 camera. All images 
were obtained while maintaining consistent parameters of light intensity, camera setup 
and calibrations. 
 
Table 34. Number and magnification of images for thresholding analysis. 
 
 
Images were analysed using Image Pro Plus software (Media Cybernetics, Chicago, IL), 
to select appropriate thresholds for every region (Figure 29). Thresholds were chosen to 
best distinguish between specific immunoreactivity for each antigen and the 
background. Results obtained for each region and each antigen was expressed as % 
immunoreactivity per image. The mean percentage immunoreactivity per region per 
animal was then obtained for further analysis. 
 
a) Qualitative image analysis 
 
GFAP staining in the prefrontal cortex was analysed qualitatively, without the need for 
quantification. Images were taken at x5 and x20 magnification on a Leica DRMB 
microscope (Leica Microscopy & GmBH, Wetzlar, Germany) with a Lumenera infinity 3 
camera. 
 
Immunostain Region of interst Number of images per section Number of sections imaged Total number of images Magnification
GFAP corpus callosum 20 5 100 x63
CD 68 prefrontal cortex 6 3 18 x20
corpus callosum 16 5 80 x63
prefrontal cortex 4 3 12 x10
corpus callosum 16 5 80 x63
prefrontal cortex 4 3 12 x10
Parvalbumin prefrontal cortex 4 to 6 6 32 x20








Figure 29. Selecting thresholds for thresholding image analysis. Representative images showing 
CD68 positive microglia (A), GFAP positive astrocytes (B) and parvalbumin positive interneuron 
(C) staining, thresholded (blue shading) to accurately discriminate positive immunostaining from 
background. 
 
b) Quantitative image analysis 
 
All measurements were performed blind to the experimental group. All statistical 
analysis was performed using GraphPad Prism software (GraphPad Software Inc., La 
Jolla, CA). The mean co-efficient of error for individual measures of cell counts was 
calculated by the Gundersen method (Gundersen & Jensen, 1987), and was between the 
recommended range of 0.05 - 0.1. Statistical analyses for measurements of cell counts 
and thresholding image analysis between two groups was calculated by a two-tailed, 







4.4 Results and discussion 
 
a) Frontal lobe 
 
To investigate the cellular correlates of MR volume and DTI differences between 
ketamine and saline treated mice (section 3.4) I began by comparing cell numbers of 
neurons, astrocytes and microglia in the frontal lobe. 
 
i) Neuron cell counts 
Comparing the number of nissl positive neurons within the frontal lobe of mice 
repeatedly given ketamine versus saline; I found no significant differences between KET-
INT mice (2.09x106 ± 1.16x105, n=9) and SAL-INT mice (2.26x106 ± 1.16x105, n=10), in my 
intermittent experiment (t=1.05, p=0.31) (Figure 30), nor between KET-DAY mice 
(1.42x106 ± 4.68x104, n=8) and SAL-DAY mice (1.35x106 ± 6.52x104, n=10), in my daily 
experiment (t=0.79, p=0.44) (Figure 31).  
 
i) Astrocyte cell counts 
Comparing the number of s100b positive astrocytes within the frontal lobe of mice 
repeatedly given ketamine versus saline; I found no significant differences between KET-
INT mice (2.72x105± 1.20x104, n=10) and SAL-INT mice (2.60x105 ± 1.21x104, n=9), in my 
intermittent experiment (t=0.71, p=0.49) (Figure 32), nor between KET-DAY mice 
(2.52x105 ± 1.15x104, n=10) and SAL-DAY mice (2.84x105 ± 1.20x104, n=9), in my daily 
experiment (t=1.94, p=0.07) (Figure 33). 
However, there was an indication of a trend towards fewer s100b positive astrocytes in 
KET-DAY mice versus SAL-DAY mice. Therefore, I decided to correlate the number of 
s100b positive astrocytes in the frontal lobe, of KET-DAY mice and SAL-DAY mice, with 
measures of MD, AD and RD; which displayed significant differences in value, at the ROI 
level, between KET-DAY and SAL-DAY mice (Figure 34).  
I did not find any significant correlation between the number of s100b positive 
astrocytes and measures of MD, AD or RD within KET-DAY mice only (MD; r=-0.011, 
p=0.98. AD; r=0.023, p=0.95. RD; r=-0.028, p=0.94), SAL-DAY mice only (MD; r=-0.05, 
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p=0.92. AD; r=0.44, p=0.32. RD; r=-0.032, p=0.70), nor within KET-DAY and SAL-DAY mice 
together (MD; r=-0.16, p=0.55. AD; r=0.26, p=0.33. RD; r=-0.08, p=0.77). 
 
ii) Microglia cell counts 
Comparing the number of Iba-1 positive microglia within the frontal lobe of mice 
repeatedly given ketamine versus saline; I found no significant differences between KET-
INT mice (3.55x105 ± 6.36x103, n=10) and SAL-INT mice (3.68x105 ± 5.26x103, n=10), in 
my intermittent experiment (t=1.59, p=0.13) (Figure 35), nor between KET-DAY mice 
(3.62x105 ± 2.23x103, n=9) and SAL-DAY mice (3.60x105 ± 5.06x103, n=10), in my daily 
experiment (t=0.36, p=0.72) (Figure 36). 
However, there was an indication of a trend towards fewer Iba-1 positive microglia in 
KET-INT mice versus SAL-INT mice. Therefore, I decided to correlate the number of Iba-
1 positive microglia in the frontal lobe, of KET-INT mice and SAL-INT mice, with measures 
of FA; which displayed significant differences in value, at the ROI level, between KET-INT 
and SAL-INT mice (Figure 37).  
I found a positive trend between fewer Iba-1 positive microglia and lower FA in KET-INT 
mice only, however this trend was not statistically significant (r=-0.58, p=0.08). 
Furthermore, I found no significant correlation between the number of Iba-1 positive 






Figure 30. No difference between the number of Nissl positive neurons in the frontal lobe of 
SAL-INT and KET-INT mice. A&B) Representative images of Nissl positive cells in SAL-INT mice. A) 
x20 magnification. B) x63 magnification.  C&D) Representative images of Nissl positive cells in 
KET-INT mice. C) x20 magnification. D) x63 magnification. E) Graph of stereological cell counts 






Figure 31. No difference between the number of Nissl positive neurons in the frontal lobe of 
SAL-DAY and KET-DAY mice. A&B) Representative images of Nissl positive cells in SAL-DAY mice. 
A) x20 magnification. B) x63 magnification.  C&D) Representative images of Nissl positive cells in 
KET-DAY mice. C) x20 magnification. D) x63 magnification. E) Graph of stereological cell counts 







Figure 32. No difference between the number of s100b cells in the frontal lobe of SAL-INT and 
KET-INT mice. A&B) Representative images of s100b cells in SAL-INT mice. A) x20 magnification. 
B) x63 magnification.  C&D) Representative images of s100b cells in KET-INT mice. C) x20 
magnification. D) x63 magnification. E) Graph of stereological cell counts of s100b positive cells 





Figure 33. No difference between the number of s100b cells in the frontal lobe of SAL-DAY and 
KET-DAY mice. A&B) Representative images of s100b cells in SAL-DAY mice. A) x20 magnification. 
B) x63 magnification.  C&D) Representative images of s100b cells in KET-DAY mice. C) x20 
magnification. D) x63 magnification. E) Graph of stereological cell counts of s100b positive cells 






Figure 34. Correlations between the number of s100b positive astrocytes and DTI measures of 






Figure 35. No difference between the number of Iba-1 cells in the frontal lobe of SAL-INT and 
KET-INT mice. A&B) Representative images of Iba-1 cells in SAL-INT mice. A) x20 magnification. 
B) x63 magnification.  C&D) Representative images of Iba-1 cells in KET-INT mice. C) x20 
magnification. D) x63 magnification. E) Graph of stereological cell counts of Iba-1 positive cells 





Figure 36. No difference between the number of Iba-1 cells in the frontal lobe of SAL-DAY and 
KET-DAY mice. A&B) Representative images of Iba-1 cells in SAL-DAY mice. A) x20 magnification. 
B) x63 magnification.  C&D) Representative images of Iba-1 cells in KET-DAY mice. C) x20 
magnification. D) x63 magnification. E) Graph of stereological cell counts of Iba-1 positive cells 
in SAL-DAY and KET-DAY mice. 
 
Figure 37. Correlations between the number of Iba-1 positive microglia and DTI measures of FA 
in the frontal lobe of KET-INT (red dots) and SAL-INT mice (blue dots). 
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b) Prefrontal cortex 
 
Although I found no significant differences in neuron, astrocyte or microglial number in 
the frontal lobe, between ketamine treated and saline treated mice, I did see a trend 
towards fewer astrocytes in KET-Day mice and fewer microglia in KET-INT mice. 
Furthermore, I found a positive trend between fewer microglia and lower FA in the 
frontal lobe of KET-INT mice. This suggests that changes to glial cells may, in part, be 
responsible for structural differences observed in the frontal lobe of ketamine treated 
and saline treated mice. However, as seen with MRI differences (section 3.4), these glial 
changes may not be generalised across the entire frontal lobe but may be specifically 
located in sub regions of the frontal lobe. For example; increased volume of the frontal 
lobe in KET-INT mice, compared to SAL-INT mice, was shown to be specific to a cluster 
of voxels within the prefrontal cortex. 
I decided to investigate possible cellular correlates of volume and DTI differences, 
between ketamine mice and saline mice, specifically in the prefrontal cortex. The 
prefrontal cortex is also an interesting sub-region to investigate as decreases in MD, AD 
and RD were seen, within this region, in KET-DAY mice (section 3.4.e). FA differences 
between KET-INT and SAL-INT mice were also observed in the prefrontal cortex (section 
3.4.e). 
Moreover, as discussed in section 1.5, both single and repeat ketamine administration 
have been shown to significantly alter the cellular and molecular organisation of neural 
networks in the prefrontal cortex of rodents. Examples include; a reduction in the 
number of parvalbumin positive GABAergic interneurons, increased extracellular 
glutamate levels  and glutamatergic disinhibition leading to increased excitatory neural 
activity (Zhang, Behrens and Lisman, 2008; Quirk et al., 2009; Kim et al., 2011b; Wang et 
al., 2014). However, the focus in the literature has been on neuronal changes. Therefore, 
I decided to take a novel approach and focus more on potential glial changes that result 
from repeat ketamine administration in mice. 
i) Activated glial cells 
As stated in the introduction to this chapter, I think that repeat ketamine administration 
may be having a plastic effect on the brain, causing remodelling of neural networks, as 
opposed to pathology. In the previous section (4.4.a) I have shown that repeat ketamine 
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administration has no effect on the number of neurons within the frontal lobe, which to 
a degree indicates a lack of pathology. However, to test my hypothesis further, I decided 
to investigate if there was any increase in the number of activated glial cells (GFAP 
positive astrocytes and CD68 positive microglia), in the prefrontal cortex, which would 
be indicative of pathology (Pekny, Wilhelmsson and Pekna, 2014; Yang and Wang, 2015; 
Hiragi, Ikegaya and Koyama, 2018; Skaper et al., 2018; Stephenson et al., 2018). 
With regards to GFAP positive, fibrous astrocytes, these cells under normal physiological 
conditions are mainly found in the white matter and only under pathological conditions 
are they seen in the mouse brain cerebral cortex (Pekny, Wilhelmsson and Pekna, 2014; 
Yang and Wang, 2015). In my qualitative analysis of GFAP immunoreactivity, in the 
prefrontal cortex of ketamine treated and saline treated mice, I observed no difference 
between KET-INT mice and SAL-INT mice (Figure 38) and no difference between KET-
DAY and SAL-DAY mice (Figure 39). I, therefore, did not pursue any quantitative analysis. 
 
Figure 38. Representative images of GFAP positive staining in the prefrontal cortex of SAL-INT 
and KET-INT mice. A&B) SAL-INT mice. A) x 5 magnification. B) x20 magnification.  C&D) KET-
INT mice. C) x 5 magnification. D) x20 magnification. 
 
CD68 is a commonly used marker of microglia activation (Van den Eynde et al., 2014; 
Hoogland et al., 2015; Lu et al., 2015). I found no significant differences in the amount 
of CD68 positive microglia in the prefrontal cortex of KET-INT mice (2.35±0.23, n=8) 
versus SAL-INT mice (2.96±0.35, n=10) , in my intermittent experiment (t=1.47, p=0.16) 
(Figure 40), nor in KET-DAY mice (1.29±0.07, n=10) versus SAL-DAY mice (1.46±0.14, 




Figure 39. Representative images of GFAP positive staining in the prefrontal cortex of SAL-DAY 
and KET-DAY mice. A&B) SAL-DAY mice. A) x 5 magnification. B) x20 magnification.  C&D) KET-
DAY mice. C) x 5 magnification. D) x20 magnification. 
 
The lack of astrocyte or microglial activation between ketamine and saline treated mice 
further supports my hypothesis that repeat ketamine administration is not having a 







Figure 40. No difference between the percentage area of CD68 positive staining in the prefrontal 
cortex of SAL-INT and KET-INT mice. A) Representative images of CD68 positive cells in SAL-INT 
mice. x20 magnification.  B) Representative images of CD68 positive cells in KET-INT mice. x20 






Figure 41. No difference between the percentage area of CD68 positive staining in the prefrontal 
cortex of SAL-DAY and KET-DAY mice. A) Representative images of CD68 positive cells in SAL-
DAY mice. x20 magnification.  B) Representative images of CD68 positive cells in KET-DAY mice. 











i) Myelin, axons and synapses 
Having so far shown no signs of glia pathology, I decided to investigate potential markers 
of plasticity in the prefrontal cortex of ketamine administered mice. I looked to see 
whether there was any difference in the amount of myelin basic protein, neurofilament 
and/or synaptophysin between ketamine and saline treated mice, within the prefrontal 
cortex. This would tell me, indirectly, whether there was any difference in the amount 
of myelin, density of axons and/or density of synapses between these groups of mice, 
within the prefrontal cortex. Changes in myelin content, axon density and the number 
of synapses have all previously been shown to occur in learning and memory, adaptation 
to new experiences, as well as repetitive drug use, and are signs of activity dependent 
remodelling of neural circuits (Bowers, Chen, & Bonci, 2010; Canu, Carnaud, Picquet, & 
Goutebroze, 2009; Fields, 2008; Johansen-Berg, 2007; Lüscher & Malenka, 2011; 
Markham, Herting, Luszpak, Juraska, & Greenough, 2009; Nickel & Gu, 2018; Ramirez-
Amaya, Escobar, Chao, & Bermidez-Rattoni, 1999; Van den Oever, Spijker, & Smit, 2012; 
van Huijstee & Mansvelder, 2015; G. Yang, Pan, & Gan, 2009; Zatorre et al., 2012). 
I first assessed whether there was any difference in the amount of myelin basic protein 
(MBP) between KET-INT (1.16±0.01, n=9) and SAL-INT mice (1.17±0.02, n=8). I found no 
significant difference (t=0.47, p=0.65), Figure 42. 
Nor did I find any significant difference in the amount of MBP in the prefrontal cortex 
between KET-DAY mice (1.10±0.02, n=10) and SAL-DAY mice (1.08±0.02, n=9), (t=1.05, 






Figure 42. Myelin basic protein (MBP) staining in the prefrontal cortex of SAL-INT and KET-INT 
mice. A) Representative images of MBP staining in SAL-INT mice. x10 magnification.  B) 
Representative images of MBP staining in KET-INT mice. x10 magnification. C) Graph of 







Figure 43. Myelin basic protein (MBP) staining in the prefrontal cortex of SAL-DAY and KET-DAY 
mice. A) Representative images of MBP staining in SAL-DAY mice. x10 magnification.  B) 
Representative images of MBP staining in KET-DAY mice. x10 magnification. C) Graph of 
normalised MBP staining intensity across the prefrontal cortex. 
 
Next, I investigated whether there was any difference in the amount of neurofilament 
staining in the prefrontal cortex of ketamine treated and saline treated mice. I found a 
significant increase in the amount of neurofilament staining in KET-INT mice 
(100.9±1.52, n=9) compared to SAL-INT mice (96.21±1.65, n=8), (t=2.11, p=0.05), Figure 
44. However, I found no significant difference between KET-DAY mice (97.4±0.86, n=9) 




Figure 44. Neurofilament (NF) staining in the prefrontal cortex of SAL-INT and KET-INT mice. A) 
Representative images of NF staining in SAL-INT mice. x10 magnification.  B) Representative 
images of NF staining in KET-INT mice. x10 magnification. C) Graph of NF staining intensity 





Figure 45. Neurofilament (NF) staining in the prefrontal cortex of SAL-DAY and KET-DAY mice. 
A) Representative images of NF staining in SAL-DAY mice. x10 magnification.  B) 
Representative images of NF staining in KET-DAY mice. x10 magnification. C) Graph of NF 
staining intensity across the prefrontal cortex.  
 
I then investigated whether there was any difference in the amount of synaptophysin 
staining, in the prefrontal cortex, between ketamine and saline treated mice. I found a 
significant increase in the amount of synaptophysin in KET-INT mice (2.44±0.06, n=7) 
compared to SAL-INT mice (2.25±0.03, n=6), (t=2.81, p=0.017), Figure 46. 
However, I did not find any significant difference in the amount of synaptophysin 
between KET-DAY mice (2.40±0.05, n=9) and SAL-DAY mice (2.41±0.07, n=9), (t=0.13, 






Figure 46. Synaptophysin (Syn) positive staining in the prefrontal cortex of SAL-INT and KET-
INT mice. A&B) Representative images of Syn positive staining in SAL-INT mice. A) x10 
magnification. B) x63 magnification C&D) Representative images of Syn positive cells in KET-
INT mice. C) x10 magnification. D) x63 magnification. E) Graph of normalised Syn staining 






Figure 47. Synaptophysin (Syn) positive staining in the prefrontal cortex of SAL-DAY and KET-
DAY mice. A&B) Representative images of Syn positive staining in SAL-DAY mice. A) x10 
magnification. B) x63 magnification C&D) Representative images of Syn positive cells in KET-
DAY mice. C) x10 magnification. D) x63 magnification. E) Graph of normalised Syn staining 
intensity in SAL-DAY and KET-DAY mice. 
 
The significant increase in the amount of neurofilament and synaptophysin in the 
prefrontal cortex of KET-INT mice suggests that ketamine might be having a remodelling 
effect on neural circuits within this brain region. In turn, this might be responsible for 
the increase in volume and FA observed in this region. Interestingly, within the 
literature, increased axon sprouting, and synaptogenesis have been hypothesised to 
correlate with increases in volume and FA and are indicative of activity-dependent 
remodelling of neural circuits (Zatorre, Fields and Johansen-Berg, 2012). 
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As discussed earlier, ketamine administration has been shown to significantly alter 
excitatory neural activity via a reduction in the number of parvalbumin positive 
GABAergic interneurons, increased extracellular glutamate levels  and glutamatergic 
disinhibition (Zhang, Behrens and Lisman, 2008; Quirk et al., 2009; Kim et al., 2011b; 
Wang et al., 2014).  
Thus, to investigate whether repeat ketamine administration in my experiments was 
driving activity dependent remodelling of prefrontal circuits, I decided to assess whether 
there were any differences in the amount of parvalbumin positive GABAergic 
interneurons between ketamine and saline treated mice. I decided to focus on the 
amount of parvalbumin positive staining as a marker of altered neuronal activity as it 
was one, I could assess using histology. 
However, I found no significant difference in the amount of parvalbumin positive 
interneuron staining between KET-INT (2.68±0.32, n=8) and SAL-INT mice (2.65±0.36, 
n=9), (t=0.06, p=0.96), Figure48. Nor did I find any significant difference between KET-
DAY (2.96±0.24, n=8) and SAL-DAY mice (3.11±0.12, n=12), (t=0.61, p=0.55), Figure 49. 
Although it might initially look as if repeat ketamine administration is not inducing any 
activity dependent plasticity. The lack of any difference in the amount of parvalbumin 
expressing interneurons, as seen in the literature (Quirk et al., 2009; Wang et al., 2014; 
Yang et al., 2016), could be attributed to a two-day wash out period used before 
sacrificing the mice and processing the tissue. In other words, a change in the amount 
of parvalbumin expressing interneurons might be a temporary one and after two days 
when there is no ketamine left in the mice, parvalbumin levels might restore to baseline. 
If this is the case, a temporary reduction in parvalbumin expression may have a 
functional consequence in terms of a reduction of GABAergic inhibition. This in turn 
might lead to increased glutamatergic activity within neuronal circuits and changes in 
behaviour, which subsequently return to baseline.  Electrophysiology and the 
implantation of electrodes into the prefrontal cortex would be a way in which to test 
whether there is any change in the level of excitatory neuronal activity within the region. 
These type of experiments can be performed at various time points throughout a 
ketamine administration experiment and after the cessation of administration, in-vivo 
in freely moving mice (Long and Lee, 2012). Such an experiment would highlight if and 
when neuronal activity is affected during repeat ketamine exposure. Coupled with 
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molecular biology techniques, such as western blot, which can more accurately quantify 
the amount of parvalbumin protein within the region. One could ascertain if and when 
parvalbumin protein expression is altered and if this leads to a change in functional 
activity within neuronal networks. One could take sub-groups of ketamine treated mice 
at different stages of ketamine exposure and/or wash-out and perform western blot 
experiments to test whether parvalbumin expression is temporarily reduced and then 
returns to baseline. 
Moreover, behavioural experiments could be used at various time points to establish 
whether changes in parvalbumin expression and functional activity (due to repeat 
ketamine exposure) within the prefrontal cortex lead to any changes in behaviour.  
 
 
Figure 48. Parvalbumin (PV) positive neurons in the prefrontal cortex. A) Representative 
images of PV positive cells in SAL-INT mice. x20 magnification.  B) Representative images of PV 
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positive cells in KET-INT mice. x20 magnification. C) Graph of the percentage area of PV 




Figure 49. Parvalbumin (PV) positive neurons in the prefrontal cortex. A) Representative 
images of PV positive cells in SAL-DAY mice. x20 magnification.  B) Representative images of PV 
positive cells in KET-DAY mice. x20 magnification. C) Graph of the percentage area of PV 








c) Corpus callosum 
 
Next, I went on to investigate what cellular differences might be present in ketamine 
and saline treated mice, within the corpus callosum. As stated in the introduction to this 
chapter, KET-DAY mice presented with smaller volumes in this region, whereas KET-INT 
mice presented with larger volumes, as seen using sMRI. Furthermore, both daily and 
intermittent dosing of ketamine in mice resulted in reduced MD, AD and RD values in 
this region, along with increases in FA. 
Like my approach in the frontal lobe, I first looked to see whether there was any 
difference in the number of glial cells, in the corpus callosum, between ketamine and 
saline treated mice. 
I found no significant difference in the amount of GFAP positive fibrous astrocytes, which 
normally reside in the white matter, between KET-INT mice (17.27±1.22, n= 10) and SAL-
INT mice (16.32±1.32, n=10), (t=0.53, p=0.60), Figure 50. Nor did I find any significant 
difference in the amount of GFAP positive astrocytes between KET-DAY mice (5.43±0.97, 
n=10) and SAL-DAY mice (5.17±1.15, n=10), (t=0.17, p=0.87), Figure 51. 
Furthermore, I found no significant difference in the number of Iba-1 positive microglia 
between KET-INT mice (46502±2003, n=10) and SAL-INT mice (48785±1274, n=10), 
(t=0.96, p=0.35), Figure 52. Nor did I find any significant difference between the number 
of Iba-1 positive microglia between KET-DAY (45360±2022, n=9) and SAL-DAY mice 






Figure 50. GFAP positive staining in the corpus callosum of SAL-INT and KET-INT mice. A&B) 
Representative images of GFAP positive staining in SAL-INT mice. A) x5 magnification. B) x63 
magnification C&D) Representative images of GFAP positive cells in KET-INT mice. C) x5 
magnification. D) x63 magnification. E) Graph of the percentage area of GFAP positive staining 






Figure 51. GFAP positive staining in the corpus callosum of SAL-DAY and KET-DAY mice. A&B) 
Representative images of GFAP positive staining in SAL-DAY mice. A) x5 magnification. B) x63 
magnification C&D) Representative images of GFAP positive cells in KET-DAY mice. C) x5 
magnification. D) x63 magnification. E) Graph of the percentage area of GFAP positive staining 







Figure 52. Iba-1 positive staining in the corpus callosum of SAL-INT and KET-INT mice. A&B) 
Representative images of Iba-1 positive staining in SAL-INT mice. A) x20 magnification. B) x63 
magnification C&D) Representative images of Iba-1 positive cells in KET-INT mice. C) x20 
magnification. D) x63 magnification. E) Graph of the stereological counts of Iba-1 positive cells 






Figure 53. Iba-1 positive staining in the corpus callosum of SAL-DAY and KET-DAY mice. A&B) 
Representative images of Iba-1 positive staining in SAL-DAY mice. A) x20 magnification. B) x63 
magnification C&D) Representative images of Iba-1 positive cells in KET-DAY mice. C) x20 
magnification. D) x63 magnification. E) Graph of the stereological counts of Iba-1 positive cells 
in the corpus callosum in SAL-DAY and KET-DAY mice. 
 
As there was no significant difference in the number of glia in the corpus callosum, 
between ketamine and saline treated mice, and there was no significant difference in 
the amount of GFAP reactive astrocytes (a marker of activated astrocytes), I took these 
results to mean that there was no glial pathology in this region. These results then are 
like my findings in the frontal lobe and prefrontal cortex. 
I next looked to see whether there were any signs of cellular plasticity, and possible 
remodelling of neural circuits in the corpus callosum, by investigating the amount of 
MBP and neurofilament in the region. 
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I found a significant increase in the amount of MBP in KET-INT mice (117.8±3.01, n=10) 




Figure 54. Myelin basic protein (MBP) positive staining in the corpus callosum of SAL-INT and 
KET-INT mice. A&B) Representative images of MBP positive staining in SAL-INT mice. A) x5 
magnification. B) x63 magnification C&D) Representative images of MBP positive cells in KET-
INT mice. C) x5 magnification. D) x63 magnification. E) Graph of the percentage area of MBP 
positive staining in the corpus callosum in SAL-INT and KET-INT mice. ***; p<0.001 (T-test). 
 
However, I found no significant difference in the amount of MBP positive staining 
between KET-DAY (1.65±0.04, n=10) and SAL-DAY mice (1.62±0.03, n=8), (t=0.54, 






Figure 55. Myelin basic protein (MBP) positive staining in the corpus callosum of SAL-DAY and 
KET-DAY mice. A&B) Representative images of MBP positive staining in SAL-DAY mice. A) x5 
magnification. B) x63 magnification C&D) Representative images of MBP positive cells in KET-
DAY mice. C) x5 magnification. D) x63 magnification. E) Graph of the percentage area of MBP 
positive staining in the corpus callosum in SAL-DAY and KET-DAY mice. 
 
I also found a significant increase in the amount of neurofilament between KET-INT mice 
(135.9±1.91, n=10) and SAL-INT mice (127.2±2.70, n=10), (t=2.62, p=0.02), Figure 56. 
However, I did not find any significant difference in the amount of neurofilament 
positive staining between KET-DAY (116.9±1.15, n=9) and SAL-DAY mice (116.5±1.54, 





Figure 56. Neurofilament (NF) positive staining in the corpus callosum of SAL-INT and KET-INT 
mice. A&B) Representative images of NF positive staining in SAL-INT mice. A) x5 magnification. 
B) x63 magnification C&D) Representative images of NF positive cells in KET-INT mice. C) x5 
magnification. D) x63 magnification. E) Graph of the percentage area of NF positive staining in 







Figure 57. Neurofilament (NF) positive staining in the corpus callosum of SAL-DAY and KET-DAY 
mice. A&B) Representative images of NF positive staining in SAL-DAY mice. A) x5 
magnification. B) x63 magnification C&D) Representative images of NF positive cells in KET-
DAY mice. C) x5 magnification. D) x63 magnification. E) Graph of the percentage area of NF 
positive staining in the corpus callosum in SAL-DAY and KET-DAY mice. 
 
The significant increase in the amount of MBP and neurofilament in KET-INT mice would 
suggest that, like in the prefrontal cortex, ketamine might be having a remodelling effect 
on neural circuits within this brain region (Markham et al., 2009; Zatorre, Fields and 
Johansen-Berg, 2012; Nickel and Gu, 2018). In turn, this might be responsible for the 
increase in FA observed in this region. Thus, I decided to see whether there was any 




I found no significant correlation between FA and the amount of MBP in the corpus 
callosum; neither in KET-INT mice alone (r=-0.14, p=0.70), SAL-INT mice alone (r=0.02, 
p=0.96), nor in KET-INT and SAL-INT mice combined (r=0.09, p=0.70), Figure 58. 
 
 
Figure 58. Correlations between the intensity of MBP immunostaining and DTI measures of FA 
in the corpus callosum of KET-INT (red dots) and SAL-INT mice (blue dots). 
 
However, I did find a significant negative correlation between FA and neurofilament in 
KET-INT mice alone (r=-0.79, p<0.0017), Figure 59. There was no significant correlation 




Figure 59. Correlations between the intensity of neurofilament immunostaining and DTI 
measures of FA in the corpus callosum of KET-INT (red dots) and SAL-INT mice (blue dots). 
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This correlation suggests that ketamine, through repeat intermittent administration, 
might be remodelling neural circuitry in the corpus callosum which presents as an 
increase in the amount of neurofilament, at the cellular level, and an increase in FA at 




To summarise, in this chapter I have shown that repeat ketamine administration does 
not induce any change in neuron or glial cell number in the frontal lobe nor corpus 
callosum. Furthermore, repeat ketamine administration, in mice, be it daily or 
intermittent, does not induce gliosis. The lack of these changes would suggest that 
repeat ketamine administration is not having a pathological effect on the mouse brain 
as it appears to in human ketamine users. 
Moreover, I have shown that under repeat intermittent administration, ketamine 
induces an increase in the amount of neurofilament and synaptophysin in the prefrontal 
cortex, markers of axons and synapses. These results suggest, indirectly, that repeat 
intermittent ketamine administration is remodelling neuronal circuitry in this region. 
Similarly, the increase in MBP and neurofilament in the corpus callosum of mice given 
repeat ketamine intermittently, suggests rewiring of neuronal circuitry in this region. 
These structural changes, in both regions, may have functional and behavioural 
consequences, something which should be investigated further. 
As, ketamine was given systemically, it is tempting to speculate that the drug may be 
rewiring neuronal circuitry in other brain regions as well. This, however, would need 
further experimental verification. Furthermore, the results presented here are only 
preliminary and would need further confirmation using other techniques. For example, 
the increase in synaptophysin staining in KET-INT mice is only an indicator of an increase 
in one pre-synaptic protein which may or may not correlate with an increase in the size 
or number of synapses. To understand better what is occurring further experiments 
should be performed, including a mixture of further histological stainings, coupled with 
biochemical analysis of the levels of other synaptic proteins and electron microscope 
investigation of synapse number and distribution. Similarly, these techniques should be 
applied to investigate further the structural changes behind an increase in 
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neurofilament (in the prefrontal cortex and corpus callosum) and MBP (in the corpus 























As discussed in the general introduction in chapter 1, ketamine over the last 10-12 years 
has been used as a revolutionary “off-label” treatment for depression. This has led to 
the establishment of multiple, specialised ketamine clinics in both the UK and USA. 
These clinics offer ketamine treatment plans at a cost of £1,200 in the UK and $2400-
$4800 in the USA. Unfortunately, these treatment plans are not covered by the NHS in 
the UK nor medical insurance in the USA. Hence, there is a foreseeable risk of self-
medication with ketamine by people suffering with depression. The risk here is that 
patients will self-medicate with incorrect, too high and too frequent doses of ketamine, 
which may have unknown long-term detrimental effects on physical and psychological 
wellbeing. 
Currently, there is a lack of understanding as to the long-term effects and safety profile 
of ketamine treatment for depression, particularly with regards to the effects on brain 
structure, function and psychological wellbeing. Our best understanding of the long-
term effects of ketamine on brain structure and function come from a handful of studies 
which assessed the effects of repeat ketamine use by poly-drug users. These studies 
suggest that repeat ketamine use may cause altered neuronal activity in the cortex, 
alongside cortical atrophy and cognitive deficits. However, these studies are heavily 
confounded by the fact that other psychotropic drug use is poorly controlled for within 
these studies. Thus, within the literature, it remains unclear what effects repeat 
ketamine alone is having on the brain. 
The aims of my PhD thesis were to elucidate what effects repeat ketamine exposure, 
alone, has on brain structure. To investigate this, I contrasted the effects of repeat 
ketamine use, on brain structure, by recreational users, against repeat ketamine 
administration (alone) in mice.  
My major findings, in humans, were that ketamine users exhibit reduced brain volume 
in the cerebral cortices, cerebellar cortices and striatum. This is in line with previously 
published studies showing atrophy in the cerebral cortex frontal lobe and cerebellum 
(Liao et al., 2011; Wang et al., 2013). Furthermore, ketamine users, in my study, 
demonstrated reduced psychological wellbeing compared to poly-drug controls, which 
has been reported previously (Edward Roberts et al., 2014; Morgan et al., 2014). 
However, the structural changes observed in ketamine users did not correlate with 
reduced scores of psychological wellbeing. Nor did structural alterations or reduced 
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scores of psychological wellbeing correlate with either the amount, frequency or 
duration of ketamine use. Thus, I cannot confidently state that the differences observed 
in brain structure and psychological wellbeing seen in ketamine users, versus poly-drug 
controls, is due to ketamine alone. It is my conclusion that other drug use contributes to 
these changes observed, This is reinforced by studies showing that other psychotropic  
drugs, used by ketamine users in my study, have been shown to impact on brain 
structure and psychological wellbeing in similar ways to the results I have observed (Lim 
et al., 2008; Van Dam, Earleywine and DiGiacomo, 2008b; Compton, Chien and Bollini, 
2009; Liu et al., 2009; Fridberg et al., 2011; Baskak et al., 2012; Grodin, Lin, C. a. Durkee, 
et al., 2013; Li et al., 2015). 
Turning to my studies on repeat ketamine administration in mice, I have found both 
similar and disparate results to those observed in repeat ketamine users. I have seen 
volume changes in the cerebral cortex, cerebellum and striatum. However, in contrast 
to volume reductions seen in the frontal lobe of human ketamine users, in mice, I have 
seen increased cortical volume in the frontal lobe. Furthermore, I have observed clusters 
of increased volume, as well as clusters of decreased volume, throughout the cerebral 
cortex of mice given repeat daily or intermittent ketamine. This discrepancy in results 
observed between humans and mice suggests that other drug use in humans might be 
confounding the effect of ketamine on brain volume. 
In addition to the volume differences observed in mice, I have also observed structural 
differences, as observed by DTI. These structural differences presented as decreased FA 
and AD in both KET-INT and KET-DAY mice in the frontal lobe and parieto-temporal lobe. 
Furthermore, in KET-DAY mice, I found significant decreases in AD in the following 
cerebral white matter bundles; corpus callosum, cerebral peduncle, fasciculus 
retroflexus, fimbria, fornix, mammillothalamic tract and stria medullaris. These changes 
are like those observed in human ketamine users and suggest that a common 







Table 35. Summary of MRI changes observed after repeat ketamine exposure across species 
Species Structural changes Source 
Human 
Smaller cerebral cortices: 
• inferior parietal cortex 
• temporal pole 
• supramarginal gyrus 
• paracentral gyrus 
• middle temporal gyrus 
• superior frontal gyrus 
• isthmus of the cingulate cortex 
• superior temporal gyrus 
• banks of the superior temporal sulcus 
Chapter 2 of this thesis 
Smaller cerebellar cortices 
Smaller striatum 
Smaller cerebral cortex: 
• superior frontal cortex 
• middle frontal cortex 
Liao et al (2011) 
Cortical atrophy Wang et al (2013) 
Reduced FA: 
• frontal cortex 
• temporoparietal cortex 
Liao et al (2010) 
Reduced AD: 
• frontal cortex 
• parietal cortex 
• somatosensory cortex 




• frontal gyrus 
• middle temporal gyrus 
Li et al (2017) 
C57BL/6J mice 
Larger frontal cortex 
Chapter 3 of this thesis 
Reduced FA: 
• frontal cortex 
• parieto-temporal cortex 
Reduced AD: 
• frontal cortex 




I have shown that, within the frontal lobe and corpus callosum, of mice given repeat 
doses of ketamine, there is no change in the number of neurons nor glia. Furthermore, 
there is no change in the level of gliosis in these regions. This evidence leads me to 
conclude, at least in these two regions, that there is a lack of pathology.  
Rather, as reinforced by an increase in neurofilament and synaptophysin levels 
(prefrontal cortex) and neurofilament and MBP (corpus callosum), of mice given repeat 
intermittent doses of ketamine, ketamine is remodelling neural circuitry. These are only 
preliminary data, however, and would need further confirmation using other 
techniques. For example, the increase in synaptophysin staining in KET-INT mice is only 
an indicator of an increase in one pre-synaptic protein which may or may not correlate 
with an increase in the size or number of synapses. To understand better what is 
occurring, further experiments need performing. These could include a mixture of 
further histological stainings, coupled with biochemical analysis (e.g. western blot) of 
the levels of other proteins located at the presynaptic terminal / postsynaptic 
membrane  and electron microscope investigation of synapse number and distribution. 
Of interest would be to investigate whether the expression of proteins in cell signalling 
pathways, thought to be involved in the anti-depressant effects of ketamine, are altered 
following repeat ketamine exposure. As discussed in chapter 1, the primary mechanism 
of action of ketamine’s antidepressant effect is thought to involve the restoration of 
synaptic connectivity and glutamatergic signalling (which is thought to be disrupted in 
depression) (Abdallah et al., 2014). This is thought to involve preferential inhibition of 
NMDA receptors on inhibitory GABAergic interneurons, a widespread prefrontal 
glutamate surge and activation of post-synaptic AMPA receptors.  Combined with 
ketamine’s blockade of extra synaptic NMDA receptors on post-synaptic neurons, this 
leads to increased BDNF release in the post-synaptic neuron and activation of the 
mTORC1 signalling pathway. The increase in mTORC1 signalling in turn increases post-
synaptic protein synthesis and AMPA cycling. This results in the restoration of AMPA 
receptors to the post-synaptic membrane (thought to be deficient in depression) and 
the restoration of glutamatergic neurotransmission to normal levels.  
It is my hypothesis that mTORC1 signalling, in KET-INT mice, is increased after each 
ketamine infusion leading to an increase in AMPA receptors and a strengthening of 
glutamatergic neurotransmission. In turn, I hypothesise, an increase in BDNF induced 
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dendritic spine formation and new synapse formation (Wohleb et al., 2017). I further 
hypothesise that these changes are responsible for the structural MRI changes observed 
within the frontal cortex of KET-INT mice. Such changes would explain an increase in 
volume as well as a decrease in AD; a measure of the rate of water diffusion in a given 
volume (the more structures present in a given volume the greater the impedance of 
water diffusion). 
Moreover, I hypothesise that the increase in MBP and neurofilament; observed within 
the prefrontal cortex of KET-INT mice, are secondary to an increase in dendritic spine 
formation and synapse formation. An increase in synapse formation and increased 
glutamatergic neurotransmission requires a subsequent increase in the rate of action 
potential propagation. An increase in axon width (neurofilament increase) and an 
increase in myelin thickness (MBP increase), and thus insulation, would facilitate faster 
action potential propagation and increased glutamatergic signalling. 
Changes in glutamatergic signalling within the prefrontal cortex would subsequently 
alter neuronal activity in other brain regions, requiring structural changes in those 
regions. I hypothesise that the increase in MBP and neurofilament, observed within the 
corpus callosum of KET-INT mice, is reflective of this and the need for faster action 
potential propagation across the brain; particularly in axonal pathways travelling to the 
frontal cortex. 
In KET-DAY mice changes in synaptophysin, MBP and neurofilament were not observed. 
In these mice, increased volume was seen in the prefrontal cortex, but this change was 
not as wide spread as in KET-INT mice. Decreases in FA and AD were also seen in KET-
DAY mice, within the frontal cortex, as was observed in KET-INT mice. It might be that 
cellular and molecular changes are occurring within KET-DAY mice as observed in KET-
INT mice but that the histological techniques used in this thesis lack the sensitivity to 
detect them. In this case, molecular biology techniques; such as western blot or mass 
spectrometry, can more accurately measure protein expression in a given region. 
Another factor to consider, is that KET-DAY mice compared to KET-INT mice may have 
built up greater tolerance to ketamine’s effects due to a higher frequency of exposure 
and therefore the cellular changes observed in KET-INT mice is not detectable using 




Eventually, the functional and behavioural consequences of these potential structural 
changes require investigation to determine if the outcome is positive or detrimental. 
This will require a combination of electrophysiological and behavioural experiments in 
mice give ketamine at different frequencies and for different durations. If the 
remodelling of neural circuits is positive and not detrimental to brain function or 
behaviour, then it may be a starting point for further understanding the antidepressant 
mechanism of depression. It has been demonstrated, in numerous studies now, that 
acute doses of ketamine, both in-vitro and in-vivo, increase the number of synapses and 
dendritic spines within neural circuits, particularly the prefrontal cortex. This rewiring of 
neural circuits is thought to be the therapeutic base for how ketamine induces anti-
depressant effect in patients with depression (Duman and Duman, 2015; Thompson et 
al., 2015; Wohleb et al., 2017; Zanos et al., 2018).  
If it is confirmed that repeat, intermittent doses of ketamine do lead to upregulation of 
synapses and dendritic spines, and rewiring of neural circuits, without detrimental 
effects on brain activity and behaviour, then that is one step in the right direction to 
showing that ketamine is a safe treatment for depression in the long-term. 
It would also be good to see experiments in the future being performed on animal 
models of stress/depression to see whether repeat intermittent ketamine 
administration has a positive effect in relieving stress/depressive symptoms, and 
possibly reversing any structural, functional and behavioural pathology without 
detrimental side effects. 
Furthermore, what would be good to see happen in parallel are longitudinal MRI studies 
of depressed patients being treated with ketamine in ketamine clinics. These studies 
would show if repeat ketamine infusions ameliorate the structural and psychological 
pathologies of depressed patients, as well as highlight any long-term side effects. This 
data could then be compared to that obtained from animal models of depression, and 
if the same or similar structural, and or functional / behavioural, changes are observed 
then this would suggest that a common cellular and molecular pathway is affected by 
ketamine. Ultimately, this may help us to understand better the pathophysiology of 
depression and the mechanism by which to treat it.  
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